<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1" specific-use="sps-1.9" xml:lang="pt" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
	<front>
		<journal-meta>
			<journal-id journal-id-type="nlm-ta">Rev Lat Am Enfermagem</journal-id>
			<journal-id journal-id-type="publisher-id">rlae</journal-id>
			<journal-title-group>
				<journal-title>Revista Latino-Americana de Enfermagem</journal-title>
				<abbrev-journal-title abbrev-type="publisher">Rev. Latino-Am. Enfermagem</abbrev-journal-title>
			</journal-title-group>
			<issn pub-type="ppub">0104-1169</issn>
			<issn pub-type="epub">1518-8345</issn>
			<publisher>
				<publisher-name>Escola de Enfermagem de Ribeirão Preto / Universidade de São Paulo</publisher-name>
			</publisher>
		</journal-meta>
		<article-meta>
			<article-id pub-id-type="other">00313</article-id>
			<article-id pub-id-type="doi">10.1590/1518-8345.5794.3569</article-id>
			<article-categories>
				<subj-group subj-group-type="heading">
					<subject>Artigo Original</subject>
				</subj-group>
			</article-categories>
			<title-group>
				<article-title>Análise dos fatores associados ao retransplante de células-tronco hematopoiéticas: estudo caso-controle</article-title>
			</title-group>
			<contrib-group>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-5322-7987</contrib-id>
					<name>
						<surname>Azevedo</surname>
						<given-names>Isabelle Campos de</given-names>
					</name>
					<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
					<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-9123-232X</contrib-id>
					<name>
						<surname>Ferreira</surname>
						<given-names>Marcos Antonio</given-names>
						<suffix>Júnior</suffix>
					</name>
					<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-7492-2735</contrib-id>
					<name>
						<surname>Nascimento</surname>
						<given-names>Anália Andréia de Araújo</given-names>
					</name>
					<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-4672-2303</contrib-id>
					<name>
						<surname>Vitor</surname>
						<given-names>Allyne Fortes</given-names>
					</name>
					<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-6835-0574</contrib-id>
					<name>
						<surname>Teston</surname>
						<given-names>Elen Ferraz</given-names>
					</name>
					<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0003-3586-1313</contrib-id>
					<name>
						<surname>Frota</surname>
						<given-names>Oleci Pereira</given-names>
					</name>
					<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-8140-8320</contrib-id>
					<name>
						<surname>Santos</surname>
						<given-names>Viviane Euzébia Pereira</given-names>
					</name>
					<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
				</contrib>
			</contrib-group>
			<aff id="aff1">
				<label>1</label>
				<institution content-type="original"> Universidade Federal do Rio Grande do Norte, Departamento de Enfermagem, Natal, RN, Brasil.</institution>
				<institution content-type="normalized">Universidade Federal do Rio Grande do Norte</institution>
				<institution content-type="orgname">Universidade Federal do Rio Grande do Norte</institution>
				<institution content-type="orgdiv1">Departamento de Enfermagem</institution>
				<addr-line>
					<city>Natal</city>
					<state>RN</state>
				</addr-line>
				<country country="BR">Brazil</country>
			</aff>
			<aff id="aff2">
				<label>2</label>
				<institution content-type="original"> Bolsista da Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brasil.</institution>
				<institution content-type="orgname">Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)</institution>
				<country country="BR">Brasil</country>
			</aff>
			<aff id="aff3">
				<label>3</label>
				<institution content-type="original"> Universidade Federal de Mato Grosso do Sul, Instituto Integrado de Saúde, Campo Grande, MS, Brasil.</institution>
				<institution content-type="normalized">Universidade Federal de Mato Grosso do Sul</institution>
				<institution content-type="orgname">Universidade Federal de Mato Grosso do Sul</institution>
				<institution content-type="orgdiv1">Instituto Integrado de Saúde</institution>
				<addr-line>
					<city>Campo Grande</city>
					<state>MS</state>
				</addr-line>
				<country country="BR">Brazil</country>
			</aff>
			<author-notes>
				<corresp id="c1">
					<label>Autor correspondente:</label> Isabelle Campos de Azevedo. E-mail: <email>isabellebr2511@gmail.com</email>
				</corresp>
				<fn fn-type="edited-by" id="fn1">
					<label>Editor Associado</label>
					<p> Juan Manuel Carmona Torres</p>
				</fn>
				<fn fn-type="con" id="fn2">
					<label>Contribuição dos autores</label>
					<p><bold>Concepção e desenho da pesquisa:</bold> Isabelle Campos De Azevedo, Marcos Antonio Ferreira Júnior, Allyne Fortes Vitor, Elen Ferraz Teston, Oleci Pereira Frota, Viviane Euzébia Pereira Santos. <bold>Obtenção de dados:</bold> Isabelle Campos De Azevedo, Anália Andréia De Araújo Nascimento. <bold>Análise e interpretação dos dados:</bold> Isabelle Campos De Azevedo, Marcos Antonio Ferreira Júnior, Anália Andréia De Araújo Nascimento, Oleci Pereira Frota, Viviane Euzébia Pereira Santos. <bold>Análise estatística:</bold> Isabelle Campos De Azevedo, Marcos Antonio Ferreira Júnior, Anália Andréia De Araújo Nascimento, Allyne Fortes Vitor, Elen Ferraz Teston. <bold>Obtenção de financiamento:</bold> Isabelle Campos De Azevedo, Marcos Antonio Ferreira Júnior. <bold>Redação do manuscrito:</bold> Isabelle Campos De Azevedo, Marcos Antonio Ferreira Júnior, Anália Andréia De Araújo Nascimento, Allyne Fortes Vitor, Elen Ferraz Teston, Oleci Pereira Frota, Viviane Euzébia Pereira Santos. <bold>Revisão crítica do manuscrito quanto ao conteúdo intelectual importante:</bold> Isabelle Campos De Azevedo, Marcos Antonio Ferreira Júnior, Allyne Fortes Vitor, Elen Ferraz Teston, Oleci Pereira Frota, Viviane Euzébia Pereira Santos. Todos os autores aprovaram a versão final do texto.</p>
				</fn>
				<fn fn-type="conflict" id="fn3">
					<label>Conflito de interesse</label>
					<p> Os autores declararam que não há conflito de interesse.</p>
				</fn>
			</author-notes>
			<pub-date date-type="collection" publication-format="electronic">
				<year>2022</year>
			</pub-date>
			<pub-date date-type="pub" publication-format="electronic">
				<day>16</day>
				<month>05</month>
				<year>2022</year>
			</pub-date>
			<volume>30</volume>
			<elocation-id>e3569</elocation-id>
			<history>
				<date date-type="received">
					<day>23</day>
					<month>12</month>
					<year>2021</year>
				</date>
				<date date-type="accepted">
					<day>11</day>
					<month>02</month>
					<year>2022</year>
				</date>
			</history>
			<permissions>
				<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/" xml:lang="pt">
					<license-p>Este é um artigo publicado em acesso aberto sob uma licença Creative Commons</license-p>
				</license>
			</permissions>
			<abstract>
				<title>Resumo</title>
				<sec>
					<title>Objetivo:</title>
					<p> analisar os fatores associados ao insucesso do Transplante de Células-Tronco Hematopoiéticas (TCTH) em pacientes submetidos ao retransplante de Células-Tronco Hematopoiéticas (RCTH). </p>
				</sec>
				<sec>
					<title>Método:</title>
					<p> estudo quantitativo do tipo caso-controle para avaliar pacientes submetidos ao RCTH. Para tanto, utilizou-se amostra pareada de dois controles para cada caso (2:1). O grupo caso foi constituído pelos prontuários de saúde com todos os pacientes que foram submetidos ao RCTH (28) e o grupo controle (56) incluiu pacientes que receberam apenas um transplante. Três variáveis nortearam o pareamento: sexo, diagnóstico e tipo de transplante. </p>
				</sec>
				<sec>
					<title>Resultados: </title>
					<p>vinte e quatro (85,71%) pacientes do grupo caso receberam retransplante devido a recidiva da doença e quatro (14.29%) devido a falha do enxerto. Uma diferença estatística foi encontrada na análise entre os pacientes que não usaram o ácido ursodesoxicólico, analgésicos opioides ou imunossupressores. A necessidade de um RCTH entre aqueles que usaram estes medicamentos de forma inapropriada foi 16,12, 12,79 e 4,5 vezes maior, respectivamente, do que entre os que as usaram corretamente.</p>
				</sec>
				<sec>
					<title>Conclusão:</title>
					<p> houve uma diferença relacionada ao motivo que levou ao retransplante e os indivíduos analisados. A conclusão é que a razão preditiva para retransplante nesta amostra foi a recidiva da doença.</p>
				</sec>
			</abstract>
			<kwd-group xml:lang="pt">
				<title>Descritores:</title>
				<kwd>Rejeição de Enxerto</kwd>
				<kwd>Recidiva</kwd>
				<kwd>Transplante de Células-Tronco Hematopoéticas</kwd>
				<kwd>Transplante de Medula Óssea</kwd>
				<kwd>Análise de Sobrevida</kwd>
				<kwd>Epidemiologia Analítica</kwd>
			</kwd-group>
			<counts>
				<fig-count count="6"/>
				<table-count count="9"/>
				<equation-count count="3"/>
				<ref-count count="33"/>
				<page-count count="0"/>
			</counts>
		</article-meta>
	</front>
	<body>
		<boxed-text id="bx1">
			<sec>
				<title>Destaques</title>
				<p>(1) Primeiro estudo brasileiro abordando o retransplante de células-tronco hematopoiéticas (RCTH).</p>
				<p>(2) Apresenta evidência do perfil clínico de pacientes submetidos ao RCTH.</p>
				<p>(3) A razão preditiva para RCTH foi recidiva da doença.</p>
				<p>(4) A recidiva da doença pode estar associada ao insucesso do tratamento.</p>
			</sec>
		</boxed-text>
		<sec sec-type="intro">
			<title>Introdução</title>
			<p>O transplante de células-tronco hematopoiéticas (TCTH) é considerado uma modalidade de tratamento para hemopatias malignas, assim como outras doenças hematopoiéticas, linfáticas, e do sistema imunológico<xref ref-type="bibr" rid="B1"><sup>1</sup></xref>. Caracteriza-se pela infusão intravenosa de células progenitoras hematopoiéticas (CPH) para corrigir falhas quantitativas ou qualitativas da medula óssea<xref ref-type="bibr" rid="B2"><sup>2</sup></xref>.</p>
			<p>O TCTH pode ser classificado de acordo com seu tipo: autólogo, quando as CPH são do próprio paciente, como alogênico quando as células são de doadores (parentes ou não) com antígeno leucocitário humano (ALH) compatível, ou singênico quando as CPH são de um gêmeo idêntico. As células utilizadas para este tipo de transplante podem ser coletadas da medula óssea, sangue periférico ou sangue do cordão umbilical e placentário<xref ref-type="bibr" rid="B2"><sup>2</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B3"><sup>3</sup></xref>.</p>
			<p>É fundamental que as células infundidas proliferem no receptor de forma permanente para evitar a rejeição e garantir o sucesso do TCTH, e que o sistema imune recebido do doador tolere os tecidos do receptor para evitar infecções, doença do Enxerto Contra Hospedeiro (DECH) e outras morbidades, que podem ser graves e fatais. Além disso, o sistema imune deve estar funcionando adequadamente e o estágio da doença, suas complicações, comorbidades no momento do transplante, e assistência prestada ao longo do processo também devem ser considerados<xref ref-type="bibr" rid="B4"><sup>4</sup></xref>. </p>
			<p>Para fins deste estudo, a condição em que o TCTH não se estabelece no paciente que o recebeu e, portanto, requer um retransplante como condição terapêutica para resolver a falha da medula óssea inicial, será considerada insucesso. </p>
			<p>O insucesso de TCTH está diretamente relacionado a todas as fases do procedimento, sendo representada pela falha ou rejeição do enxerto ou recidiva da doença, que ocorre em aproximadamente 20% dos pacientes transplantados<xref ref-type="bibr" rid="B5"><sup>5</sup></xref>. Um estudo conduzido na Alemanha corrobora esta estatística, considerando que 24,89% dos 229 pacientes submetidos ao TCTH entre janeiro 2005 e dezembro de 2015 precisaram de retransplante<xref ref-type="bibr" rid="B6"><sup>6</sup></xref>. Não há dados epidemiológicos considerando os RCTH realizados no Brasil e este é o primeiro estudo abordando este assunto.</p>
			<p>Nesta perspectiva, se trata de um estudo epidemiológico com o objetivo de investigar os fatores associados ao RCTH, com vistas a identificar possíveis características ou complicações que ocorreram durante o processo de transplante, que podem contribuir de forma significativa para o sucesso ou insucesso do procedimento como por exemplo DECH, falha do enxerto ou recidiva da doença, entre outros<xref ref-type="bibr" rid="B6"><sup>6</sup></xref>.</p>
			<p>A falha do TCTH pode culminar na necessidade de um retransplante, mais uma vez expondo o paciente a todos os estágios do procedimento e riscos de morbidade e mortalidade. O Retransplante de Células-Tronco Hematopoiéticas (RCTH) pode ser definido como a única opção/forma de tratamento para a rejeição, falha do enxerto ou recidiva da doença com chance de aumentar a sobrevida ou promover a remissão da doença em pacientes previamente submetidos ao TCTH<xref ref-type="bibr" rid="B7"><sup>7</sup></xref>. O prognóstico para pacientes com progressão da doença após o primeiro TCTH é sombrio e o RCTH é uma opção com potencial de cura<xref ref-type="bibr" rid="B8"><sup>8</sup></xref>.</p>
			<p>Ao considerar que o perfil epidemiológico dos pacientes, assim como os fatores associados a um retransplante, varia de acordo com a doença subjacente e o curso clínico do tratamento, este estudo foi norteado pela seguinte questão de pesquisa: as características clínicas e sociodemográficas estão associadas às características do retransplante de células-tronco hematopoiéticas?</p>
			<p>Este estudo se justifica pela complexidade envolvida no procedimento do TCTH<xref ref-type="bibr" rid="B9"><sup>9</sup></xref> e também porque a identificação de variáveis que impõem riscos ao RCTH demandam uma investigação minuciosa. Por sua vez, há a necessidade de conduzir estudos longitudinais como este para identificar e analisar fatores intrínsecos ao processo de retransplante e produzir conhecimento que subsidie a assistência à saúde, o desenvolvimento ou aprimoramento dos protocolos institucionais e políticas públicas para o funcionamento efetivo dos serviços de transplante. </p>
			<p>Neste contexto, espera-se que os resultados apresentados aqui contribuam para sistematizar e aprimorar a organização e planejamento da assistência prestada aos pacientes submetidos ao TCTH, promover o treinamento de profissionais da saúde, especialmente enfermeiros(as), com vistas a capacitá-los(as) para a prestação de cuidados especializados em TCTH e suas interfaces com base na identificação dos fatores que levam ao RCTH, e na prevenção de complicações associadas.</p>
			<p>Portanto, este estudo objetiva analisar os fatores associados ao insucesso do transplante de células-tronco hematopoiéticas em pacientes submetidos ao RCTH. </p>
		</sec>
		<sec sec-type="methods">
			<title>Método</title>
			<sec>
				<title>Desenho do estudo</title>
				<p>Estudo quantitativo do tipo caso-controle, analítico, observacional, longitudinal e individuado com proporção de 1 caso/2 controles em pacientes submetidos ao TCTH. O guia <italic>Strengthening the Reporting of Observational Studies in Epidemiology</italic> (<italic>STROBE</italic>) para estudos observacionais foi utilizado, como recomendado pela <italic>EQUATOR network.</italic></p>
			</sec>
			<sec>
				<title>Local e período do estudo</title>
				<p>O estudo foi conduzido em um hospital de referência de alta complexidade localizado em Natal/RN, Brasil, autorizado, acreditado e qualificado a partir de 2004 para conduzir TCTH pelo Sistema Único de Saúde (SUS). Os dados foram coletados entre julho e agosto de 2018.</p>
			</sec>
			<sec>
				<title>Participantes</title>
				<p>A amostra incluiu todos os pacientes com prontuários de saúde cadastrados e que foram submetidos ao TCTH no serviço em questão entre janeiro de 2008 e dezembro de 2017, ou seja, 10 anos de procedimentos. Este recorte temporal se justifica pelo fato de que os prontuários referentes aos anos de 2004 a 2007 não foram cadastrados no Serviço de Arquivo Médico e Estatístico.</p>
				<p>A população do estudo inclui todos os prontuários cadastrados no serviço, com uma amostra inicial de 389 prontuários de pacientes que receberam TCTH, independente do tipo de transplante realizado. No entanto, cinco destes foram excluídos por inelegibilidade ou informações incompletas. Depois de excluir os prontuários inelegíveis; ou com informação incompleta, o coorte final consistiu de 384 prontuários de pacientes que receberam TCTH. </p>
				<p>Trinta e um indivíduos do total de pacientes que receberam um RCTH foram caracterizados como o grupo caso, e aqueles com o registro de um único transplante compuseram o grupo controle. Três casos foram excluídos da amostra porque não foi possível compará-los aos controles disponíveis na população de estudo: um deles com o diagnóstico de trombocitemia essencial, outro com síndrome mielodisplásica, e o último com diagnóstico de mieloma múltiplo, um dos tipos de câncer hematológico mais prevalente; no entanto o tipo de transplante realizado foi alogênico devido à impossibilidade de utilizar o CPH do próprio paciente para TCTH autólogo, totalizando 28 casos. </p>
				<p>O emparelhamento amostral buscou máxima similaridade entre os indivíduos. O grupo controle foi estabelecido comparando as variáveis sexo, diagnóstico e tipo de TCTH realizado. A variável idade foi usada para proporcionar maior similaridade entre as idades dos casos e controles, considerando que as idades não eram exatamente a mesma entre alguns pares, mas aproximadas. </p>
				<p>A variável de registro foi utilizada como informação adicional para melhor diferenciar os prontuários e minimizar o viés de seleção. É importante destacar que faz parte da amostra prontuários de 12 crianças e adolescentes, e que estes foram pareados entre si para que o grau de semelhança fosse atendido. Nesse contexto, a amostra final foi composta por 84 pacientes, sendo 28 casos e 56 controles, estes últimos extraídos dos 353 prontuários restantes. Foi elaborado um fluxograma apresentado na <xref ref-type="fig" rid="f1">Figura 1</xref> para melhor compreensão da seleção dos prontuários por grupo.</p>
				<p>
					<fig id="f1">
						<label>Figura 1</label>
						<caption>
							<title>Fluxograma de síntese da seleção dos prontuários que compuseram os grupos caso e controle. Natal, RN, Brasil, 2019 (n=84)</title>
						</caption>
						<graphic xlink:href="1518-8345-rlae-30-e3569-gf1.png"/>
					</fig>
				</p>
				<p>Os critérios de inclusão para o grupo de casos foram: pacientes submetidos a RCTH autólogo, alogênico ou singênico, independentemente da idade ou sexo. Os critérios de inclusão para o grupo de controle foram: pacientes submetidos a apenas um TCTH autólogo, alogênico ou singênico independentemente da idade ou sexo. </p>
			</sec>
			<sec>
				<title>Coleta de dados e variáveis</title>
				<p>O instrumento de coleta de dados abordou variáveis sociodemográficas e clínicas: data e local de nascimento, local de residência, idade, sexo, raça, escolaridade, estado civil, profissão, situação com o serviço de transplante, tempo entre a admissão e TCTH, duração do seguimento pelo serviço de transplante, diagnóstico/doença subjacente, tipo de RCTH realizado, tipo de células infundidas, motivo/indicação para o transplante, toxicidades apresentadas, tratamentos administrados, presença de DECH aguda ou crônica e sobrevida do(a) paciente transplantado. Vale ressaltar que todas as variáveis foram coletadas dos prontuários de saúde.</p>
				<p>Os pesquisadores que coletaram os dados receberam treinamento em duas etapas: a primeira etapa envolveu o objeto de estudo e suas interfaces e a segunda focou no instrumento de coleta de dados e suas especificidades. Os pesquisadores estavam cegos aos objetivos do estudo assim como em relação a hipótese a ser testada com o intuito de minimizar viés de confusão numa tentativa de fazer qualquer associação entre as respostas.</p>
			</sec>
			<sec>
				<title>Processamento e análise dos dados</title>
				<p>As tabelas foram construídas com as frequências absolutas e relativas por sexo e total, as médias e desvios padrão para descrever a amostra. O teste Qui-quadrado foi usado para testar significância estatística. O teste exato de Fisher foi realizado para calcular a probabilidade de associação entre as características analisadas e o grupo caso, de acordo com a natureza de cada variável, enquanto que o teste U de Mann-Whitney foi adotado para comparar as tendências centrais de duas amostras de tamanhos iguais e independentes e comparar dois grupos pareados ou não para verificar se pertencem à mesma população, e cujos requisitos para aplicação do teste t de Student não foram atendidos. O teste de Kolmogorov-Smirnov foi usado para verificar a normalidade dos dados.</p>
				<p>Análises bivariadas e multivariadas foram realizadas para avaliar a associação entre as variáveis selecionadas e estimar a magnitude do <italic>Odds Ratio</italic> (OR), respectivamente. A razão de verossimilhança, os testes de Wald e <italic>Pseudo R<sup>2</sup></italic> (Cox e Snell = 0,240; Nagelkerke = 0,333) foram usados para garantir a significância das variáveis nos modelos de Regressão Logística, assim como o teste de hipótese para determinar se as variáveis independentes no modelo apresentavam relação significante com a variável dependente.</p>
				<p>Uma variável dependente (retransplante de células-tronco hematopoiéticas = Y) foi adotada para a regressão logística, verificando-se a influência de uma ou mais variáveis independentes, causais ou explicativas (X1, X2, X3,...) na variável dependente. A seguinte equação foi usada para esta análise: </p>
				<p>
					<disp-formula id="e1">
						<mml:math>
							<mml:msub>
								<mml:mrow>
									<mml:mi>γ</mml:mi>
								</mml:mrow>
								<mml:mrow>
									<mml:mi>i</mml:mi>
								</mml:mrow>
							</mml:msub>
							<mml:mi>
							</mml:mi>
							<mml:mo>=</mml:mo>
							<mml:msub>
								<mml:mrow>
									<mml:mi>β</mml:mi>
								</mml:mrow>
								<mml:mrow>
									<mml:mn>0</mml:mn>
								</mml:mrow>
							</mml:msub>
							<mml:mo>+</mml:mo>
							<mml:msub>
								<mml:mrow>
									<mml:mi>β</mml:mi>
								</mml:mrow>
								<mml:mrow>
									<mml:mn>1</mml:mn>
								</mml:mrow>
							</mml:msub>
							<mml:msub>
								<mml:mrow>
									<mml:mi>X</mml:mi>
								</mml:mrow>
								<mml:mrow>
									<mml:mn>1</mml:mn>
								</mml:mrow>
							</mml:msub>
							<mml:mo>+</mml:mo>
							<mml:msub>
								<mml:mrow>
									<mml:mi>β</mml:mi>
								</mml:mrow>
								<mml:mrow>
									<mml:mn>2</mml:mn>
								</mml:mrow>
							</mml:msub>
							<mml:msub>
								<mml:mrow>
									<mml:mi>X</mml:mi>
								</mml:mrow>
								<mml:mrow>
									<mml:mn>2</mml:mn>
								</mml:mrow>
							</mml:msub>
							<mml:mo>+</mml:mo>
							<mml:mi>
							</mml:mi>
							<mml:mo>…</mml:mo>
							<mml:mo>+</mml:mo>
							<mml:msub>
								<mml:mrow>
									<mml:mi>β</mml:mi>
								</mml:mrow>
								<mml:mrow>
									<mml:mi>i</mml:mi>
								</mml:mrow>
							</mml:msub>
							<mml:msub>
								<mml:mrow>
									<mml:mi>X</mml:mi>
								</mml:mrow>
								<mml:mrow>
									<mml:mi>i</mml:mi>
								</mml:mrow>
							</mml:msub>
							<mml:mo>+</mml:mo>
							<mml:msub>
								<mml:mrow>
									<mml:mi>ε</mml:mi>
								</mml:mrow>
								<mml:mrow>
									<mml:mi>i</mml:mi>
								</mml:mrow>
							</mml:msub>
						</mml:math>
					</disp-formula>
				</p>
				<p>Ao analisar o modelo final de regressão logística, a estatística Qui-quadrado dos resíduos (<italic>Overall Statistics</italic>) apresentou um p-valor &gt;0.05, ou seja, nenhuma das variáveis excluídas do modelo contribuiriam significantemente para o poder preditivo do modelo. Verificou-se que o p-valor &gt;0.05 não foi estatisticamente significante no teste Hosmer-Lemeshow, o que indica que foi obtido um bom ajuste do modelo final. Portanto, concluiu-se que o modelo de regressão logística ajustado final foi adequado.</p>
				<p>Os cálculos de sobrevida foram realizados aplicando-se o método de Kaplan-Meier com o ponto de entrada inicial do(a) paciente no estudo sendo a data do TCTH e o último evento como ponto final, i.e., óbito, abandono, seguimento no momento da coleta de dados, ou tratamento finalizado. O método estatístico <italic>log-rank</italic> foi utilizado para comparar as taxas de sobrevida pelas variáveis a serem listadas. O nível de significância adotado em todas as análises foi 0.05.</p>
			</sec>
			<sec>
				<title>Aspectos éticos</title>
				<p>Atendendo à Resolução Nº. 466/12 do Conselho Nacional de Saúde do Ministério da Saúde, que regulamenta pesquisa com seres humanos, submetemos o Protocolo de Pesquisa deste estudo ao Comitê de Ética da Universidade Federal do Rio Grande do Norte para avaliação de seus aspectos éticos e metodológicos<xref ref-type="bibr" rid="B10"><sup>10</sup></xref>, o qual foi aprovado em 18 de abril de 2018 sob o parecer 2.596.384 e CAAE: 80927417.9.0000.5537.</p>
			</sec>
		</sec>
		<sec sec-type="results">
			<title>Resultados</title>
			<p>A idade variou entre dois e 55 anos e a média foi 34.11 anos (± 14.20) (<xref ref-type="table" rid="t1">Tabela 1</xref>); 51 (60,71%) participantes eram homens; 65 (77,38%) moravam no estado do Rio Grande do Norte; 41 (48,81%) eram casados, e 49 (58,33%) estavam empregados. A idade média era 34 anos e esta variável apresentou variância significante. Desta forma, para melhor organizar esta informação na <xref ref-type="table" rid="t1">Tabela 1</xref>, considerou-se duas faixas etárias: até 35 anos e acima de 35 anos. A idade foi considerada uma variável contínua para cálculos de associação e outros.</p>
			<p>Do total, 42 (50,00%) pacientes receberam atendimento no setor de TCTH por aproximadamente 21 meses e 43 (51,19%; p&lt;0,001) esperaram até 15 dias entre o início do regime de condicionamento até o primeiro TCTH.</p>
			<p>A <xref ref-type="table" rid="t1">Tabela 1</xref> apresenta os diagnósticos que culminaram em RCTH. Trinta e cinco (41,67%) dos pacientes foram à óbito; 16 (57,14%) destes óbitos ocorreram entre pacientes retransplantados. As causas de morte mais prevalentes foram sepse, 28 (33,34%), falência de múltiplos órgãos, 14 (16,67%), e infecção pulmonar em oito (9,52%) pacientes. Além disso, foram realizados 51 (60,71%) TCTHs alogênicos, 17 (60,71%) destes foram retransplantes (<xref ref-type="table" rid="t1">Tabela 1</xref>).</p>
			<p>O TCTH alogênico ocorreu em 39 (76,47%) indivíduos; a fonte de CPH mais frequente foi sangue periférico em 64 (85,33%) TCTHs; e o motivo mais indicado para retransplante foi recidiva da doença, em 24 (85,71%) indivíduos. Além disso, RCTH alogênico foi realizado em 26 (92,86%) pacientes, sendo de familiares em 21 (75.00%) casos com CPH de sangue periférico (75,00%). Os pacientes que desenvolveram DECH tinham 9,17 vezes mais chances de receber um RCTH.</p>
			<p>O tempo médio para a realização do retransplante foi de 14,74 meses, e o motivo mais prevalente para o TCTH foi recidiva da doença (24; 85,14%), enquanto 42 (50,00%) pacientes tiveram sobrevida de 17 meses.</p>
			<p>
				<table-wrap id="t1">
					<label>Tabela 1</label>
					<caption>
						<title>Análise bivariada entre desempenho e não desempenho do RCTH e variáveis independentes (n=84). Natal, RN, Brasil, 2019</title>
					</caption>
					<table>
						<colgroup>
							<col/>
							<col span="4"/>
							<col/>
							<col/>
						</colgroup>
						<thead>
							<tr>
								<th align="left" rowspan="3">Variáveis</th>
								<th align="center" colspan="4">Grupos </th>
								<th align="center" rowspan="3"><italic>Odds Ratio</italic> [95%IC<sup>*</sup>]</th>
								<th align="center" rowspan="3"><italic>p</italic><sup>†</sup></th>
							</tr>
							<tr>
								<th align="center" colspan="2"><italic>Caso</italic> (n=28)</th>
								<th align="center" colspan="2"><italic>controle</italic> (n=56)</th>
							</tr>
							<tr>
								<th align="center">n</th>
								<th align="center">%</th>
								<th align="center">n</th>
								<th align="center">%</th>
							</tr>
						</thead>
						<tbody>
							<tr>
								<td align="left" colspan="7"><bold>Sexo</bold></td>
							</tr>
							<tr>
								<td align="left">Masculino</td>
								<td align="center">17</td>
								<td align="center">60,71</td>
								<td align="center">34</td>
								<td align="center">60,71</td>
								<td align="center" rowspan="2">1,00 [0,39; 2,53]</td>
								<td align="center" rowspan="2">1,000<sup>‡</sup></td>
							</tr>
							<tr>
								<td align="left">Feminino</td>
								<td align="center">11</td>
								<td align="center">39,29</td>
								<td align="center">22</td>
								<td align="center">39,29</td>
							</tr>
							<tr>
								<td align="left" colspan="7"><bold>Faixa etária</bold></td>
							</tr>
							<tr>
								<td align="left">Até 35 anos</td>
								<td align="center">13</td>
								<td align="center">46,43</td>
								<td align="center">26</td>
								<td align="center">46,43</td>
								<td align="center" rowspan="2">1,00 [0,40; 2,48]</td>
								<td align="center" rowspan="2">1,000<sup>‡</sup></td>
							</tr>
							<tr>
								<td align="left">Acima de 35 anos</td>
								<td align="center">15</td>
								<td align="center">53,57</td>
								<td align="center">30</td>
								<td align="center">53,57</td>
							</tr>
							<tr>
								<td align="left" colspan="7"><bold>Diagnósticos</bold></td>
							</tr>
							<tr>
								<td align="left">Leucemia mielóide aguda</td>
								<td align="center">8</td>
								<td align="center">28,57</td>
								<td align="center">16</td>
								<td align="center">28,57</td>
								<td align="center" rowspan="7">--</td>
								<td align="center" rowspan="7">1,000<sup>‡</sup></td>
							</tr>
							<tr>
								<td align="left">Linfoma não-Hodgkin</td>
								<td align="center">6</td>
								<td align="center">21,43</td>
								<td align="center">12</td>
								<td align="center">21,43</td>
							</tr>
							<tr>
								<td align="left">Mieloma múltiplo</td>
								<td align="center">5</td>
								<td align="center">17,86</td>
								<td align="center">10</td>
								<td align="center">17,86</td>
							</tr>
							<tr>
								<td align="left">Leucemia linfoblástica aguda</td>
								<td align="center">4</td>
								<td align="center">14,29</td>
								<td align="center">8</td>
								<td align="center">14,29</td>
							</tr>
							<tr>
								<td align="left">Anemia aplástica</td>
								<td align="center">3</td>
								<td align="center">10,71</td>
								<td align="center">6</td>
								<td align="center">10,71</td>
							</tr>
							<tr>
								<td align="left">Doença de Hodgkin</td>
								<td align="center">1</td>
								<td align="center">3,57</td>
								<td align="center">2</td>
								<td align="center">3,57</td>
							</tr>
							<tr>
								<td align="left">Leucemia mielóide crônica</td>
								<td align="center">1</td>
								<td align="center">3,57</td>
								<td align="center">2</td>
								<td align="center">3,57</td>
							</tr>
							<tr>
								<td align="left" colspan="7"><bold>Tipo de TCTH<sup>§</sup></bold></td>
							</tr>
							<tr>
								<td align="left">Alogênico</td>
								<td align="center">17</td>
								<td align="center">60,71</td>
								<td align="center">34 </td>
								<td align="center">60,71</td>
								<td align="center">1,00 [0,39; 2,53] </td>
								<td align="center">1,000<sup>‡</sup></td>
							</tr>
							<tr>
								<td align="left">Autólogo</td>
								<td align="center">11</td>
								<td align="center">39,29</td>
								<td align="center">22 </td>
								<td align="center">39,29</td>
								<td align="center" colspan="2">
								</td>
							</tr>
							<tr>
								<td align="left" colspan="7"><bold>DECH<sup>||</sup></bold></td>
							</tr>
							<tr>
								<td align="left">Não </td>
								<td align="center">24</td>
								<td align="center">85,71</td>
								<td align="center">55 </td>
								<td align="center">98,21</td>
								<td align="center">9,17 [0,97; 86,38] </td>
								<td align="center">0,040<sup>¶</sup></td>
							</tr>
							<tr>
								<td align="left">Sim</td>
								<td align="center">4</td>
								<td align="center">14,29</td>
								<td align="center" colspan="2">1 </td>
								<td align="center">1,79</td>
								<td align="center" colspan="2">
								</td>
							</tr>
							<tr>
								<td align="left" colspan="7"><bold>Situação com RGH<sup>**</sup></bold></td>
							</tr>
							<tr>
								<td align="left">Tratamento finalizado</td>
								<td align="center">12</td>
								<td align="center">42,86</td>
								<td align="center">37 </td>
								<td align="center">66,07</td>
								<td align="center">,38 [0,15; 0,97] </td>
								<td align="center">0,042<sup>‡</sup></td>
							</tr>
							<tr>
								<td align="left">Óbito </td>
								<td align="center">16</td>
								<td align="center">57,14</td>
								<td align="center">19 </td>
								<td align="center">33,93</td>
								<td align="center" colspan="2">
								</td>
							</tr>
							<tr>
								<td align="left" colspan="7"><bold>Seguimento até TCTH</bold></td>
							</tr>
							<tr>
								<td align="left">Até 15 dias</td>
								<td align="center">17</td>
								<td align="center">39,53</td>
								<td align="center">26 </td>
								<td align="center">60,47</td>
								<td align="center">1,78 [0,71; 4,49] </td>
								<td align="center">0,217<sup>‡</sup></td>
							</tr>
							<tr>
								<td align="left">Mais de 15 dias</td>
								<td align="center">11</td>
								<td align="center">26,83</td>
								<td align="center">30 </td>
								<td align="center">73,17</td>
								<td align="center" colspan="2">
								</td>
							</tr>
							<tr>
								<td align="left" colspan="7"><bold>Tempo total de seguimento no serviço de TCTH<sup>§</sup></bold></td>
							</tr>
							<tr>
								<td align="left">Até 21 meses</td>
								<td align="center">12</td>
								<td align="center">28,57</td>
								<td align="center">30 </td>
								<td align="center">71,43</td>
								<td align="center">0,65 [0,26; 1,62] </td>
								<td align="center">0,355<sup>‡</sup></td>
							</tr>
							<tr>
								<td align="left">Mais que 21 meses</td>
								<td align="center">16</td>
								<td align="center">38,10</td>
								<td align="center">26 </td>
								<td align="center">61,90</td>
								<td align="center" colspan="2">
								</td>
							</tr>
							<tr>
								<td align="left" colspan="7"><bold>Sobrevida</bold></td>
							</tr>
							<tr>
								<td align="left">Até 17,5 meses</td>
								<td align="center">13</td>
								<td align="center">30,95</td>
								<td align="center">29 </td>
								<td align="center">69,05</td>
								<td align="center">0,81 [0,32; 2,00] </td>
								<td align="center">0,643<sup>‡</sup></td>
							</tr>
							<tr>
								<td align="left">Mais que 17,5 meses</td>
								<td align="center">15</td>
								<td align="center">35,71</td>
								<td align="center">27 </td>
								<td align="center">64,29</td>
								<td align="center" colspan="2">
								</td>
							</tr>
						</tbody>
					</table>
					<table-wrap-foot>
						<fn id="TFN1">
							<p><sup>*</sup>Intervalo de Confiança; <sup>†</sup>p-valor; <sup>‡</sup>Teste Qui-quadrado; <sup>§</sup>Transplante de Células-Tronco Hematopoiéticas; <sup>||</sup>Doença do Enxerto contra Hospedeiro; <sup>¶</sup>Teste exato de Fisher; <sup>**</sup>Hospital Rio Grande</p>
						</fn>
					</table-wrap-foot>
				</table-wrap>
			</p>
			<p>Vinte e quatro (85,71%) pacientes do grupo de caso receberam retransplantes devido à recidiva da doença, e quatro (14,29%) por falha do enxerto. Ao considerar o número médio de meses de seguimento realizado pelo serviço de transplante (29,26; p&lt;0,001) e a situação com o serviço em relação aos óbitos (OR = 0,38; IC = 95%: 0,15-0,97; p = 0,042), respectivamente, pudemos inferir que quanto mais longa a internação hospitalar, maiores as chances do(a) paciente ser retransplantado e evoluir a óbito. A razão é que a permanência hospitalar neste contexto está diretamente relacionada a complicações graves, como infecção ou sepse, que levam à falha do enxerto e recidiva da doença.</p>
			<p>A <xref ref-type="table" rid="t2">Tabela 2</xref> apresenta as variáveis referentes aos medicamentos que levaram os pacientes a uma maior chance de retransplante. Além disso, uma diferença estatisticamente significante foi encontrada entre os pacientes que receberam um TCTH e os que desenvolveram comorbidades geniturinárias, toxicidades hematológicas ou edema. As chances desses pacientes serem retransplantados eram respectivamente 3,32, 3,22 e 2,81 vezes maiores, quando comparados aos pacientes que não desenvolveram as comorbidades e toxicidades mencionadas acima.</p>
			<p>
				<table-wrap id="t2">
					<label>Tabela 2</label>
					<caption>
						<title>Análise bivariada dos medicamentos administrados e toxicidades apresentadas de acordo com os grupos estudados (n=84). Natal, RN, Brasil, 2019</title>
					</caption>
					<table>
						<colgroup>
							<col/>
							<col span="4"/>
							<col/>
							<col/>
						</colgroup>
						<thead>
							<tr>
								<th align="left" rowspan="3">Variáveis</th>
								<th align="center" colspan="4">Grupos </th>
								<th align="center" rowspan="3"><italic>Odds Ratio</italic>[95%IC <sup>*</sup>]</th>
								<th align="center" rowspan="3"><italic>p</italic> <sup>†</sup></th>
							</tr>
							<tr>
								<th align="center" colspan="2"><italic>caso</italic> (n=28)</th>
								<th align="center" colspan="2"><italic>controle</italic> (n=56)</th>
							</tr>
							<tr>
								<th align="center">n</th>
								<th align="center">%</th>
								<th align="center">n</th>
								<th align="center">%</th>
							</tr>
						</thead>
						<tbody>
							<tr>
								<td align="left" colspan="7"><bold>Medicamentos administrados</bold></td>
							</tr>
							<tr>
								<td align="left" colspan="7"><bold>Ácido ursodesoxicólico</bold></td>
							</tr>
							<tr>
								<td align="left">sim</td>
								<td align="center">27</td>
								<td align="center">96,43</td>
								<td align="center">35</td>
								<td align="center">62,50</td>
								<td align="center" rowspan="2">16,12 [2,05-128,12]</td>
								<td align="center" rowspan="2">0,001<sup>‡</sup></td>
							</tr>
							<tr>
								<td align="left">Não</td>
								<td align="center">1</td>
								<td align="center">3,57</td>
								<td align="center">21</td>
								<td align="center">37,50</td>
							</tr>
							<tr>
								<td align="left" colspan="7"><bold>Imunossupressores</bold></td>
							</tr>
							<tr>
								<td align="left">sim</td>
								<td align="center">24</td>
								<td align="center">85,71</td>
								<td align="center">32</td>
								<td align="center">57,14</td>
								<td align="center" rowspan="2">4,50 [1,38-14,69]</td>
								<td align="center" rowspan="2">0,009<sup>‡</sup></td>
							</tr>
							<tr>
								<td align="left">Não</td>
								<td align="center">4</td>
								<td align="center">14,29</td>
								<td align="center">24</td>
								<td align="center">42,86</td>
							</tr>
							<tr>
								<td align="left" colspan="7"><bold>Toxicidades apresentadas</bold></td>
							</tr>
							<tr>
								<td align="left" colspan="7"><bold>Geniturinário</bold></td>
							</tr>
							<tr>
								<td align="left">Sim</td>
								<td align="center">9</td>
								<td align="center">32,14</td>
								<td align="center">7</td>
								<td align="center">12,50</td>
								<td align="center" rowspan="2">3,32 [1,08; 10,17]</td>
								<td align="center" rowspan="2">0,031<sup>‡</sup></td>
							</tr>
							<tr>
								<td align="left">Não</td>
								<td align="center">19</td>
								<td align="center">67,86</td>
								<td align="center">49</td>
								<td align="center">87,50</td>
							</tr>
							<tr>
								<td align="left" colspan="7"><bold>Hematológico</bold></td>
							</tr>
							<tr>
								<td align="left">Sim</td>
								<td align="center">21</td>
								<td align="center">75,00</td>
								<td align="center">27</td>
								<td align="center">48,21</td>
								<td align="center" rowspan="2">3,22 [1,18; 8,79]</td>
								<td align="center" rowspan="2">0,019<sup>‡</sup></td>
							</tr>
							<tr>
								<td align="left">Não</td>
								<td align="center">7</td>
								<td align="center">25,00</td>
								<td align="center">29</td>
								<td align="center">51,79</td>
							</tr>
							<tr>
								<td align="left" colspan="7"><bold>Edema</bold></td>
							</tr>
							<tr>
								<td align="left">Sim</td>
								<td align="center">19</td>
								<td align="center">67,86</td>
								<td align="center">24</td>
								<td align="center">42,86</td>
								<td align="center" rowspan="2">2,81 [1,08; 7,30]</td>
								<td align="center" rowspan="2">0,031<sup>‡</sup></td>
							</tr>
							<tr>
								<td align="left">Não</td>
								<td align="center">9</td>
								<td align="center">32,14</td>
								<td align="center">32</td>
								<td align="center">57,14</td>
							</tr>
							<tr>
								<td align="left" colspan="7"><bold>Oftalmológico</bold></td>
							</tr>
							<tr>
								<td align="left">Sim</td>
								<td align="center">8</td>
								<td align="center">28,57</td>
								<td align="center">7</td>
								<td align="center">12,50</td>
								<td align="center" rowspan="2">2,80 [0,90; 8,75]</td>
								<td align="center" rowspan="2">0,070<sup>‡</sup></td>
							</tr>
							<tr>
								<td align="left">Não</td>
								<td align="center">20</td>
								<td align="center">71,43</td>
								<td align="center">49</td>
								<td align="center">87,50</td>
							</tr>
							<tr>
								<td align="left" colspan="7"><bold>Sepse</bold></td>
							</tr>
							<tr>
								<td align="left">Sim</td>
								<td align="center">8</td>
								<td align="center">28,57</td>
								<td align="center">8</td>
								<td align="center">14,29</td>
								<td align="center" rowspan="2">2,40 [0,79; 7,28]</td>
								<td align="center" rowspan="2">0,116<sup>‡</sup></td>
							</tr>
							<tr>
								<td align="left">Não </td>
								<td align="center">20</td>
								<td align="center">71,43</td>
								<td align="center">48</td>
								<td align="center">85,71</td>
							</tr>
						</tbody>
					</table>
					<table-wrap-foot>
						<fn id="TFN2">
							<p><sup>*</sup>Intervalo de Confiança; <sup>†</sup>p-valor; <sup>‡</sup>Teste Qui-quadrado</p>
						</fn>
					</table-wrap-foot>
				</table-wrap>
			</p>
			<p>Uma diferença estatística foi encontrada na análise entre os pacientes que não usaram ácido ursodesoxicólico ou imunossupressores. As chances de ser submetido a um RCTH entre aqueles que usaram esses medicamentos inapropriadamente devido a não aderência ao tratamento foram 16,12 e 4,5 vezes maior, respectivamente, do que entre aqueles que usaram os medicamentos corretamente. Note que estes medicamentos são obrigatórios nos protocolos de transplante e retransplante alogênicos. Não aderência ao ácido ursodesoxicólico e imunossupressores foi encontrada em 51 (60,71%) prontuários.</p>
			<p>Retransplante foi considerado uma variável dependente para a aplicação do modelo de regressão logística adotado neste estudo, e os grupos foram codificados como controle (0) ou caso (1). A variável dependente foi subsequentemente convertida em razão de probabilidade e depois em uma variável baseada em logarítmica. As variáveis que se mostraram estaticamente significantes (p&lt;0,05) foram organizadas num modelo de regressão logística múltipla, o que em princípio assumiu um p-valor &lt;0.20 para analisá-las em conjunto (<xref ref-type="table" rid="t3">Tabela 3</xref>).</p>
			<p>
				<table-wrap id="t3">
					<label>Tabela 3</label>
					<caption>
						<title>Regressão logística múltipla ajustada de acordo com as variáveis que apresentaram significância estatística agrupadas ao desfecho do retransplante (n=84). Natal, RN, Brasil, 2019</title>
					</caption>
					<table>
						<colgroup>
							<col span="2"/>
							<col span="2"/>
							<col/>
							<col/>
						</colgroup>
						<thead>
							<tr>
								<th align="left" colspan="2">Variáveis </th>
								<th align="center" colspan="2">Frequência</th>
								<th align="center"><italic>Odds Ratio</italic> [95%IC<sup>*</sup>]</th>
								<th align="center"><italic>p</italic><sup>†</sup></th>
							</tr>
						</thead>
						<tbody>
							<tr>
								<td align="left" colspan="6"><bold>Diagnóstico</bold></td>
							</tr>
							<tr>
								<td align="left" colspan="2">Leucemia mielóide aguda </td>
								<td align="center">24</td>
								<td align="center">1<sup>‡</sup></td>
								<td align="center" rowspan="7">--</td>
								<td align="center" rowspan="7">1,000<sup>§</sup></td>
							</tr>
							<tr>
								<td align="left" colspan="2">Leucemia mielóide crônica </td>
								<td align="center">3</td>
								<td align="center">1<sup>‡</sup></td>
								<td align="center" colspan="2">
								</td>
							</tr>
							<tr>
								<td align="left" colspan="2">Leucemia linfoblástica aguda </td>
								<td align="center">12</td>
								<td align="center">1<sup>‡</sup></td>
								<td align="center" colspan="2">
								</td>
							</tr>
							<tr>
								<td align="left" colspan="2">Linfoma não-Hodgkin </td>
								<td align="center">18</td>
								<td align="center">1<sup>‡</sup></td>
								<td align="center" colspan="2">
								</td>
							</tr>
							<tr>
								<td align="left" colspan="2">Doença de Hodgkin </td>
								<td align="center">3</td>
								<td align="center">1<sup>‡</sup></td>
								<td align="center" colspan="2">
								</td>
							</tr>
							<tr>
								<td align="left" colspan="2">Mieloma múltiplo </td>
								<td align="center">15</td>
								<td align="center">1<sup>‡</sup></td>
								<td align="center" colspan="2">
								</td>
							</tr>
							<tr>
								<td align="left" colspan="2">Anemia aplástica </td>
								<td align="center">9</td>
								<td align="center">0<sup>||</sup></td>
								<td align="center" colspan="2">
								</td>
							</tr>
							<tr>
								<td align="left" colspan="6"><bold>Toxicidades</bold></td>
							</tr>
							<tr>
								<td align="left" rowspan="2">Hematológica</td>
								<td align="left">Sim</td>
								<td align="center">48</td>
								<td align="center">1<sup>‡</sup></td>
								<td align="center">3,22 [1,18; 8,79]</td>
								<td align="center">0,019<sup>§</sup></td>
							</tr>
							<tr>
								<td align="left">Não </td>
								<td align="center">36</td>
								<td align="center">0<sup>||</sup></td>
								<td align="center" colspan="2">
								</td>
							</tr>
							<tr>
								<td align="left" rowspan="2">Edema</td>
								<td align="left">Sim</td>
								<td align="center">43</td>
								<td align="center">1<sup>‡</sup></td>
								<td align="center">2,81 [1,08; 7,30]</td>
								<td align="center">0,031<sup>§</sup></td>
							</tr>
							<tr>
								<td align="left">Não</td>
								<td align="center">41</td>
								<td align="center">0<sup>||</sup></td>
								<td align="center" colspan="2">
								</td>
							</tr>
							<tr>
								<td align="left" colspan="6"><bold>Comorbidades</bold></td>
							</tr>
							<tr>
								<td align="left" rowspan="2">DECH<sup>¶</sup></td>
								<td align="left">Sim</td>
								<td align="center">5</td>
								<td align="center">1<sup>‡</sup></td>
								<td align="center">9,17 [0,97; 86,38]</td>
								<td align="center">0,040<sup>§</sup></td>
							</tr>
							<tr>
								<td align="left">Não</td>
								<td align="center">79</td>
								<td align="center">0<sup>||</sup></td>
								<td align="center" colspan="2">
								</td>
							</tr>
							<tr>
								<td align="left" colspan="6"><bold>Infecções</bold></td>
							</tr>
							<tr>
								<td align="left" rowspan="2">Geniturinárias</td>
								<td align="left">Sim </td>
								<td align="center">16</td>
								<td align="center">1<sup>‡</sup></td>
								<td align="center">3,32 [1,08; 10,17]</td>
								<td align="center">0,031<sup>§</sup></td>
							</tr>
							<tr>
								<td align="left">Não</td>
								<td align="center">68</td>
								<td align="center">0<sup>||</sup></td>
								<td align="center" colspan="2">
								</td>
							</tr>
							<tr>
								<td align="left" rowspan="2">Sepse</td>
								<td align="left">Sim</td>
								<td align="center">16</td>
								<td align="center">1<sup>‡</sup></td>
								<td align="center">6,03 [1,386-26,205]</td>
								<td align="center">0,017<sup>§</sup></td>
							</tr>
							<tr>
								<td align="left">Não</td>
								<td align="center">68</td>
								<td align="center">0<sup>||</sup></td>
								<td align="center" colspan="2">
								</td>
							</tr>
							<tr>
								<td align="left" colspan="6"><bold>Medicamentos usados</bold></td>
							</tr>
							<tr>
								<td align="left" rowspan="2">Vitaminas e suplementos</td>
								<td align="left">Sim</td>
								<td align="center">67</td>
								<td align="center">1<sup>‡</sup></td>
								<td align="center">2,78 [0,72;10,63]</td>
								<td align="center">0,124<sup>§</sup></td>
							</tr>
							<tr>
								<td align="left">Não</td>
								<td align="center">17</td>
								<td align="center">0<sup>||</sup></td>
								<td align="center" colspan="2">
								</td>
							</tr>
							<tr>
								<td align="left" rowspan="2">Ácido biliar</td>
								<td align="left">Sim</td>
								<td align="center">62</td>
								<td align="center">1<sup>‡</sup></td>
								<td align="center">24,32 [27,321; 261,608]</td>
								<td align="center">0,004<sup>§</sup></td>
							</tr>
							<tr>
								<td align="left">Não</td>
								<td align="center">22</td>
								<td align="center">0<sup>||</sup></td>
								<td align="center" colspan="2">
								</td>
							</tr>
							<tr>
								<td align="left" rowspan="2">Antianêmicos</td>
								<td align="left">Sim</td>
								<td align="center">35</td>
								<td align="center">1<sup>‡</sup></td>
								<td align="center">2,60 [1,02; 6,58]</td>
								<td align="center">0,042<sup>§</sup></td>
							</tr>
							<tr>
								<td align="left">Não</td>
								<td align="center">49</td>
								<td align="center">0<sup>||</sup></td>
								<td align="center" colspan="2">
								</td>
							</tr>
							<tr>
								<td align="left" rowspan="2">Anti-hemorrágico</td>
								<td align="left">Sim </td>
								<td align="center">33</td>
								<td align="center">1<sup>‡</sup></td>
								<td align="center">1,95 [0,77; 4,91]</td>
								<td align="center">0,155<sup>§</sup></td>
							</tr>
							<tr>
								<td align="left">Não</td>
								<td align="center">51</td>
								<td align="center">0<sup>||</sup></td>
								<td align="center" colspan="2">
								</td>
							</tr>
							<tr>
								<td align="left" rowspan="2">Anticoagulante</td>
								<td align="left">Sim</td>
								<td align="center">20</td>
								<td align="center">1<sup>‡</sup></td>
								<td align="center">3,12 [0,91;7,17]</td>
								<td align="center">0,046<sup>§</sup></td>
							</tr>
							<tr>
								<td align="left">Não</td>
								<td align="center">64</td>
								<td align="center">0<sup>||</sup></td>
								<td align="center" colspan="2">
								</td>
							</tr>
							<tr>
								<td align="left" rowspan="2">Diuréticos de alça</td>
								<td align="left">Sim</td>
								<td align="center">55</td>
								<td align="center">1<sup>‡</sup></td>
								<td align="center">2,56 [0,90;7,29]</td>
								<td align="center">0,074<sup>§</sup></td>
							</tr>
							<tr>
								<td align="left">Não</td>
								<td align="center">29</td>
								<td align="center">0<sup>||</sup></td>
								<td align="center" colspan="2">
								</td>
							</tr>
							<tr>
								<td align="left" rowspan="2">Antiviral</td>
								<td align="left">Sim</td>
								<td align="center">79</td>
								<td align="center">1<sup>‡</sup></td>
								<td align="center">0,164<sup>**</sup></td>
								<td align="center">--</td>
							</tr>
							<tr>
								<td align="left">Não</td>
								<td align="center">5</td>
								<td align="center">0<sup>||</sup></td>
								<td align="center" colspan="2">
								</td>
							</tr>
							<tr>
								<td align="left" rowspan="2">Imunossupressor</td>
								<td align="left">Sim </td>
								<td align="center">56</td>
								<td align="center">1<sup>‡</sup></td>
								<td align="center">4,50 [1,38;14,69]</td>
								<td align="center">0,009<sup>§</sup></td>
							</tr>
							<tr>
								<td align="left">Não</td>
								<td align="center">28</td>
								<td align="center">0<sup>||</sup></td>
								<td align="center">
								</td>
								<td align="center">
								</td>
							</tr>
						</tbody>
					</table>
					<table-wrap-foot>
						<fn id="TFN3">
							<p><sup>*</sup>Intervalo de Confiança; <sup>†</sup>p-valor; <sup>‡</sup>Sim; <sup>§</sup>Teste Qui-quadrado; <sup>||</sup>Não; <sup>¶</sup>Doença do Enxerto contra Hospedeiro; <sup>**</sup>Teste exato de Fisher.</p>
						</fn>
					</table-wrap-foot>
				</table-wrap>
			</p>
			<p>O modelo ajustado mostrou que o maior peso para o diagnóstico foi apresentado para o grupo caso, de modo que apenas a Anemia Aplástica não apresentou diferença estatística entre os grupos. As outras variáveis testadas relacionaram-se à chance de realizar o RCTH em menor ou maior proporção, de acordo com os resultados apresentados na <xref ref-type="table" rid="t3">Tabela 3</xref>.</p>
			<p>O modelo final de regressão logística múltipla apresentou nível de significância com p-valor &lt;0.05, com evidência estatística de associação para o grupo caso com as variáveis sepse e ácido biliar. Portanto, a chance dos pacientes acometidos por sepse que usaram ácido biliar de serem submetidos a um retransplante foi maior do que entre os pacientes que não desenvolveram sepse e nem usaram tais medicamentos.</p>
			<p>Vale ressaltar que a Hipótese 1 “Variáveis clinicas e sociodemográficas estão associadas com a necessidade de receber um RCTH entre pacientes submetidos a um TCTH”, foi testada e aceita.</p>
			<p>A probabilidade de sobrevida acumulada foi calculada a partir do total de pacientes investigados neste estudo (n = 84), dos quais 49 (58,33%) completaram o tratamento e receberam alta hospitalar, enquanto que 35 (41.67%) evoluíram a óbito. O ponto zero (início) foi considerado a entrada do(a) paciente no serviço em questão para o início do tratamento, e o encerramento foi caracterizado pelo término do tratamento (alta hospitalar) ou óbito. O tempo de sobrevida mínimo foi de 6,67 meses, e o máximo foi 91,7 meses. A média de sobrevida global (SG) foi 26,97 meses e 50% da amostra teve uma SG de 17,55 meses. </p>
			<p>Em geral, quanto maior o número de meses, mais baixa a SG. A <xref ref-type="fig" rid="f2">Figura 2</xref> apresenta a curva de SG do total dos indivíduos analisados neste estudo.</p>
			<p>
				<fig id="f2">
					<label>Figura 2</label>
					<caption>
						<title>Curva de sobrevida global entre os grupos de <italic>caso</italic> e <italic>controle</italic>. Natal, RN, Brasil, 2019 (n=84)</title>
					</caption>
					<graphic xlink:href="1518-8345-rlae-30-e3569-gf2.png"/>
				</fig>
			</p>
			<p>Não houve diferença estatisticamente significante para a SG entre os grupos (<italic>Log-rank</italic> = 0,583). Ao determinar a sobrevida por grupo de estudo, pudemos observar que a curva permaneceu similar para ambos até o desfecho (<xref ref-type="fig" rid="f2">Figura 2</xref>), independente do tratamento ter sido concluído ou evoluído a óbito, com uma pequena diferença para o grupo de controle: a SG do grupo de controle foi até 91,7 meses enquanto que no grupo de caso foi de aproximadamente 80 meses.</p>
		</sec>
		<sec sec-type="discussion">
			<title>Discussão</title>
			<p>O perfil epidemiológico dos pacientes transplantados revela uma discreta predominância do sexo masculino com o diagnóstico de leucemia mielóide aguda, enquanto que a principal causa de morte foi sepse. Os dados sociodemográficos relatados por um estudo multicêntrico conduzido na Europa e que acompanhou retrospectivamente pacientes com recidiva de leucemia aguda após o primeiro TCTH, são similares aos encontrados neste estudo em que a idade média dos pacientes foi de 36.76 anos, 58,04% do sexo masculino; 21% apresentou ± 24 meses de sobrevida; 90% pacientes foram a óbito, e as causas mais frequentes foram doença progressiva em 136 (55,06%), sepse em 34 (13,76%), e DECH em 29 (11.74%) indivíduos<xref ref-type="bibr" rid="B11"><sup>11</sup></xref>.</p>
			<p>O RCTH é considerado um procedimento complexo e agressivo porque expõe os pacientes a um novo regime de condicionamento e toxicidades debilitantes. Assim como no primeiro transplante, esta fase demanda cuidados específicos, tendo uma equipe multidisciplinar oferecendo suporte assistencial durante a hospitalização e no pós-transplante com atendimento ambulatorial. O tratamento é longo e envolve riscos que predispõem o paciente a uma grande grama de complicações que precisam ser administradas de forma a evitar que ameacem a sobrevida e qualidade de vida dos pacientes<xref ref-type="bibr" rid="B12"><sup>12</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B13"><sup>13</sup></xref>.</p>
			<p>Assim como no pós-TCTH, o pós transplante alogênico pode apresentar algumas complicações como por exemplo infecções, toxicidades, DECH e falha do enxerto, que compreendem as principais causas de longos períodos de hospitalização e morte<xref ref-type="bibr" rid="B14"><sup>14</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B15"><sup>15</sup></xref>. Os mecanismos celulares e moleculares que medeiam a rejeição de enxerto também são gatilhos para o desenvolvimento de DECH e o controle é feito com o uso de imunossupressores. Estas intercorrências são relevantes e causam morbidade e mortalidade significantes, limitando o sucesso do transplante, o que pode culminar em RCTH<xref ref-type="bibr" rid="B4"><sup>4</sup></xref>.</p>
			<p>Um estudo<xref ref-type="bibr" rid="B16"><sup>16</sup></xref> relata que a falha do enxerto e recidiva da doença são as principais razões que levam ao retransplante. Os fatores associados à falha do enxerto incluem incompatibilidade de ALH, doença subjacente, tipo de regime de condicionamento, fonte da CPH empregada, baixa dose de CPH, depleção de células T <italic>ex vivo</italic>, incompatibilidade ABO maior, enxertos de doadores do sexo feminino para receptores do sexo masculino, estado da doença no momento do transplante, infecção ou sepse, e não aderência a terapia medicamentosa com ácido ursodesoxicólico e imunossupressores no período pós-TCTH<xref ref-type="bibr" rid="B17"><sup>17</sup></xref>. Os dois últimos foram apontados nos resultados desta pesquisa como fatores que aumentam as chances de retransplante.</p>
			<p>A recaída é a principal causa de falha no tratamento e seu prognóstico é desfavorável<xref ref-type="bibr" rid="B18"><sup>18</sup></xref>. Células malignas podem escapar da lesão citotóxica associada ao regime de condicionamento pré-transplante e ao controle imunológico criado pela reconstituição medular e imune no pós-transplante e causar recidiva da doença que não responde aos quimioterápicos utilizados anteriormente, necessitando de um arsenal de drogas mais citotóxicas<xref ref-type="bibr" rid="B19"><sup>19</sup></xref>.</p>
			<p>O TCTH afeta a microbiota intestinal, microbioma-metaboloma e eixo hepático que podem alterar a homeostase intestinal e a gravidade da DECH<xref ref-type="bibr" rid="B20"><sup>20</sup></xref>. O uso do ácido ursodesoxicólico é considerado útil na profilaxia e tratamento de algumas condições hepáticas, principalmente da DECH por ser um dos motivos que podem levar à necessidade de RCTH de acordo com os resultados apresentados neste estudo. Um estudo retrospectivo investigou o uso do ácido ursodesoxicólico e descobriu uma incidência menor da síndrome de obstrução sinusoidal e outras complicações no fígado<xref ref-type="bibr" rid="B21"><sup>21</sup></xref>.</p>
			<p>O ácido biliar mais utilizado nos protocolos de TCTH é o ursodesoxicólico e seu uso inadequado com doses abaixo da prescrita teve relação direta com retransplantes (OR = 16,12; IC = 95%: 2,05-128,12; p = 0,001) entre os participantes deste estudo com relação aos fatores de proteção contra DECH e outras doenças hepáticas. O fígado é um dos órgãos-alvo da DECH, e mudanças significativas nos níveis séricos de bilirrubina e fosfatase alcalina podem indicar o acometimento dessa condição<xref ref-type="bibr" rid="B22"><sup>22</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref>.</p>
			<p>Os imunossupressores são usados para proteger contra a rejeição do enxerto e a necessidade de RCTH. Neste estudo, o uso inapropriado deste medicamento está relacionado a maiores chances de RCTH (OR = 4,50; IC = 95 %; 1,38-14,69; p = 0,009), sugerindo que doses abaixo da recomendada na prescrição médica aumenta as chances de um novo transplante. Os pacientes que receberam um transplante alogênico, tomaram imunossupressores regularmente, começando com D-1 (um dia antes do procedimento) para evitar a rejeição ou falha do enxerto, e por um longo período depois do TCTH, incluindo inibidores de calcineurina e outros<xref ref-type="bibr" rid="B4"><sup>4</sup></xref>. </p>
			<p>No entanto, a polifarmácia que os pacientes vivenciam por usar diversos medicamentos orais, especialmente na fase ambulatorial do pós-TCTH é um fator limitante que dificulta a aderência ao tratamento de forma apropriada e contínua<xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>. Sem a ingestão correta das doses diárias dos medicamentos, como imunossupressores e ácido ursodesoxicólico, o paciente pode evoluir para a falha do enxerto, recidiva da doença ou DECH, como mostram os resultados deste estudo.</p>
			<p>Estes medicamentos são prescritos para controlar os sintomas, infecções, rejeição do enxerto, e os medicamentos de suporte, entre outros. O esquema terapêutico é complexo devido ao tipo, número e horários diferenciados dos medicamentos, além das mudanças frequentes nas prescrições. Os pacientes e seus familiares assumem o ônus do manejo da polifarmácia depois da alta hospitalar, e a aderência farmacológica é essencial para minimizar as chances de infecção, DECH, ou recidiva da doença<xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>.</p>
			<p>Embora esta estratégia tenha apoiado grandes avanços na medicina moderna de transplantes, especialmente no controle da rejeição aguda, a mesma está ligada a problemas significativos que incluem a toxicidade dos medicamentos e o risco aumentado de infecções oportunistas, entre outros. Além disso, o regime de imunossupressores escolhidos pode ser insuficiente para controlar a rejeição ou falha do enxerto, assim como da DECH. Consequentemente, muitos pacientes precisam de retransplante, o que pode ser um desafio do ponto de vista clínico, que é limitado a baixa disponibilidade de órgãos, tecidos ou células doados<xref ref-type="bibr" rid="B4"><sup>4</sup></xref>.</p>
			<p>Os fatores sociodemográficos como baixa escolaridade e baixo nível socioeconômico, além da falta de suporte social podem estar diretamente relacionados às taxas de infecção, considerando que o paciente pode não entender as orientações para evitar infecções ou não ter as condições econômicas necessárias para continuar com o tratamento. Um estudo conduzido pelos pesquisadores de vários países mostra que 66,49% dos pacientes não aderiram ao tratamento com imunossupressores<xref ref-type="bibr" rid="B27"><sup>27</sup></xref>. </p>
			<p>Dificuldade em aderir ao tratamento farmacológico depois do TCTH tem um impacto negativo significativo na sobrevida, porque aumenta o risco de infecções e a recidiva da doença, duas das razões que apresentaram os maiores <italic>Odds Ratios</italic> para retransplante neste estudo<xref ref-type="bibr" rid="B28"><sup>28</sup></xref>.</p>
			<p>As infecções podem evoluir facilmente para sepse entre candidatos ao TCTH imunossuprimidos<xref ref-type="bibr" rid="B29"><sup>29</sup></xref>. Como mostram os resultados deste estudo, os pacientes com sepse são mais propensos a um retransplante (OR = 6,03; IC = 95%: 1,386-26,205; p = 0,017).</p>
			<p>Muitas vezes, os pacientes não conseguem ingerir os medicamentos orais devido a mucosite orofaríngea, náuseas ou vômitos durante a hospitalização, e os que tem apresentação intravenosa substituem as orais. No entanto, a apresentação farmacêutica do ácido biliar é apenas na forma de comprimidos de 50 mg, 150 mg e 300 mg; os comprimidos de 300 mg são geralmente prescritos a cada 12 horas de acordo com os protocolos de transplante alogênico. Como discutido acima, o acido biliar é um fator protetor contra a DECH hepática, síndrome de obstrução sinusoidal e dislipidemia, entre outras condições que afetam o fígado.</p>
			<p>A recorrência de doenças depois do primeiro TCTH e falha ou rejeição do enxerto normalmente apresentam um prognóstico desfavorável. A tentativa de obter um desfecho melhor para a sobrevida do(a) paciente com a adição de um RCTH aumentou a sobrevida global em 10%. Uma indicação de retransplante concentra-se apenas entre pacientes com doença persistente após o primeiro TCTH e pelos motivos citados acima<xref ref-type="bibr" rid="B5"><sup>5</sup></xref>.</p>
			<p>O RCTH parece uma abordagem pouca promissora, mas existem poucos tratamentos para recidiva após o primeiro transplante como quimioterapia com novas drogas, infusão de linfócitos de doador para transplante alogênico, retransplante ou uma combinação destes. Neste contexto, o RCTH é um tratamento que favorece maior SG<xref ref-type="bibr" rid="B7"><sup>7</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B16"><sup>16</sup></xref>.</p>
			<p>Um estudo americano foi conduzido com crianças e adolescentes com recidiva de leucemia mielóide aguda após o primeiro TCTH e revelou uma sobrevida de 88% em 100 dias, 56% em 12 meses, e 48% em 120 meses. Este achado sugere que o RCTH após insucesso inicial de transplante resultou na sobrevida livre da doença a longo prazo em 50% das crianças com leucemia mielóide aguda recorrente<xref ref-type="bibr" rid="B30"><sup>30</sup></xref>.</p>
			<p>Os pacientes submetidos a um TCTH ou RCTH geralmente demandam cuidado complexo e assistência de enfermagem ao longo de todas as fases, desde a indicação do(a) paciente para realizar o procedimento até a alta hospitalar e seguimento hospitalar. A implantação da Sistematização da Assistência de Enfermagem (SAE) e o cumprimento de todas as suas etapas é urgente neste contexto<xref ref-type="bibr" rid="B31"><sup>31</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B33"><sup>33</sup></xref>, visto que o paciente pode evoluir rapidamente com complicações associadas à doença subjacente ou toxicidades. </p>
			<p>É esperada a promoção de dados que suportem a tomada de decisão e sua implementação adequada na assistência ao paciente para contribuir de forma substancial a prática clinica dos profissionais da saúde, especialmente enfermeiros, para que se tornem profissionais decisivos na prestação de cuidado ao paciente, capazes de reconhecer os possíveis fatores de risco responsáveis por situações de RCTH.</p>
			<p>É importante que a equipe multidisciplinar, especialmente enfermeiros(as), desenvolvam planos de cuidado que apoiem aderência ao tratamento e façam o uso correto das doses de medicamentos, como imunossupressores e ácido ursodesoxicólico, com vistas a minimizar infecções, recidiva da doença, e falha do enxerto, pois estes constituem fatores importantes que levam ao retransplante. </p>
			<p>Além de um plano de cuidados personalizado que atenda as necessidades de saúde de cada paciente é essencial investir no suporte social, o que pode ser representado pela figura da família/cuidador(a) familiar e a equipe de saúde, especialmente a equipe de enfermagem. O trabalho em equipe envolvendo o(a) paciente, o(a) cuidador(a) familiar, e os profissionais de saúde deve ser desenvolvido com vistas a melhorar a qualidade de vida e sobrevida após o retransplante.</p>
			<p>Note que este estudo utilizou uma fonte de dados secundários e, portanto, pode existir algum viés como falta de informação devido a deficiências nos sistemas de informação e registros. Além disso, também enfatizamos o tamanho da amostra e o desenho do estudo, que apesar de atender aos objetivos propostos e responder a questão de pesquisa e hipótese, 84 dos prontuários não padronizaram o contexto do TCTH e RCTH no Brasil, o que impede generalizações e impossibilita análises estatísticas mais elaboradas.</p>
		</sec>
		<sec sec-type="conclusions">
			<title>Conclusão</title>
			<p>Este estudo caso-controle apresentou evidências cientificas sobre a atuação do RCTH com relação ao perfil clinico-epidemiológico, assim como uma comparação dos fatores associados ao procedimento e sobrevida dos pacientes. A conclusão é que o motivo que prediz o retransplante na amostra deste estudo foi a recidiva da doença. As variáveis clínicas da sepse e ácido biliar mostraram uma relação direta e o <italic>Odds Ratio</italic> com retransplante. Os fatores sociodemográficos também estão relacionados ao RCTH, especialmente em relação a importância de aderir ao tratamento, na fase intra-hospitalar e após o TCTH.</p>
		</sec>
	</body>
	<back>
		<ack>
			<title>Agradecimentos</title>
			<p>A equipe de pesquisadores agradece ao Hospital Rio Grande por consentir e autorizar a condução desta pesquisa, assim como aos pacientes que concordaram em participar deste estudo, e sua relevante contribuição à ciência.</p>
		</ack>
		<ref-list>
			<title>Referências</title>
			<ref id="B1">
				<label>1</label>
				<mixed-citation>1. Fernandes JF, Bonfim C. Hematopoietic stem cell transplantation for Inborn Errors of Immunity. JBMTCT [Internet]. 2021 [cited 2020 Jul 30];2(4):104-8. Available from: https://doi.org/10.46765/2675-374X.2021v2n4p146</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Fernandes</surname>
							<given-names>JF</given-names>
						</name>
						<name>
							<surname>Bonfim</surname>
							<given-names>C</given-names>
						</name>
					</person-group>
					<article-title>Hematopoietic stem cell transplantation for Inborn Errors of Immunity</article-title>
					<source>JBMTCT</source>
					<comment>Internet</comment>
					<year>2021</year>
					<date-in-citation content-type="access-date" iso-8601-date="2020-07-30">2020 Jul 30</date-in-citation>
					<volume>2</volume>
					<issue>4</issue>
					<fpage>104</fpage>
					<lpage>108</lpage>
					<pub-id pub-id-type="doi">https://doi.org/10.46765/2675-374X.2021v2n4p146</pub-id>
				</element-citation>
			</ref>
			<ref id="B2">
				<label>2</label>
				<mixed-citation>2. Azevedo IC, MA Ferreira Júnior , Aquino LAP, Oliveira AA, Cruz GKP, Cardoso AIQ, et al. Epidemiologic Profile of Patients Transplanted with Hematopoietic Stem Cells in a Reference Service in the State of Rio Grande do Norte, Brazil. Transplant Proc [Internet]. 2018 [cited 2019 Oct 11];50(3):819-23. doi: https://doi.org/10.1016/j.transproceed.2018.02.015</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Azevedo</surname>
							<given-names>IC</given-names>
						</name>
						<name>
							<surname>Ferreira</surname>
							<given-names>MA</given-names>
							<suffix>Júnior</suffix>
						</name>
						<name>
							<surname>Aquino</surname>
							<given-names>LAP</given-names>
						</name>
						<name>
							<surname>Oliveira</surname>
							<given-names>AA</given-names>
						</name>
						<name>
							<surname>Cruz</surname>
							<given-names>GKP</given-names>
						</name>
						<name>
							<surname>Cardoso</surname>
							<given-names>AIQ</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Epidemiologic Profile of Patients Transplanted with Hematopoietic Stem Cells in a Reference Service in the State of Rio Grande do Norte, Brazil</article-title>
					<source>Transplant Proc</source>
					<comment>Internet</comment>
					<year>2018</year>
					<date-in-citation content-type="access-date" iso-8601-date="2019-10-11">2019 Oct 11</date-in-citation>
					<volume>50</volume>
					<issue>3</issue>
					<fpage>819</fpage>
					<lpage>823</lpage>
					<pub-id pub-id-type="doi">https://doi.org/10.1016/j.transproceed.2018.02.015</pub-id>
				</element-citation>
			</ref>
			<ref id="B3">
				<label>3</label>
				<mixed-citation>3. Sarmiento M, Ramirez P, Jara V, Bertin P, Galleguillos M, Rodriguez I, et al. Haploidentical transplantation outcomes are comparable with those obtained with identical human leukocyte antigen allogeneic transplantation in Chilean patients with benign and malignant hemopathies. Hematol Transfus Cell Ther [Internet]. 2020 [cited 2020 Jun 21];42(1):40-5. Available from: https://doi.org/10.1016/j.htct.2019.01.010</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Sarmiento</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Ramirez</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Jara</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>Bertin</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Galleguillos</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Rodriguez</surname>
							<given-names>I</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Haploidentical transplantation outcomes are comparable with those obtained with identical human leukocyte antigen allogeneic transplantation in Chilean patients with benign and malignant hemopathies</article-title>
					<source>Hematol Transfus Cell Ther</source>
					<comment>Internet</comment>
					<year>2020</year>
					<date-in-citation content-type="access-date" iso-8601-date="2020-06-21">2020 Jun 21</date-in-citation>
					<volume>42</volume>
					<issue>1</issue>
					<fpage>40</fpage>
					<lpage>45</lpage>
					<pub-id pub-id-type="doi">https://doi.org/10.1016/j.htct.2019.01.010</pub-id>
				</element-citation>
			</ref>
			<ref id="B4">
				<label>4</label>
				<mixed-citation>4. Thangavelu G, Blazar BR. Achievement of tolerance induction to prevent acute graft-vs.-host disease. Front Immunol [Internet]. 2019 [cited 2019 Oct 11];10:319. Available from: https://doi.org/10.3389/fimmu.2019.00309</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Thangavelu</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Blazar</surname>
							<given-names>BR</given-names>
						</name>
					</person-group>
					<article-title>Achievement of tolerance induction to prevent acute graft-vs.-host disease</article-title>
					<source>Front Immunol</source>
					<comment>Internet</comment>
					<year>2019</year>
					<date-in-citation content-type="access-date" iso-8601-date="2019-10-11">2019 Oct 11</date-in-citation>
					<volume>10</volume>
					<fpage>319</fpage>
					<lpage>319</lpage>
					<pub-id pub-id-type="doi">https://doi.org/10.3389/fimmu.2019.00309</pub-id>
				</element-citation>
			</ref>
			<ref id="B5">
				<label>5</label>
				<mixed-citation>5. Burt RK, Balabanov R, Burman J, Sharrack B, Snowden JA, Oliveira MC, et al. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA [Internet]. 2019 [cited 2020 May 15];321(2):165-74. Available from: https://doi.org/10.1001/jama.2018.18743</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Burt</surname>
							<given-names>RK</given-names>
						</name>
						<name>
							<surname>Balabanov</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Burman</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Sharrack</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Snowden</surname>
							<given-names>JA</given-names>
						</name>
						<name>
							<surname>Oliveira</surname>
							<given-names>MC</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial</article-title>
					<source>JAMA</source>
					<comment>Internet</comment>
					<year>2019</year>
					<date-in-citation content-type="access-date" iso-8601-date="2020-05-15">2020 May 15</date-in-citation>
					<volume>321</volume>
					<issue>2</issue>
					<fpage>165</fpage>
					<lpage>174</lpage>
					<pub-id pub-id-type="doi">https://doi.org/10.1001/jama.2018.18743</pub-id>
				</element-citation>
			</ref>
			<ref id="B6">
				<label>6</label>
				<mixed-citation>6. Hierlmeier S, Wölfl M, Schlegel PG, Wiegering V. Early and late complications following hematopoietic stem cell transplantation in pediatric patients - A retrospective analysis over 11 years. PLoS One [Internet]. 2018 [cited 2021 Dec 26];13(10):e0204914. Available from: https://doi.org/10.1371/journal.pone.0204914</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Hierlmeier</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Wölfl</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Schlegel</surname>
							<given-names>PG</given-names>
						</name>
						<name>
							<surname>Wiegering</surname>
							<given-names>V</given-names>
						</name>
					</person-group>
					<article-title>Early and late complications following hematopoietic stem cell transplantation in pediatric patients - A retrospective analysis over 11 years</article-title>
					<source>PLoS One</source>
					<comment>Internet</comment>
					<year>2018</year>
					<date-in-citation content-type="access-date" iso-8601-date="2021-12-26">2021 Dec 26</date-in-citation>
					<volume>13</volume>
					<issue>10</issue>
					<elocation-id>e0204914</elocation-id>
					<pub-id pub-id-type="doi">https://doi.org/10.1371/journal.pone.0204914</pub-id>
				</element-citation>
			</ref>
			<ref id="B7">
				<label>7</label>
				<mixed-citation>7. Azevedo IC, Bezerril MS, Soares RDA, Vitor AF, Nascimento AAA, Azevedo VD, et al. Hematopoietic stem cell retransplantation: concept analysis and development from Rodgers' evolutionary perspective. Res Society Develop [Internet]. 2021 [cited 2021 Dec 24];10(16):e382101623995. Available from: https://doi.org/10.33448/rsd-v10i16.23995</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Azevedo</surname>
							<given-names>IC</given-names>
						</name>
						<name>
							<surname>Bezerril</surname>
							<given-names>MS</given-names>
						</name>
						<name>
							<surname>Soares</surname>
							<given-names>RDA</given-names>
						</name>
						<name>
							<surname>Vitor</surname>
							<given-names>AF</given-names>
						</name>
						<name>
							<surname>Nascimento</surname>
							<given-names>AAA</given-names>
						</name>
						<name>
							<surname>Azevedo</surname>
							<given-names>VD</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Hematopoietic stem cell retransplantation: concept analysis and development from Rodgers' evolutionary perspective</article-title>
					<source>Res Society Develop</source>
					<comment>Internet</comment>
					<year>2021</year>
					<date-in-citation content-type="access-date" iso-8601-date="2021-12-24">2021 Dec 24</date-in-citation>
					<volume>10</volume>
					<issue>16</issue>
					<elocation-id>e382101623995</elocation-id>
					<pub-id pub-id-type="doi">https://doi.org/10.33448/rsd-v10i16.23995</pub-id>
				</element-citation>
			</ref>
			<ref id="B8">
				<label>8</label>
				<mixed-citation>8. Yaniv I, Krauss AC, Beohou E, Varotto S, Peters C, Bader P. Second hematopoietic stem cell transplantation for post-transplantation relapsed acute leukemia in children: a retrospective EBMT-PDWP study. Biol Blood Marrow Transplant [Internet]. 2018 [cited 2021 Dec 31];24(8):1629-42. Available from: https://doi.org/10.1016/j.bbmt.2018.03.002</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Yaniv</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Krauss</surname>
							<given-names>AC</given-names>
						</name>
						<name>
							<surname>Beohou</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Varotto</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Peters</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Bader</surname>
							<given-names>P</given-names>
						</name>
					</person-group>
					<article-title>Second hematopoietic stem cell transplantation for post-transplantation relapsed acute leukemia in children: a retrospective EBMT-PDWP study</article-title>
					<source>Biol Blood Marrow Transplant</source>
					<comment>Internet</comment>
					<year>2018</year>
					<date-in-citation content-type="access-date" iso-8601-date="2021-12-31">2021 Dec 31</date-in-citation>
					<volume>24</volume>
					<issue>8</issue>
					<fpage>1629</fpage>
					<lpage>1642</lpage>
					<pub-id pub-id-type="doi">https://doi.org/10.1016/j.bbmt.2018.03.002</pub-id>
				</element-citation>
			</ref>
			<ref id="B9">
				<label>9</label>
				<mixed-citation>9. Rodrigues JAP, Stelmatchuk AM, Lacerda MR, Galvao CM. Covid-19 containment measures adopted in bone marrow transplantation service. Rev Bras Enferm [Internet]. 2020 [cited 2020 Sep 27];73(2). Available from: https://doi.org/10.1590/0034-7167-2020-0476</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Rodrigues</surname>
							<given-names>JAP</given-names>
						</name>
						<name>
							<surname>Stelmatchuk</surname>
							<given-names>AM</given-names>
						</name>
						<name>
							<surname>Lacerda</surname>
							<given-names>MR</given-names>
						</name>
						<name>
							<surname>Galvao</surname>
							<given-names>CM</given-names>
						</name>
					</person-group>
					<article-title>Covid-19 containment measures adopted in bone marrow transplantation service</article-title>
					<source>Rev Bras Enferm</source>
					<comment>Internet</comment>
					<year>2020</year>
					<date-in-citation content-type="access-date" iso-8601-date="2020-09-27">2020 Sep 27</date-in-citation>
					<volume>73</volume>
					<issue>2</issue>
					<pub-id pub-id-type="doi">https://doi.org/10.1590/0034-7167-2020-0476</pub-id>
				</element-citation>
			</ref>
			<ref id="B10">
				<label>10</label>
				<mixed-citation>10. Ministério da Saúde (BR), Conselho Nacional de Saúde. Resolução Nº 466, de 12 de dezembro de 2012. Regulamenta a pesquisa com seres humanos no Brasil [Internet]. Diário Oficial da União, 13 de junho de 2013 [cited 2018 Oct 01]. <comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://bvsms.saude.gov.br/bvs/saudelegis/cns/2013/res0466_12_12_2012.html">http://bvsms.saude.gov.br/bvs/saudelegis/cns/2013/res0466_12_12_2012.html</ext-link>
					</comment>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<collab>Ministério da Saúde (BR), Conselho Nacional de Saúde</collab>
					</person-group>
					<article-title>Resolução Nº 466, de 12 de dezembro de 2012. Regulamenta a pesquisa com seres humanos no Brasil</article-title>
					<comment>Internet</comment>
					<source>Diário Oficial da União</source>
					<year>2013</year>
					<date-in-citation content-type="access-date" iso-8601-date="2018-10-01">2018 Oct 01</date-in-citation>
					<comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://bvsms.saude.gov.br/bvs/saudelegis/cns/2013/res0466_12_12_2012.html">http://bvsms.saude.gov.br/bvs/saudelegis/cns/2013/res0466_12_12_2012.html</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B11">
				<label>11</label>
				<mixed-citation>11. Andreola G, Labopin M, Beelen D, Chevallier P, Tabrizi R, Bosi A, et al. Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of =10 years. Bone Marrow Transplant [Internet]. 2015 [cited 2019 Sep 27];50:1508-12. Available from: https://doi.org/10.1038/bmt.2015.193</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Andreola</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Labopin</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Beelen</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Chevallier</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Tabrizi</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Bosi</surname>
							<given-names>A</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of =10 years</article-title>
					<source>Bone Marrow Transplant</source>
					<comment>Internet</comment>
					<year>2015</year>
					<date-in-citation content-type="access-date" iso-8601-date="2019-09-27">2019 Sep 27</date-in-citation>
					<volume>50</volume>
					<fpage>1508</fpage>
					<lpage>1512</lpage>
					<pub-id pub-id-type="doi">https://doi.org/10.1038/bmt.2015.193</pub-id>
				</element-citation>
			</ref>
			<ref id="B12">
				<label>12</label>
				<mixed-citation>12. Silva D, J Zanis Neto , Dóro MP, Menegatti CL. Narrative review about psychological assessment in hematopoietic stem cell pre-transplant patients. Braz J Develop [Internet]. 2021 [cited 2021 Apr 01];7(2):16048-69. <comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://www.brazilianjournals.com/index.php/BRJD/article/view/24787/19765">https://www.brazilianjournals.com/index.php/BRJD/article/view/24787/19765</ext-link>
					</comment>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Silva</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Zanis</surname>
							<given-names>J</given-names>
							<suffix>Neto</suffix>
						</name>
						<name>
							<surname>Dóro</surname>
							<given-names>MP</given-names>
						</name>
						<name>
							<surname>Menegatti</surname>
							<given-names>CL</given-names>
						</name>
					</person-group>
					<article-title>Narrative review about psychological assessment in hematopoietic stem cell pre-transplant patients</article-title>
					<source>Braz J Develop</source>
					<comment>Internet</comment>
					<year>2021</year>
					<date-in-citation content-type="access-date" iso-8601-date="2021-04-01">2021 Apr 01</date-in-citation>
					<volume>7</volume>
					<issue>2</issue>
					<fpage>16048</fpage>
					<lpage>16069</lpage>
					<comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://www.brazilianjournals.com/index.php/BRJD/article/view/24787/19765">https://www.brazilianjournals.com/index.php/BRJD/article/view/24787/19765</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B13">
				<label>13</label>
				<mixed-citation>13. Gomes IM, Lacerda MR, Hermann AP, Rodrigues JAP, Zatoni DCP, Tonin L. Care performed by family caregivers of children submitted to hematopoietic stem cell transplantation. Rev. Latino-Am. Enfermagem [Internet]. 2019 [cited 2021 Sep 29];27:e3120. Available from: https://doi.org/10.1590/1518-8345.2298-3120</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Gomes</surname>
							<given-names>IM</given-names>
						</name>
						<name>
							<surname>Lacerda</surname>
							<given-names>MR</given-names>
						</name>
						<name>
							<surname>Hermann</surname>
							<given-names>AP</given-names>
						</name>
						<name>
							<surname>Rodrigues</surname>
							<given-names>JAP</given-names>
						</name>
						<name>
							<surname>Zatoni</surname>
							<given-names>DCP</given-names>
						</name>
						<name>
							<surname>Tonin</surname>
							<given-names>L</given-names>
						</name>
					</person-group>
					<article-title>Care performed by family caregivers of children submitted to hematopoietic stem cell transplantation</article-title>
					<source>Rev. Latino-Am. Enfermagem</source>
					<comment>Internet</comment>
					<year>2019</year>
					<date-in-citation content-type="access-date" iso-8601-date="2021-09-29">2021 Sep 29</date-in-citation>
					<volume>27</volume>
					<elocation-id>e3120</elocation-id>
					<pub-id pub-id-type="doi">https://doi.org/10.1590/1518-8345.2298-3120</pub-id>
				</element-citation>
			</ref>
			<ref id="B14">
				<label>14</label>
				<mixed-citation>14. Russo R, Mendes ET, Levin AS, Dulley F, Oliveira MS, Yasuda MAS, et al. Bloodstream infection in hematopoietic stem cell transplantation outpatients: risk factors for hospitalization and death. Rev Inst Med Trop São Paulo [Internet]. 2019 [cited 2019 Oct 9];61. Available from: https://doi.org/10.1590/S1678-9946201961003</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Russo</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Mendes</surname>
							<given-names>ET</given-names>
						</name>
						<name>
							<surname>Levin</surname>
							<given-names>AS</given-names>
						</name>
						<name>
							<surname>Dulley</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Oliveira</surname>
							<given-names>MS</given-names>
						</name>
						<name>
							<surname>Yasuda</surname>
							<given-names>MAS</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Bloodstream infection in hematopoietic stem cell transplantation outpatients: risk factors for hospitalization and death</article-title>
					<source>Rev Inst Med Trop São Paulo</source>
					<comment>Internet</comment>
					<year>2019</year>
					<date-in-citation content-type="access-date" iso-8601-date="2019-10-09">2019 Oct 9</date-in-citation>
					<volume>61</volume>
					<pub-id pub-id-type="doi">https://doi.org/10.1590/S1678-9946201961003</pub-id>
				</element-citation>
			</ref>
			<ref id="B15">
				<label>15</label>
				<mixed-citation>15. Styczynski J, Tridello G, Koster L, Iacobelli S, Biezen AV, van der Werf S, at el. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. Bone Marrow Transplant [Internet]. 2020 [cited 2020 Oct 9];54(8). Available from: https://doi.org/10.1038/s41409-019-0624-z</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Styczynski</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Tridello</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Koster</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Iacobelli</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Biezen</surname>
							<given-names>AV</given-names>
						</name>
						<name>
							<surname>van der Werf</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>el</surname>
							<given-names>at</given-names>
						</name>
					</person-group>
					<article-title>Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors</article-title>
					<source>Bone Marrow Transplant</source>
					<comment>Internet</comment>
					<year>2020</year>
					<date-in-citation content-type="access-date" iso-8601-date="2020-10-09">2020 Oct 9</date-in-citation>
					<volume>54</volume>
					<issue>8</issue>
					<pub-id pub-id-type="doi">https://doi.org/10.1038/s41409-019-0624-z</pub-id>
				</element-citation>
			</ref>
			<ref id="B16">
				<label>16</label>
				<mixed-citation>16. Vaht K, Göransson M, Carlson K, Ljungman P, Andersson PO, Brune M. High Graft-versus-host disease-free, relapse/rejection-free survival and similar outcome of related and unrelated allogeneic stem cell transplantation for aplastic anemia: a nationwide Swedish cohort study. Biol Blood Marrow Transplant [Internet]. 2019 [cited 2021 Oct 4];25(10):1970-4. Available from: https://doi.org/10.1016/j.bbmt.2019.05.032</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Vaht</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Göransson</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Carlson</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Ljungman</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Andersson</surname>
							<given-names>PO</given-names>
						</name>
						<name>
							<surname>Brune</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<article-title>High Graft-versus-host disease-free, relapse/rejection-free survival and similar outcome of related and unrelated allogeneic stem cell transplantation for aplastic anemia: a nationwide Swedish cohort study</article-title>
					<source>Biol Blood Marrow Transplant</source>
					<comment>Internet</comment>
					<year>2019</year>
					<date-in-citation content-type="access-date" iso-8601-date="2021-10-04">2021 Oct 4</date-in-citation>
					<volume>25</volume>
					<issue>10</issue>
					<fpage>1970</fpage>
					<lpage>1974</lpage>
					<pub-id pub-id-type="doi">https://doi.org/10.1016/j.bbmt.2019.05.032</pub-id>
				</element-citation>
			</ref>
			<ref id="B17">
				<label>17</label>
				<mixed-citation>17. Sun YQ, Wang Y, Wang FR, Yan CH, Cheng YF, Chen YH, et al. Graft failure in patients with hematological malignancies: a successful salvage with a second transplantation from a different haploidentical donor. Front Med (Lausanne) [Internet]. 2021 [cited 2021 Oct 4];8:604085. Available from: https://doi.org/10.3389/fmed.2021.604085</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Sun</surname>
							<given-names>YQ</given-names>
						</name>
						<name>
							<surname>Wang</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Wang</surname>
							<given-names>FR</given-names>
						</name>
						<name>
							<surname>Yan</surname>
							<given-names>CH</given-names>
						</name>
						<name>
							<surname>Cheng</surname>
							<given-names>YF</given-names>
						</name>
						<name>
							<surname>Chen</surname>
							<given-names>YH</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Graft failure in patients with hematological malignancies: a successful salvage with a second transplantation from a different haploidentical donor</article-title>
					<source>Front Med (Lausanne)</source>
					<comment>Internet</comment>
					<year>2021</year>
					<date-in-citation content-type="access-date" iso-8601-date="2021-10-04">2021 Oct 4</date-in-citation>
					<volume>8</volume>
					<elocation-id>604085</elocation-id>
					<pub-id pub-id-type="doi">https://doi.org/10.3389/fmed.2021.604085</pub-id>
				</element-citation>
			</ref>
			<ref id="B18">
				<label>18</label>
				<mixed-citation>18. Rautenberg C, Germing U, Haas R, Kobbe G, Schroeder T. Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: prevention, detection, and treatment. Int J Mol Sci [Internet]. 2019 [cited 2019 Oct 4];20(1):1-20. Available from: https://doi.org/10.3390/ijms20010228</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Rautenberg</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Germing</surname>
							<given-names>U</given-names>
						</name>
						<name>
							<surname>Haas</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Kobbe</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Schroeder</surname>
							<given-names>T</given-names>
						</name>
					</person-group>
					<article-title>Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: prevention, detection, and treatment</article-title>
					<source>Int J Mol Sci</source>
					<comment>Internet</comment>
					<year>2019</year>
					<date-in-citation content-type="access-date" iso-8601-date="2019-10-04">2019 Oct 4</date-in-citation>
					<volume>20</volume>
					<issue>1</issue>
					<fpage>1</fpage>
					<lpage>20</lpage>
					<pub-id pub-id-type="doi">https://doi.org/10.3390/ijms20010228</pub-id>
				</element-citation>
			</ref>
			<ref id="B19">
				<label>19</label>
				<mixed-citation>19. Elmariah H, Brunstein CG, Bejanyan N. Immune reconstitution after haploidentical donor and umbilical cord blood allogeneic hematopoietic cell transplantation. Life [Internet]. 2021 [cited 2021 Oct 3];11(2):102. Available from: https://doi.org/10.3390/life11020102</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Elmariah</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Brunstein</surname>
							<given-names>CG</given-names>
						</name>
						<name>
							<surname>Bejanyan</surname>
							<given-names>N</given-names>
						</name>
					</person-group>
					<article-title>Immune reconstitution after haploidentical donor and umbilical cord blood allogeneic hematopoietic cell transplantation</article-title>
					<source>Life</source>
					<comment>Internet</comment>
					<year>2021</year>
					<date-in-citation content-type="access-date" iso-8601-date="2021-10-03">2021 Oct 3</date-in-citation>
					<volume>11</volume>
					<issue>2</issue>
					<fpage>102</fpage>
					<lpage>102</lpage>
					<pub-id pub-id-type="doi">https://doi.org/10.3390/life11020102</pub-id>
				</element-citation>
			</ref>
			<ref id="B20">
				<label>20</label>
				<mixed-citation>20. Fujiwara H. Crosstalk between intestinal microbiota derived metabolites and tissues in allogeneic hematopoietic cell transplantation. Front Immunol [Internet]. 2021 [cited 2021 Dec 30];12:e703298. Available from: https://doi.org/10.3389/fimmu.2021.703298</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Fujiwara</surname>
							<given-names>H</given-names>
						</name>
					</person-group>
					<article-title>Crosstalk between intestinal microbiota derived metabolites and tissues in allogeneic hematopoietic cell transplantation</article-title>
					<source>Front Immunol</source>
					<comment>Internet</comment>
					<year>2021</year>
					<date-in-citation content-type="access-date" iso-8601-date="2021-12-30">2021 Dec 30</date-in-citation>
					<volume>12</volume>
					<elocation-id>e703298</elocation-id>
					<pub-id pub-id-type="doi">https://doi.org/10.3389/fimmu.2021.703298</pub-id>
				</element-citation>
			</ref>
			<ref id="B21">
				<label>21</label>
				<mixed-citation>21. El-Serafi I, Remberger M, Ringdèn O, Törlén J, Sundin M, Björklund A, et al. Reduced risk of sinusoidal obstruction syndrome of the liver after busulfan-cyclophosphamide conditioning prior to allogeneic hematopoietic stem cell transplantation. Clin Transl Sci [Internet]. 2020 [cited 2020 Oct 9];13(2):293-300. Available from: https://doi.org/10.1111/cts.12709</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>El-Serafi</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Remberger</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Ringdèn</surname>
							<given-names>O</given-names>
						</name>
						<name>
							<surname>Törlén</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Sundin</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Björklund</surname>
							<given-names>A</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Reduced risk of sinusoidal obstruction syndrome of the liver after busulfan-cyclophosphamide conditioning prior to allogeneic hematopoietic stem cell transplantation</article-title>
					<source>Clin Transl Sci</source>
					<comment>Internet</comment>
					<year>2020</year>
					<date-in-citation content-type="access-date" iso-8601-date="2020-10-09">2020 Oct 9</date-in-citation>
					<volume>13</volume>
					<issue>2</issue>
					<fpage>293</fpage>
					<lpage>300</lpage>
					<pub-id pub-id-type="doi">https://doi.org/10.1111/cts.12709</pub-id>
				</element-citation>
			</ref>
			<ref id="B22">
				<label>22</label>
				<mixed-citation>22. Pereira AZ, Vigorito AC, Almeida AM, Candolo AA, Silva ACL, Brandão-Anjos AEP, et al. Brazilian nutritional consensus in hematopoietic stem cell transplantation: graft-versus-host disease. Einstein (São Paulo) [Internet]. 2020 [cited 2021 Oct 4];18:1-20. Available from: https://doi.org/10.31744/einstein_journal/2020AE4799</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Pereira</surname>
							<given-names>AZ</given-names>
						</name>
						<name>
							<surname>Vigorito</surname>
							<given-names>AC</given-names>
						</name>
						<name>
							<surname>Almeida</surname>
							<given-names>AM</given-names>
						</name>
						<name>
							<surname>Candolo</surname>
							<given-names>AA</given-names>
						</name>
						<name>
							<surname>Silva</surname>
							<given-names>ACL</given-names>
						</name>
						<name>
							<surname>Brandão-Anjos</surname>
							<given-names>AEP</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Brazilian nutritional consensus in hematopoietic stem cell transplantation: graft-versus-host disease</article-title>
					<source>Einstein (São Paulo)</source>
					<comment>Internet</comment>
					<year>2020</year>
					<date-in-citation content-type="access-date" iso-8601-date="2021-10-04">2021 Oct 4</date-in-citation>
					<volume>18</volume>
					<fpage>1</fpage>
					<lpage>20</lpage>
					<pub-id pub-id-type="doi">https://doi.org/10.31744/einstein_journal/2020AE4799</pub-id>
				</element-citation>
			</ref>
			<ref id="B23">
				<label>23</label>
				<mixed-citation>23. Mohty M, Malard F, Abecasis M, Aerts E, Alaskar AS, Aljurf M, et al. Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. Bone Marrow Transplant . [Internet]. 2020 [cited 2020 Oct 9];55:485-95. Available from: https://doi.org/10.1038/s41409-019-0705-z</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Mohty</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Malard</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Abecasis</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Aerts</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Alaskar</surname>
							<given-names>AS</given-names>
						</name>
						<name>
							<surname>Aljurf</surname>
							<given-names>M</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group</article-title>
					<source>Bone Marrow Transplant</source>
					<comment>Internet</comment>
					<year>2020</year>
					<date-in-citation content-type="access-date" iso-8601-date="2020-10-09">2020 Oct 9</date-in-citation>
					<volume>55</volume>
					<fpage>485</fpage>
					<lpage>495</lpage>
					<pub-id pub-id-type="doi">https://doi.org/10.1038/s41409-019-0705-z</pub-id>
				</element-citation>
			</ref>
			<ref id="B24">
				<label>24</label>
				<mixed-citation>24. Michonneau D, Latis E, Curis E, Dubouchet L, Ramamoorthy S, Ingram B, et al. Metabolomics analysis of human acute graft-versus-host disease reveals changes in host and microbiota-derived metabolites. Nature Commun [Internet]. 2019 [cited 2021 Dec 30];10:e5695. Available from: https://doi.org/10.1038/s41467-019-13498-3</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Michonneau</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Latis</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Curis</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Dubouchet</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Ramamoorthy</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Ingram</surname>
							<given-names>B</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Metabolomics analysis of human acute graft-versus-host disease reveals changes in host and microbiota-derived metabolites</article-title>
					<source>Nature Commun</source>
					<comment>Internet</comment>
					<year>2019</year>
					<date-in-citation content-type="access-date" iso-8601-date="2021-12-30">2021 Dec 30</date-in-citation>
					<volume>10</volume>
					<elocation-id>e5695</elocation-id>
					<pub-id pub-id-type="doi">https://doi.org/10.1038/s41467-019-13498-3</pub-id>
				</element-citation>
			</ref>
			<ref id="B25">
				<label>25</label>
				<mixed-citation>25. Ribaut J, Leppla L, Teynor A, Valenta S, Dobbels F, Zullig LL, et al. Theory-driven development of a medication adherence intervention delivered by eHealth and transplant team in allogeneic stem cell transplantation: the SMILe implementation science project. BMC Health Serv Res [Internet]. 2020 [cited 2021 Oct 11];20(827). Available from: https://doi.org/10.1186/s12913-020-05636-1</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ribaut</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Leppla</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Teynor</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Valenta</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Dobbels</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Zullig</surname>
							<given-names>LL</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Theory-driven development of a medication adherence intervention delivered by eHealth and transplant team in allogeneic stem cell transplantation: the SMILe implementation science project</article-title>
					<source>BMC Health Serv Res</source>
					<comment>Internet</comment>
					<year>2020</year>
					<date-in-citation content-type="access-date" iso-8601-date="2021-10-11">2021 Oct 11</date-in-citation>
					<volume>20</volume>
					<issue>827</issue>
					<pub-id pub-id-type="doi">https://doi.org/10.1186/s12913-020-05636-1</pub-id>
				</element-citation>
			</ref>
			<ref id="B26">
				<label>26</label>
				<mixed-citation>26. Ice LL, Bartoo GT, McCullough KB, Wolf RC, Dierkhising RA, Mara KC, et al. A prospective survey of outpatient medication adherence in adult allogeneic hematopoietic stem cell transplantation patients. Biol Blood Marrow Transplant [Internet]. 2020 [cited 2021 Jan 01];26(9):1627-34. Available from: https://doi.org/10.1016/j.bbmt.2020.05.020</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ice</surname>
							<given-names>LL</given-names>
						</name>
						<name>
							<surname>Bartoo</surname>
							<given-names>GT</given-names>
						</name>
						<name>
							<surname>McCullough</surname>
							<given-names>KB</given-names>
						</name>
						<name>
							<surname>Wolf</surname>
							<given-names>RC</given-names>
						</name>
						<name>
							<surname>Dierkhising</surname>
							<given-names>RA</given-names>
						</name>
						<name>
							<surname>Mara</surname>
							<given-names>KC</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>A prospective survey of outpatient medication adherence in adult allogeneic hematopoietic stem cell transplantation patients</article-title>
					<source>Biol Blood Marrow Transplant</source>
					<comment>Internet</comment>
					<year>2020</year>
					<date-in-citation content-type="access-date" iso-8601-date="2021-01-01">2021 Jan 01</date-in-citation>
					<volume>26</volume>
					<issue>9</issue>
					<fpage>1627</fpage>
					<lpage>1634</lpage>
					<pub-id pub-id-type="doi">https://doi.org/10.1016/j.bbmt.2020.05.020</pub-id>
				</element-citation>
			</ref>
			<ref id="B27">
				<label>27</label>
				<mixed-citation>27. Song Y, Chen S, Roseman J, Scigliano E, Redd WH, Stadler G. It takes a team to make it through: the role of social support for survival and self-care after allogeneic hematopoietic stem cell transplant. Front Psychol [Internet]. 2021 [cited 2022 Jan 01];12:624906. Available from: https://doi.org/10.3389/fpsyg.2021.624906</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Song</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Chen</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Roseman</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Scigliano</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Redd</surname>
							<given-names>WH</given-names>
						</name>
						<name>
							<surname>Stadler</surname>
							<given-names>G</given-names>
						</name>
					</person-group>
					<article-title>It takes a team to make it through: the role of social support for survival and self-care after allogeneic hematopoietic stem cell transplant</article-title>
					<source>Front Psychol</source>
					<comment>Internet</comment>
					<year>2021</year>
					<date-in-citation content-type="access-date" iso-8601-date="2022-01-01">2022 Jan 01</date-in-citation>
					<volume>12</volume>
					<elocation-id>624906</elocation-id>
					<pub-id pub-id-type="doi">https://doi.org/10.3389/fpsyg.2021.624906</pub-id>
				</element-citation>
			</ref>
			<ref id="B28">
				<label>28</label>
				<mixed-citation>28. García-Basas L, Sánchez-Cuervo M, Silanes EGSL, Pueyo-López C, Núñez-Torrón-Stock C, Herrera-Puente P. Evaluation of adherence and clinical outcomes in patients undergoing allogeneic haematopoietic stem cell transplantation. Farmacia Hospitalaria [Internet]. 2020 [cited 2021 Oct 13];44(3):87-91. Available from: https://doi.org/10.7399/fh.11352</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>García-Basas</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Sánchez-Cuervo</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Silanes</surname>
							<given-names>EGSL</given-names>
						</name>
						<name>
							<surname>Pueyo-López</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Núñez-Torrón-Stock</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Herrera-Puente</surname>
							<given-names>P</given-names>
						</name>
					</person-group>
					<article-title>Evaluation of adherence and clinical outcomes in patients undergoing allogeneic haematopoietic stem cell transplantation</article-title>
					<source>Farmacia Hospitalaria</source>
					<comment>Internet</comment>
					<year>2020</year>
					<date-in-citation content-type="access-date" iso-8601-date="2021-10-13">2021 Oct 13</date-in-citation>
					<volume>44</volume>
					<issue>3</issue>
					<fpage>87</fpage>
					<lpage>91</lpage>
					<pub-id pub-id-type="doi">https://doi.org/10.7399/fh.11352</pub-id>
				</element-citation>
			</ref>
			<ref id="B29">
				<label>29</label>
				<mixed-citation>29. Ferdjallah A, Young JAH, MacMillan ML. A Review of infections after hematopoietic cell transplantation requiring picu care: transplant timeline is key. Front Pediatr [Internet]. 2021 [cited 2021 Oct 13];9:634449. Available from: https://doi.org/10.3389/fped.2021.634449</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ferdjallah</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Young</surname>
							<given-names>JAH</given-names>
						</name>
						<name>
							<surname>MacMillan</surname>
							<given-names>ML</given-names>
						</name>
					</person-group>
					<article-title>A Review of infections after hematopoietic cell transplantation requiring picu care: transplant timeline is key</article-title>
					<source>Front Pediatr</source>
					<comment>Internet</comment>
					<year>2021</year>
					<date-in-citation content-type="access-date" iso-8601-date="2021-10-13">2021 Oct 13</date-in-citation>
					<volume>9</volume>
					<elocation-id>634449</elocation-id>
					<pub-id pub-id-type="doi">https://doi.org/10.3389/fped.2021.634449</pub-id>
				</element-citation>
			</ref>
			<ref id="B30">
				<label>30</label>
				<mixed-citation>30. Meshinchi S, Leisenring WM, Carpenter PA, Woolfrey AE, Sievers EL, Radich JP, et al. Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leucemia. Biol Blood Marrow Transplant [Internet]. 2003 [cited 2019 Oct 12];9(11):706-13. Available from: https://doi.org/10.1016/j.bbmt.2003.08.003</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Meshinchi</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Leisenring</surname>
							<given-names>WM</given-names>
						</name>
						<name>
							<surname>Carpenter</surname>
							<given-names>PA</given-names>
						</name>
						<name>
							<surname>Woolfrey</surname>
							<given-names>AE</given-names>
						</name>
						<name>
							<surname>Sievers</surname>
							<given-names>EL</given-names>
						</name>
						<name>
							<surname>Radich</surname>
							<given-names>JP</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leucemia</article-title>
					<source>Biol Blood Marrow Transplant</source>
					<comment>Internet</comment>
					<year>2003</year>
					<date-in-citation content-type="access-date" iso-8601-date="2019-10-12">2019 Oct 12</date-in-citation>
					<volume>9</volume>
					<issue>11</issue>
					<fpage>706</fpage>
					<lpage>713</lpage>
					<pub-id pub-id-type="doi">https://doi.org/10.1016/j.bbmt.2003.08.003</pub-id>
				</element-citation>
			</ref>
			<ref id="B31">
				<label>31</label>
				<mixed-citation>31. Rodrigues JAP, Lacerda MR, Galvão CM, Gomes IM, Meier MJ, Caceres MTG. Nursing care for patients in post-transplantation of hematopoietic stem cells: an integrative review. Rev Bras Enferm [Internet]. 2021 [cited 2021 Dec 30];74(3):e20200097. Available from: https://doi.org/10.1590/0034-7167-2020-0097</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Rodrigues</surname>
							<given-names>JAP</given-names>
						</name>
						<name>
							<surname>Lacerda</surname>
							<given-names>MR</given-names>
						</name>
						<name>
							<surname>Galvão</surname>
							<given-names>CM</given-names>
						</name>
						<name>
							<surname>Gomes</surname>
							<given-names>IM</given-names>
						</name>
						<name>
							<surname>Meier</surname>
							<given-names>MJ</given-names>
						</name>
						<name>
							<surname>Caceres</surname>
							<given-names>MTG</given-names>
						</name>
					</person-group>
					<article-title>Nursing care for patients in post-transplantation of hematopoietic stem cells: an integrative review</article-title>
					<source>Rev Bras Enferm</source>
					<comment>Internet</comment>
					<year>2021</year>
					<date-in-citation content-type="access-date" iso-8601-date="2021-12-30">2021 Dec 30</date-in-citation>
					<volume>74</volume>
					<issue>3</issue>
					<elocation-id>e20200097</elocation-id>
					<pub-id pub-id-type="doi">https://doi.org/10.1590/0034-7167-2020-0097</pub-id>
				</element-citation>
			</ref>
			<ref id="B32">
				<label>32</label>
				<mixed-citation>32. Pinho VFS. Clinical characteristics and complications of the haploidentical transplantation with post-transplant cyclophosphamide: implications for nursing. Rev Bras Cancerol [Internet]. 2020 [cited 2021 Dec 30];66(1):e-01361. Available from: https://doi.org/10.32635/2176-9745.RBC.2020v66n1.361</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Pinho</surname>
							<given-names>VFS</given-names>
						</name>
					</person-group>
					<article-title>Clinical characteristics and complications of the haploidentical transplantation with post-transplant cyclophosphamide: implications for nursing</article-title>
					<source>Rev Bras Cancerol</source>
					<comment>Internet</comment>
					<year>2020</year>
					<date-in-citation content-type="access-date" iso-8601-date="2021-12-30">2021 Dec 30</date-in-citation>
					<volume>66</volume>
					<issue>1</issue>
					<elocation-id>e-01361</elocation-id>
					<pub-id pub-id-type="doi">https://doi.org/10.32635/2176-9745.RBC.2020v66n1.361</pub-id>
				</element-citation>
			</ref>
			<ref id="B33">
				<label>33</label>
				<mixed-citation>33. Sandri LCS, Pontes L, Bonfim CMS, Kusma SZ. Nursing diagnosis after hematopoietic stem cell transplant due to Fanconi anemia. Rev Bras Enferm [Internet]. 2022 [cited 2022 Jan 02];75(03):e20190864. Available from: https://doi.org/10.1590/0034-7167-2019-0864</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Sandri</surname>
							<given-names>LCS</given-names>
						</name>
						<name>
							<surname>Pontes</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Bonfim</surname>
							<given-names>CMS</given-names>
						</name>
						<name>
							<surname>Kusma</surname>
							<given-names>SZ</given-names>
						</name>
					</person-group>
					<article-title>Nursing diagnosis after hematopoietic stem cell transplant due to Fanconi anemia</article-title>
					<source>Rev Bras Enferm</source>
					<comment>Internet</comment>
					<year>2022</year>
					<date-in-citation content-type="access-date" iso-8601-date="2022-01-02">2022 Jan 02</date-in-citation>
					<volume>75</volume>
					<issue>03</issue>
					<elocation-id>e20190864</elocation-id>
					<pub-id pub-id-type="doi">https://doi.org/10.1590/0034-7167-2019-0864</pub-id>
				</element-citation>
			</ref>
		</ref-list>
		<fn-group>
			<fn fn-type="presented-at" id="fn4">
				<p>Artigo extraído da tese de doutorado “Fatores associados ao retransplante de células-tronco hematopoéticas: um estudo caso-controle”, apresentada à Universidade Federal do Rio Grande do Norte, Natal, RN, Brasil. O presente trabalho foi realizado com apoio da Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) - Código de Financiamento 001, Brasil.</p>
			</fn>
		</fn-group>
	</back>
	<sub-article article-type="translation" id="s1" xml:lang="en">
		<front-stub>
			<article-id pub-id-type="doi">10.1590/1518-8345.5794.3535</article-id>
			<article-categories>
				<subj-group subj-group-type="heading">
					<subject>Original Article</subject>
				</subj-group>
			</article-categories>
			<title-group>
				<article-title>Analysis of factors associated with hematopoietic stem-cell retransplantation: a case-control study</article-title>
			</title-group>
			<contrib-group>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-5322-7987</contrib-id>
					<name>
						<surname>Azevedo</surname>
						<given-names>Isabelle Campos de</given-names>
					</name>
					<xref ref-type="aff" rid="aff4"><sup>1</sup></xref>
					<xref ref-type="aff" rid="aff5"><sup>2</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-9123-232X</contrib-id>
					<name>
						<surname>Ferreira</surname>
						<given-names>Marcos Antonio</given-names>
						<suffix>Júnior</suffix>
					</name>
					<xref ref-type="aff" rid="aff6"><sup>3</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-7492-2735</contrib-id>
					<name>
						<surname>Nascimento</surname>
						<given-names>Anália Andréia de Araújo</given-names>
					</name>
					<xref ref-type="aff" rid="aff4"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-4672-2303</contrib-id>
					<name>
						<surname>Vitor</surname>
						<given-names>Allyne Fortes</given-names>
					</name>
					<xref ref-type="aff" rid="aff4"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-6835-0574</contrib-id>
					<name>
						<surname>Teston</surname>
						<given-names>Elen Ferraz</given-names>
					</name>
					<xref ref-type="aff" rid="aff6"><sup>3</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0003-3586-1313</contrib-id>
					<name>
						<surname>Frota</surname>
						<given-names>Oleci Pereira</given-names>
					</name>
					<xref ref-type="aff" rid="aff6"><sup>3</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-8140-8320</contrib-id>
					<name>
						<surname>Santos</surname>
						<given-names>Viviane Euzébia Pereira</given-names>
					</name>
					<xref ref-type="aff" rid="aff4"><sup>1</sup></xref>
				</contrib>
			</contrib-group>
			<aff id="aff4">
				<label>1</label>
				<institution content-type="original"> Universidade Federal do Rio Grande do Norte, Departamento de Enfermagem, Natal, RN, Brazil.</institution>
			</aff>
			<aff id="aff5">
				<label>2</label>
				<institution content-type="original"> Bolsista da Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brazil.</institution>
			</aff>
			<aff id="aff6">
				<label>3</label>
				<institution content-type="original"> Universidade Federal de Mato Grosso do Sul, Instituto Integrado de Saúde, Campo Grande, MS, Brazil.</institution>
			</aff>
			<author-notes>
				<corresp id="c2">
					<label>Corresponding author:</label> Isabelle Campos de Azevedo. E-mail: <email>isabellebr2511@gmail.com</email>
				</corresp>
				<fn fn-type="edited-by" id="fn5">
					<label>Associate Editor</label>
					<p> Juan Manuel Carmona Torres</p>
				</fn>
				<fn fn-type="con" id="fn6">
					<label>Authors’ contribution</label>
					<p><bold>Study concept and design:</bold> Isabelle Campos De Azevedo, Marcos Antonio Ferreira Júnior, Allyne Fortes Vitor, Elen Ferraz Teston, Oleci Pereira Frota, Viviane Euzébia Pereira Santos. <bold>Obtaining data:</bold> Isabelle Campos De Azevedo, Anália Andréia De Araújo Nascimento. <bold>Data analysis and interpretation:</bold> Isabelle Campos De Azevedo, Marcos Antonio Ferreira Júnior, Anália Andréia De Araújo Nascimento, Oleci Pereira Frota, Viviane Euzébia Pereira Santos. <bold>Statistical analysis:</bold> Isabelle Campos De Azevedo, Marcos Antonio Ferreira Júnior, Anália Andréia De Araújo Nascimento, Allyne Fortes Vitor, Elen Ferraz Teston. <bold>Obtaining financing:</bold> Isabelle Campos De Azevedo, Marcos Antonio Ferreira Júnior. <bold>Drafting the manuscript:</bold> Isabelle Campos De Azevedo, Marcos Antonio Ferreira Júnior, Anália Andréia De Araújo Nascimento, Allyne Fortes Vitor, Elen Ferraz Teston, Oleci Pereira Frota, Viviane Euzébia Pereira Santos. <bold>Critical review of the manuscript as to its relevant intellectual content:</bold> Isabelle Campos De Azevedo, Marcos Antonio Ferreira Júnior, Allyne Fortes Vitor, Elen Ferraz Teston, Oleci Pereira Frota, Viviane Euzébia Pereira Santos. All authors approved the final version of the text.</p>
				</fn>
				<fn fn-type="conflict" id="fn7">
					<label>Conflict of interest</label>
					<p> The authors have declared that there is no conflict of interest.</p>
				</fn>
			</author-notes>
			<abstract>
				<title>Abstract</title>
				<sec>
					<title>Objective:</title>
					<p> to analyze the factors associated with the failure of Hematopoietic Stem Cell Transplantation (HSCT) in patients undergoing Hematopoietic Stem Cell Retransplantation (HSCR). </p>
				</sec>
				<sec>
					<title>Method:</title>
					<p> this study implemented a quantitative approach and was a case-control type which addressed patients undergoing HSCR. To do so, a paired sample of two controls was used for each case (2:1). The case group consisted of the medical records of all patients who underwent HSCR (28) and the control group (56) of those who underwent only one transplant. Three variables guided the pairing: gender, diagnosis and type of transplant. </p>
				</sec>
				<sec>
					<title>Results:</title>
					<p> a total of 24 (85.71%) patients in the case group were re-transplanted due to disease relapse and four (14.29%) due to graft failure. There was a statistical difference in the analysis between patients who did not use ursodeoxycholic acid, opioid analgesics and immunosuppressants. The need for HSCR among those who used these medications inappropriately was 16.12, 12.79 and 4.5 times more likely, respectively, than those who used them correctly. </p>
				</sec>
				<sec>
					<title>Conclusion:</title>
					<p> there was a difference regarding the reasons which led to the retransplantation and the analyzed subjects, and this study concluded that the predictive reason for retransplantation in the studied sample was disease relapse. </p>
				</sec>
			</abstract>
			<kwd-group xml:lang="en">
				<title>Descriptors:</title>
				<kwd>Graft Rejection</kwd>
				<kwd>Recurrence</kwd>
				<kwd>Hematopoietic Stem Cell Transplantation</kwd>
				<kwd>Bone Marrow Transplantation</kwd>
				<kwd>Survival Analysis</kwd>
				<kwd>Analytical Epidemiology</kwd>
			</kwd-group>
		</front-stub>
		<body>
			<boxed-text id="bx2">
				<sec>
					<title>Highlights</title>
					<p>(1) First Brazilian study on hematopoietic stem cell retransplantation (HSCR).</p>
					<p>(2) It presents evidence on the clinical profile of patients undergoing HSCR.</p>
					<p>(3) The predictive reason for HSCR was disease relapse.</p>
					<p>(4) The disease relapse maybe is associate with the treatment fail.</p>
				</sec>
			</boxed-text>
			<sec sec-type="intro">
				<title>Introduction</title>
				<p>Hematopoietic stem cell transplantation (HSCT) is considered a treatment form for malignant hemopathies, as well as other hematopoietic, lymphatic, and immune system diseases<xref ref-type="bibr" rid="B1"><sup>1</sup></xref>. It is characterized by intravenous hematopoietic progenitor cell (HPC) grafting in order to correct quantitative or qualitative bone marrow failures<xref ref-type="bibr" rid="B2"><sup>2</sup></xref>.</p>
				<p>HSTC can be classified according to its type; as autologous when the HPC are from the patient themself, as allogeneic when the cells are from donors (related or not) with compatible human leukocyte antigen (HLA), and syngeneic when the HPC are from an identical twin. The cells used for this type of transplant can be collected from bone marrow, peripheral blood or umbilical cord and placental blood<xref ref-type="bibr" rid="B2"><sup>2</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B3"><sup>3</sup></xref>.</p>
				<p>It is essential that the infused cells proliferate in the recipient permanently to avoid rejection to achieve HSCT success, and that the new immune system received from the donor tolerates the recipient’s tissues in order to avoid infections, Graft versus Host Disease (GVHD) and other morbidities, which can be serious and fatal. In addition, the immune system must be functioning properly and the disease stage, its complications, comorbidities at the time of transplant and healthcare throughout the process must also be considered<xref ref-type="bibr" rid="B4"><sup>4</sup></xref>. </p>
				<p>For the purposes of this study, the condition in which the performed HSCT is unable to establish itself in the patient who received it and to resolve the initial bone marrow failure, and which has required retransplantation as a therapeutic condition will be considered as a failure.</p>
				<p>HSCT failure is directly related to all phases of the procedure, being represented by graft failure or rejection and disease relapse, which occurs in about 20% of transplant patients<xref ref-type="bibr" rid="B5"><sup>5</sup></xref>. A study carried out in Germany corroborates this statistic, as 24.89% of the 229 patients who underwent HSCT between January 2005 and December 2015 required retransplantation<xref ref-type="bibr" rid="B6"><sup>6</sup></xref>. There are no epidemiological data from studies on HSCR carried out in Brazil, with this being the first study on the subject.</p>
				<p>In this perspective, this constitutes an epidemiological study carried out with the objective of investigating the factors associated with HSCR which could identify possible characteristics or complications that occurred during the transplantation process and that can significantly contribute to the success or failure procedure such as GVHD, graft failure or relapse, among others<xref ref-type="bibr" rid="B6"><sup>6</sup></xref>.</p>
				<p>HSCT failure can culminate in the need for retransplantation and will again expose the patient to all of the procedure stages and to the morbidity and mortality risks. Hematopoietic Stem Cell Retransplantation (HSCR) can be defined as the only treatment option/form for rejection, graft failure or relapse with a chance of increasing survival or promoting remission of the disease in patients who have previously undergone HSCT<xref ref-type="bibr" rid="B7"><sup>7</sup></xref>. The prognosis for patients with disease progression after first HSCT is dismal, and HSCR is a potentially curative option<xref ref-type="bibr" rid="B8"><sup>8</sup></xref>.</p>
				<p>When considering that the epidemiological profile of patients as well as the factors associated with retransplantation vary according to the underlying disease and the clinical course of treatment, the present study was anchored in the following research question: Is there an association between clinical and sociodemographic characteristics with hematopoietic stem-cell retransplantation?</p>
				<p>This study is mainly justified by the complexity involved in the HSCT procedure<xref ref-type="bibr" rid="B9"><sup>9</sup></xref> and because identifying variables which can lead to the risk of an HSCR requires thorough investigation. This in turn justifies the need to carry out longitudinal studies such as this one in order to identify and analyze these intrinsic factors of the retransplantation process to produce knowledge that supports healthcare, the development or improvement of institutional care protocols and public policies for the effective functioning of transplant services.</p>
				<p>In this context, it is expected that the results presented herein can contribute to systematizing and improving the organization and planning of the care provided to HSCT patients, in addition to fostering training of health professionals, especially nurses, with a view to capacitating them to provide specialized care regarding HSCT and its interfaces based on identifying factors which lead to HSCR and the prevention of associated complications.</p>
				<p>Therefore, the objective of the present study is to analyze the factors associated with the failure of hematopoietic stem-cell transplants in patients submitted to HSCR. </p>
			</sec>
			<sec sec-type="methods">
				<title>Method</title>
				<sec>
					<title>Study design</title>
					<p>This study had a quantitative approach and was of the case-control type of analytical, observational, longitudinal and individual design with a proportion of 1 case/2 controls in patients undergoing HSCT. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guide for observational studies was followed, as recommended by the EQUATOR network.</p>
				</sec>
				<sec>
					<title>Study location and period</title>
					<p>The study was conducted in a referral hospital for high complexity care located in Natal/RN, Brazil, authorized, accredited and qualified to conduct HSCT by the Brazilian Unified Health System (<italic>SUS</italic>) starting in 2004. Data were collected between the months of July and August 2018.</p>
				</sec>
				<sec>
					<title>Participants</title>
					<p>The sample comprised all patients with registered medical records who underwent HSCT at the service under study, between January 2008 and December 2017, for a total of 10 years of the procedure. This time frame is justified by the fact that the medical records of the years between 2004 and 2007 were not registered with the Medical and Statistics Archive Service.</p>
					<p>The study population consisted of all medical records registered by the service, with an initial sample of 389 records of patients who underwent the HSCT procedure, regardless of the type of transplant adopted; however, five were excluded due to illegibility or incomplete information. After excluding illegible medical records or with incomplete information, the final cohort sample consisted of 384 medical records of patients undergoing HSCT. </p>
					<p>A total of 31 from the total number of patients underwent HSCR, characterizing them as the case group, with the record of a single transplant performed being used to compose the control group. Three cases were excluded from the sample, as it was not possible to compare them with the controls available in the population of this study; one of them with a diagnosis of essential thrombocytopenia, another of myelodysplastic syndrome and the last patient with a diagnosis of multiple myeloma, one of the most prevalent types of hematologic cancer; however, the type of transplant performed was allogeneic due to the impossibility of using the patient’s own HPC for autologous HSCT, thus totaling 28 cases. </p>
					<p>The sample matching sought maximum similarity between the individuals. The control group in relation to the case group was defined by comparing the variables of gender, diagnosis and type of HSCT performed. The age variable was used to provide greater similarity between the ages of cases and controls, since ages were not equal for some pairings, but approximate. </p>
					<p>The registry variable was used as additional information to better differentiate the medical records and minimize selection bias. It is important to highlight that the sample records of 12 children and adolescents are part of the sample, and that they were paired with each other so that the degree of similarity was met. In this context, the final sample consisted of 84 patients, 28 cases and 56 controls, the latter extracted from the 353 remaining medical records. A flowchart presented in <xref ref-type="fig" rid="f3">Figure 1</xref> was prepared for a better understanding of the selection of records by group.</p>
					<p>
						<fig id="f3">
							<label>Figure 1</label>
							<caption>
								<title>Synthesis flowchart of the selection of medical records which composed the case and control groups. Natal, RN, Brazil, 2019 (n=84)</title>
							</caption>
							<graphic xlink:href="1518-8345-rlae-30-e3569-gf3.png"/>
						</fig>
					</p>
					<p>The inclusion criteria for the case group were: being a patient submitted to autologous, allogeneic or syngeneic HSCR, of any age, and of both genders. Inclusion criteria for the control group were: patients submitted to only one autologous, allogeneic or syngeneic HSCT, of any age, and of both genders.</p>
				</sec>
				<sec>
					<title>Data collection and variables</title>
					<p>A data collection instrument was implemented which addressed sociodemographic and clinical variables, namely: date and place of birth, place of residence, age, gender, race, education level, marital status, occupation, situation with the service transplant time, time between admission and HSCT, total follow-up time by the transplant service, diagnosis/underlying disease, type of HSCT performed, type of HSCR performed, type of cells infused, reason/indication for transplantation, toxicities presented, treatments instituted, presence of acute or chronic GVHD, survival of the transplant patient. It is worth noting that all variables were collected from medical records.</p>
					<p>The researchers who collated the data received training in two stages; the first involved the study object and its interfaces, and the second was regarding the data collection instrument and its specificities. They were blinded to the study objectives as well as to the hypothesis to be tested as a way to minimize confusion bias in an attempt to make any association between the responses. </p>
				</sec>
				<sec>
					<title>Data processing and analysis</title>
					<p>Tables were constructed with absolute and relative frequencies by gender and total, means and standard deviations for the sample description. The chi-squared test was used to test for statistical significance, Fisher’s exact test was used to calculate the probability of association between the analyzed characteristics and the case group according to the nature of each variable, and the Mann-Whitney U test was used to compare central trends of two independent samples of equal sizes and to compare two paired or unpaired groups to verify whether or not they belong to the same population and whose requirements for applying the Student’s t-test were not met. The Kolmogorov-Smirnov test was used to verify the data normality.</p>
					<p>Bivariate and multivariate analyzes were used to assess the association between the selected variables and estimate the magnitude of the Odds Ratio (OR), respectively. The Likelihood Ratio, Wald and Pseudo R<sup>2</sup> tests (Cox and Snell = 0.240; Nagelkerke = 0.333) were used to ensure the significance of the variables in the Logistic Regression models, as well as for the hypothesis test to determine whether the independent variables in the model are significantly related to the dependent variable.</p>
					<p>A dependent variable (hematopoietic stem cell retransplantation = Y) was adopted for the logistic regression, and the influence of one or more independent, causal or explanatory variables (X1, X2, X3,...) was verified on the dependent variable. The following equation was used for this analysis:</p>
					<p>
						<disp-formula id="e2">
							<mml:math>
								<mml:msub>
									<mml:mrow>
										<mml:mi>γ</mml:mi>
									</mml:mrow>
									<mml:mrow>
										<mml:mi>i</mml:mi>
									</mml:mrow>
								</mml:msub>
								<mml:mi>
								</mml:mi>
								<mml:mo>=</mml:mo>
								<mml:msub>
									<mml:mrow>
										<mml:mi>β</mml:mi>
									</mml:mrow>
									<mml:mrow>
										<mml:mn>0</mml:mn>
									</mml:mrow>
								</mml:msub>
								<mml:mo>+</mml:mo>
								<mml:msub>
									<mml:mrow>
										<mml:mi>β</mml:mi>
									</mml:mrow>
									<mml:mrow>
										<mml:mn>1</mml:mn>
									</mml:mrow>
								</mml:msub>
								<mml:msub>
									<mml:mrow>
										<mml:mi>X</mml:mi>
									</mml:mrow>
									<mml:mrow>
										<mml:mn>1</mml:mn>
									</mml:mrow>
								</mml:msub>
								<mml:mo>+</mml:mo>
								<mml:msub>
									<mml:mrow>
										<mml:mi>β</mml:mi>
									</mml:mrow>
									<mml:mrow>
										<mml:mn>2</mml:mn>
									</mml:mrow>
								</mml:msub>
								<mml:msub>
									<mml:mrow>
										<mml:mi>X</mml:mi>
									</mml:mrow>
									<mml:mrow>
										<mml:mn>2</mml:mn>
									</mml:mrow>
								</mml:msub>
								<mml:mo>+</mml:mo>
								<mml:mi>
								</mml:mi>
								<mml:mo>…</mml:mo>
								<mml:mo>+</mml:mo>
								<mml:msub>
									<mml:mrow>
										<mml:mi>β</mml:mi>
									</mml:mrow>
									<mml:mrow>
										<mml:mi>i</mml:mi>
									</mml:mrow>
								</mml:msub>
								<mml:msub>
									<mml:mrow>
										<mml:mi>X</mml:mi>
									</mml:mrow>
									<mml:mrow>
										<mml:mi>i</mml:mi>
									</mml:mrow>
								</mml:msub>
								<mml:mo>+</mml:mo>
								<mml:msub>
									<mml:mrow>
										<mml:mi>ε</mml:mi>
									</mml:mrow>
									<mml:mrow>
										<mml:mi>i</mml:mi>
									</mml:mrow>
								</mml:msub>
							</mml:math>
						</disp-formula>
					</p>
					<p>When analyzing the final logistic regression model, the Chi-squared statistic of the residuals (Overall Statistics) presented a value of p&gt;0.05, meaning that none of the variables excluded from the model would significantly contribute to the model’s predictive power. It was found that the p-value &gt; 0.05 was not statistically significant by the Hosmer-Lemeshow test, which indicates that a good fit of the final model was obtained. Therefore, it was concluded that the final adjusted model of logistic regression was adequate.</p>
					<p>Survival calculations were performed by applying the Kaplan-Meier method with the patient’s initial entry point in the study being considered the date of the HSCT and the last event as the final point: death, abandonment, follow-up at the time of data collection and finalized treatment. The log-rank statistical method was used to compare the survival rates by variables to be listed. A significance level of 0.05 was adopted for all analyses.</p>
				</sec>
				<sec>
					<title>Ethical aspects </title>
					<p>The Research Protocol for this study was submitted to the Federal University of Rio Grande do Norte Research Ethics Committee in accordance with Resolution No. 466/12 of the National Health Council of the Ministry of Health which deals with research with human beings, for the evaluation of its ethical and methodological aspects<xref ref-type="bibr" rid="B10"><sup>10</sup></xref> and approved under opinion 2,596,384 and CAAE: 80927417.9.0000.5537, approved on April 18, 2018.</p>
				</sec>
			</sec>
			<sec sec-type="results">
				<title>Results</title>
				<p>The age ranged between two and 55 years and the average was 34.11 years (± 14.20) (<xref ref-type="table" rid="t4">Table 1</xref>), while 51 (60.71%) participants were male, 65 (77.38%) lived in the state of Rio Grande do Norte, 41 (48.81%) were married, and 49 (58.33%) had paid employment. As the mean age was around 34 years and the age variable presented significant variability, two age groups were considered up to 35 years old and over 35 years old to better organize this information in <xref ref-type="table" rid="t4">Table 1</xref>. The age variable was considered continuous for association calculations and others.</p>
				<p>
					<table-wrap id="t4">
						<label>Table 1</label>
						<caption>
							<title>Bivariate analysis between the performance and non-performance of HSCR and independent variables (n=84). Natal, RN, Brazil, 2019</title>
						</caption>
						<table>
							<colgroup>
								<col/>
								<col span="4"/>
								<col/>
								<col/>
							</colgroup>
							<thead>
								<tr>
									<th align="left" rowspan="3">Variables</th>
									<th align="center" colspan="4">Groups </th>
									<th align="center" rowspan="3"><italic>Odds Ratio</italic> [95%CI<sup>*</sup>]</th>
									<th align="center" rowspan="3"><italic>p</italic><sup>†</sup></th>
								</tr>
								<tr>
									<th align="center" colspan="2"><italic>case</italic> (n=28)</th>
									<th align="center" colspan="2"><italic>control</italic> (n=56)</th>
								</tr>
								<tr>
									<th align="center">n</th>
									<th align="center">%</th>
									<th align="center">n</th>
									<th align="center">%</th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td align="left" colspan="7"><bold>Gender</bold></td>
								</tr>
								<tr>
									<td align="left">Male</td>
									<td align="center">17</td>
									<td align="center">60.71</td>
									<td align="center">34</td>
									<td align="center">60.71</td>
									<td align="center" rowspan="2">1.00 [0.39; 2.53]</td>
									<td align="center" rowspan="2">1.000<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left">Female</td>
									<td align="center">11</td>
									<td align="center">39.29</td>
									<td align="center">22</td>
									<td align="center">39.29</td>
								</tr>
								<tr>
									<td align="left" colspan="7"><bold>Age range</bold></td>
								</tr>
								<tr>
									<td align="left">Up to 35 years old</td>
									<td align="center">13</td>
									<td align="center">46.43</td>
									<td align="center">26</td>
									<td align="center">46.43</td>
									<td align="center" rowspan="2">1.00 [0.40; 2.48]</td>
									<td align="center" rowspan="2">1.000<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left">Over 35 years old</td>
									<td align="center">15</td>
									<td align="center">53.57</td>
									<td align="center">30</td>
									<td align="center">53.57</td>
								</tr>
								<tr>
									<td align="left" colspan="7"><bold>Diagnosis</bold></td>
								</tr>
								<tr>
									<td align="left">Acute Myeloid Leukemia</td>
									<td align="center">8</td>
									<td align="center">28.57</td>
									<td align="center">16</td>
									<td align="center">28.57</td>
									<td align="center" rowspan="7">--</td>
									<td align="center" rowspan="7">1.000<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left">Non-Hodgkin’s lymphoma</td>
									<td align="center">6</td>
									<td align="center">21.43</td>
									<td align="center">12</td>
									<td align="center">21.43</td>
								</tr>
								<tr>
									<td align="left">Multiple Myeloma</td>
									<td align="center">5</td>
									<td align="center">17.86</td>
									<td align="center">10</td>
									<td align="center">17.86</td>
								</tr>
								<tr>
									<td align="left">Acute Lymphoblastic Leukemia</td>
									<td align="center">4</td>
									<td align="center">14.29</td>
									<td align="center">8</td>
									<td align="center">14.29</td>
								</tr>
								<tr>
									<td align="left">Aplastic Anemia</td>
									<td align="center">3</td>
									<td align="center">10.71</td>
									<td align="center">6</td>
									<td align="center">10.71</td>
								</tr>
								<tr>
									<td align="left">Hodgkin’s disease</td>
									<td align="center">1</td>
									<td align="center">3.57</td>
									<td align="center">2</td>
									<td align="center">3.57</td>
								</tr>
								<tr>
									<td align="left">Chronic myeloid leukemia</td>
									<td align="center">1</td>
									<td align="center">3.57</td>
									<td align="center">2</td>
									<td align="center">3.57</td>
								</tr>
								<tr>
									<td align="left" colspan="7"><bold>HSCT<sup>§</sup> performed</bold></td>
								</tr>
								<tr>
									<td align="left">Allogeneic</td>
									<td align="center">17</td>
									<td align="center">60.71</td>
									<td align="center">34</td>
									<td align="center">60.71</td>
									<td align="center" rowspan="2">1.00 [0.39; 2.53]</td>
									<td align="center" rowspan="2">1.000<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left">Autologous</td>
									<td align="center">11</td>
									<td align="center">39.29</td>
									<td align="center">22</td>
									<td align="center">39.29</td>
								</tr>
								<tr>
									<td align="left" colspan="7"><bold>GVHD<sup>||</sup></bold></td>
								</tr>
								<tr>
									<td align="left">No</td>
									<td align="center">24</td>
									<td align="center">85.71</td>
									<td align="center">55</td>
									<td align="center">98.21</td>
									<td align="center" rowspan="2">9.17 [0.97; 86.38]</td>
									<td align="center" rowspan="2">0.040<sup>¶</sup></td>
								</tr>
								<tr>
									<td align="left">Yes</td>
									<td align="center">4</td>
									<td align="center">14.29</td>
									<td align="center">1</td>
									<td align="center">1.79</td>
								</tr>
								<tr>
									<td align="left" colspan="7"><bold>Situation with RGH<sup>**</sup></bold></td>
								</tr>
								<tr>
									<td align="left">Treatment finished</td>
									<td align="center">12</td>
									<td align="center">42.86</td>
									<td align="center">37</td>
									<td align="center">66.07</td>
									<td align="center" rowspan="2">0.38 [0.15; 0.97]</td>
									<td align="center" rowspan="2">0.042<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left">Death</td>
									<td align="center">16</td>
									<td align="center">57.14</td>
									<td align="center">19</td>
									<td align="center">33.93</td>
								</tr>
								<tr>
									<td align="left" colspan="7"><bold>Follow-up until HSCT</bold></td>
								</tr>
								<tr>
									<td align="left">Up to 15 days</td>
									<td align="center">17</td>
									<td align="center">39.53</td>
									<td align="center">26</td>
									<td align="center">60.47</td>
									<td align="center" rowspan="2">1.78 [0.71; 4.49]</td>
									<td align="center" rowspan="2">0.217<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left">More than 15 days</td>
									<td align="center">11</td>
									<td align="center">26.83</td>
									<td align="center">30</td>
									<td align="center">73.17</td>
								</tr>
								<tr>
									<td align="left" colspan="7"><bold>Total follow-up time by the HSCT<sup>§</sup> service</bold></td>
								</tr>
								<tr>
									<td align="left">Up to 21 months</td>
									<td align="center">12</td>
									<td align="center">28.57</td>
									<td align="center">30</td>
									<td align="center">71.43</td>
									<td align="center" rowspan="2">0.65 [0.26; 1.62]</td>
									<td align="center" rowspan="2">0.355<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left">More than 21 months</td>
									<td align="center">16</td>
									<td align="center">38.10</td>
									<td align="center">26</td>
									<td align="center">61.90</td>
								</tr>
								<tr>
									<td align="left" colspan="7"><bold>Survival</bold></td>
								</tr>
								<tr>
									<td align="left">Up to 17.5 months</td>
									<td align="center">13</td>
									<td align="center">30.95</td>
									<td align="center">29</td>
									<td align="center">69.05</td>
									<td align="center" rowspan="2">0.81 [0.32; 2.00]</td>
									<td align="center" rowspan="2">0.643<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left">More than 17.5 months</td>
									<td align="center">15</td>
									<td align="center">35.71</td>
									<td align="center">27</td>
									<td align="center">64.29</td>
								</tr>
							</tbody>
						</table>
						<table-wrap-foot>
							<fn id="TFN4">
								<p><sup>*</sup>Confidence interval; <sup>†</sup>p-value; <sup>‡</sup>Chi-squared test; <sup>§</sup>Hematopoietic Stem Cell Transplantation; <sup>||</sup>Graft Versus Host Disease; <sup>¶</sup>Fisher’s exact test; <sup>**</sup>Rio Grande Hospital</p>
							</fn>
						</table-wrap-foot>
					</table-wrap>
				</p>
				<p>From the total, 42 (50.00%) received care in the HSCT sector for about 21 months and 43 (51.19%; p&lt;0.001) waited up to 15 days between the beginning of the conditioning regime until the first HSCT.</p>
				<p>The diagnoses which culminated in the HSCR are shown in <xref ref-type="table" rid="t4">Table 1</xref>. A total of 35 (41.67%) of the studied patients died, of which 16 (57.14%) occurred among those who re-transplanted. The most prevalent causes of death were sepsis with 28 (33.34%), multiple organ failure in 14 (16.67%), and pulmonary infection in eight (9.52%). Moreover, 51 (60.71%) allogeneic HSCTs were performed, of which 17 (60.71%) were retransplants (<xref ref-type="table" rid="t4">Table 1</xref>).</p>
				<p>Allogeneic HSCT occurred in 39 (76.47%) individuals, while the most used source of HPC was peripheral blood in 64 (85.33%) HSCTs, and the most indicated reason for retransplantation was disease relapse in 24 (85.71%). In addition, allogeneic HSCR was performed in 26 (92.86%) patients, being from relatives in 21 (75.00%) with peripheral blood HPC (75.00%). Patients who developed GVHD were 9.17 times more likely to perform HSCR.</p>
				<p>The mean time to perform the retransplantation was 14.74 months, with the most prevalent reason for HSCT being disease relapse (24; 85.14%), and 42 (50.00%) had a survival of about 17 months.</p>
				<p>A total of 24 (85.71%) of the patients in the case group in this study re-transplanted due to disease relapse, and four (14.29%) due to graft failure. When considering the average number of follow-up months by the transplant service (29.26; p&lt;0.001) and the situation with the service in relation to death (OR = 0.38; CI = 95%: 0.15-0.97; p = 0.042), respectively, it is possible to understand that the longer the in-hospital care period, the greater the chances of patients being re-transplanted and of progressing to death. This is because the hospital stay in this context is directly related to severe complications, such as infection or sepsis which can lead to graft failure and disease recurrence. </p>
				<p>
					<xref ref-type="table" rid="t5">Table 2</xref> presents the variables referring to the drugs which expose the patient to a greater chance of undergoing retransplantation. Furthermore, a statistically significant difference was found for patients who underwent HSCT and who developed genitourinary comorbidities, hematological toxicities and edema, where the chances of these patients undergoing retransplantation were 3.32, 3.22 and 2.81 times greater, respectively, when compared to patients who did not develop the mentioned comorbidity and toxicities. </p>
				<p>
					<table-wrap id="t5">
						<label>Table 2</label>
						<caption>
							<title>Bivariate analysis of drugs administered and toxicities presented according to the groups studied (n=84). Natal, RN, Brazil, 2019</title>
						</caption>
						<table>
							<colgroup>
								<col/>
								<col span="4"/>
								<col/>
								<col/>
							</colgroup>
							<thead>
								<tr>
									<th align="left" rowspan="3">Variables</th>
									<th align="center" colspan="4">Groups</th>
									<th align="center" rowspan="3"><italic>Odds Ratio</italic> [95%CI<sup>*</sup>]</th>
									<th align="center" rowspan="3"><italic>p</italic><sup>†</sup></th>
								</tr>
								<tr>
									<th align="center" colspan="2"><italic>case</italic> (n=28)</th>
									<th align="center" colspan="2"><italic>control</italic> (n=56)</th>
								</tr>
								<tr>
									<th align="center">n</th>
									<th align="center">%</th>
									<th align="center">n</th>
									<th align="center">%</th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td align="left" colspan="7"><bold>Drugs administered</bold></td>
								</tr>
								<tr>
									<td align="left" colspan="7"><bold>Ursodeoxycholic acid</bold></td>
								</tr>
								<tr>
									<td align="left">Yes</td>
									<td align="center">27</td>
									<td align="center">96.43</td>
									<td align="center">35</td>
									<td align="center">62.50</td>
									<td align="center" rowspan="2">16.12 [2.05-128.12]</td>
									<td align="center" rowspan="2">0.001<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left">No</td>
									<td align="center">1</td>
									<td align="center">3.57</td>
									<td align="center">21</td>
									<td align="center">37.50</td>
								</tr>
								<tr>
									<td align="left" colspan="7"><bold>Immunosuppressant</bold></td>
								</tr>
								<tr>
									<td align="left">Yes</td>
									<td align="center">24</td>
									<td align="center">85.71</td>
									<td align="center">32</td>
									<td align="center">57.14</td>
									<td align="center" rowspan="2">4.50 [1.38-14.69]</td>
									<td align="center" rowspan="2">0.009<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left">No</td>
									<td align="center">4</td>
									<td align="center">14.29</td>
									<td align="center">24</td>
									<td align="center">42.86</td>
								</tr>
								<tr>
									<td align="left" colspan="7"><bold>Toxicities presented</bold></td>
								</tr>
								<tr>
									<td align="left" colspan="7"><bold>Genitourinary</bold></td>
								</tr>
								<tr>
									<td align="left">Yes</td>
									<td align="center">9</td>
									<td align="center">32.14</td>
									<td align="center">7</td>
									<td align="center">12.50</td>
									<td align="center" rowspan="2">3.32 [1.08; 10.17]</td>
									<td align="center" rowspan="2">0.031<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left">No</td>
									<td align="center">19</td>
									<td align="center">67.86</td>
									<td align="center">49</td>
									<td align="center">87.50</td>
								</tr>
								<tr>
									<td align="left" colspan="7"><bold>Hematological</bold></td>
								</tr>
								<tr>
									<td align="left">Yes</td>
									<td align="center">21</td>
									<td align="center">75.00</td>
									<td align="center">27</td>
									<td align="center">48.21</td>
									<td align="center" rowspan="2">3.22 [1.18; 8.79]</td>
									<td align="center" rowspan="2">0.019<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left">No</td>
									<td align="center">7</td>
									<td align="center">25.00</td>
									<td align="center">29</td>
									<td align="center">51.79</td>
								</tr>
								<tr>
									<td align="left" colspan="7"><bold>Edema</bold></td>
								</tr>
								<tr>
									<td align="left">Yes</td>
									<td align="center">19</td>
									<td align="center">67.86</td>
									<td align="center">24</td>
									<td align="center">42.86</td>
									<td align="center" rowspan="2">2.81 [1.08; 7.30]</td>
									<td align="center" rowspan="2">0.031<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left">No</td>
									<td align="center">9</td>
									<td align="center">32.14</td>
									<td align="center">32</td>
									<td align="center">57.14</td>
								</tr>
								<tr>
									<td align="left" colspan="7"><bold>Ophthalmological</bold></td>
								</tr>
								<tr>
									<td align="left">Yes</td>
									<td align="center">8</td>
									<td align="center">28.57</td>
									<td align="center">7</td>
									<td align="center">12.50</td>
									<td align="center" rowspan="2">2.80 [0.90; 8.75]</td>
									<td align="center" rowspan="2">0.070<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left">No</td>
									<td align="center">20</td>
									<td align="center">71.43</td>
									<td align="center">49</td>
									<td align="center">87.50</td>
								</tr>
								<tr>
									<td align="left" colspan="7"><bold>Sepsis</bold></td>
								</tr>
								<tr>
									<td align="left">Yes</td>
									<td align="center">8</td>
									<td align="center">28.57</td>
									<td align="center">8</td>
									<td align="center">14.29</td>
									<td align="center" rowspan="2">2.40 [0.79; 7.28]</td>
									<td align="center" rowspan="2">0.116<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left">No</td>
									<td align="center">20</td>
									<td align="center">71.43</td>
									<td align="center">48</td>
									<td align="center">85.71</td>
								</tr>
							</tbody>
						</table>
						<table-wrap-foot>
							<fn id="TFN5">
								<p><sup>*</sup>Confidence interval; <sup>†</sup>p-value; <sup>‡</sup>Chi-squared test</p>
							</fn>
						</table-wrap-foot>
					</table-wrap>
				</p>
				<p>There was a statistical difference in the analysis between patients who did not use ursodeoxycholic acid and immunosuppressants. The chances of the need for HSCR among those who used these medications inappropriately due to non-adherence to treatment were 16.12 and 4.5 times more, respectively, than those who used these medications correctly. It should be noted that the first and the last are essential drugs used in a mandatory way in the allogeneic transplant and retransplantation protocols. Drug non-adherence related to ursodeoxycholic acid and immunosuppressants was recorded in 51 (60.71%) of the surveyed medical records.</p>
				<p>Retransplantation was considered a dependent variable for applying the logistic regression model adopted for this study, and the groups were coded as control (0) and case (1). The dependent variable was subsequently converted into a probability ratio and then into a logarithmic based variable. The variables which showed statistical significance (p&lt;0.05) were organized in a multiple logistic regression model, which in principle assumed a value of p&lt;0.20 to analyze them together (<xref ref-type="table" rid="t6">Table 3</xref>).</p>
				<p>
					<table-wrap id="t6">
						<label>Table 3</label>
						<caption>
							<title>Multiple logistic regression adjusted according to the variables that presented statistical significance grouped to the outcome of retransplantation (n=84). Natal, RN, Brazil, 2019</title>
						</caption>
						<table>
							<colgroup>
								<col span="2"/>
								<col span="2"/>
								<col/>
								<col/>
							</colgroup>
							<thead>
								<tr>
									<th align="left" colspan="2">Variables </th>
									<th align="center" colspan="2">Frequency </th>
									<th align="center"><italic>Odds Ratio</italic> [95%CI<sup>*</sup>]</th>
									<th align="center"><italic>p</italic> <sup>†</sup></th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td align="left" colspan="6">Diagnosis</td>
								</tr>
								<tr>
									<td align="left" colspan="2">Acute Myeloid Leukemia </td>
									<td align="center">24 </td>
									<td align="center">1<sup>‡</sup></td>
									<td align="center" rowspan="7">--</td>
									<td align="center" rowspan="7">1.000<sup>§</sup></td>
								</tr>
								<tr>
									<td align="left" colspan="2">Chronic myeloid leukemia </td>
									<td align="center">3 </td>
									<td align="center">1<sup>‡</sup></td>
									<td align="center" colspan="2">
									</td>
								</tr>
								<tr>
									<td align="left" colspan="2">Acute Lymphoblastic Leukemia </td>
									<td align="center">12 </td>
									<td align="center">1<sup>‡</sup></td>
									<td align="center" colspan="2">
									</td>
								</tr>
								<tr>
									<td align="left" colspan="2">Non-Hodgkin’s lymphoma </td>
									<td align="center">18 </td>
									<td align="center">1<sup>‡</sup></td>
									<td align="center" colspan="2">
									</td>
								</tr>
								<tr>
									<td align="left" colspan="2">Hodgkin’s disease </td>
									<td align="center">3 </td>
									<td align="center">1<sup>‡</sup></td>
									<td align="center" colspan="2">
									</td>
								</tr>
								<tr>
									<td align="left" colspan="2">Multiple Myeloma </td>
									<td align="center">15 </td>
									<td align="center">1<sup>‡</sup></td>
									<td align="center" colspan="2">
									</td>
								</tr>
								<tr>
									<td align="left" colspan="2">Aplastic Anemia </td>
									<td align="center">9 </td>
									<td align="center">0<sup>||</sup></td>
									<td align="center" colspan="2">
									</td>
								</tr>
								<tr>
									<td align="left" colspan="6"><bold>Toxicities</bold></td>
								</tr>
								<tr>
									<td align="left" rowspan="2">Hematological</td>
									<td align="center">Yes</td>
									<td align="center">48</td>
									<td align="center">1<sup>‡</sup></td>
									<td align="center">3.22 [1.18; 8.79]</td>
									<td align="center">0.019<sup>§</sup></td>
								</tr>
								<tr>
									<td align="center">No</td>
									<td align="center">36</td>
									<td align="center">0<sup>||</sup></td>
									<td align="center" colspan="2">
									</td>
								</tr>
								<tr>
									<td align="left" rowspan="2">Edema</td>
									<td align="center">Yes</td>
									<td align="center">43</td>
									<td align="center">1<sup>‡</sup></td>
									<td align="center">2.81 [1.08; 7.30]</td>
									<td align="center">0.031<sup>§</sup></td>
								</tr>
								<tr>
									<td align="center">No</td>
									<td align="center">41</td>
									<td align="center">0<sup>||</sup></td>
									<td align="center" colspan="2">
									</td>
								</tr>
								<tr>
									<td align="left" colspan="6"><bold>Comorbidity</bold></td>
								</tr>
								<tr>
									<td align="left" rowspan="2">GVHD<sup>¶</sup></td>
									<td align="center">Yes</td>
									<td align="center">5</td>
									<td align="center">1<sup>‡</sup></td>
									<td align="center">9.17 [0.97; 86.38]</td>
									<td align="center">0.040<sup>§</sup></td>
								</tr>
								<tr>
									<td align="center">No</td>
									<td align="center">79</td>
									<td align="center">0<sup>||</sup></td>
									<td align="center" colspan="2">
									</td>
								</tr>
								<tr>
									<td align="left" colspan="6"><bold>Infections</bold></td>
								</tr>
								<tr>
									<td align="left" rowspan="2">Genitourinary</td>
									<td align="center">Yes</td>
									<td align="center">16</td>
									<td align="center">1<sup>‡</sup></td>
									<td align="center">3.32 [1.08; 10.17]</td>
									<td align="center">0.031<sup>§</sup></td>
								</tr>
								<tr>
									<td align="center">No</td>
									<td align="center">68</td>
									<td align="center">0<sup>||</sup></td>
									<td align="center" colspan="2">
									</td>
								</tr>
								<tr>
									<td align="left" rowspan="2">Sepsis</td>
									<td align="center">Yes</td>
									<td align="center">16</td>
									<td align="center">1<sup>‡</sup></td>
									<td align="center">6.03 [1.386-26.205]</td>
									<td align="center">0.017<sup>§</sup></td>
								</tr>
								<tr>
									<td align="center">No</td>
									<td align="center">68</td>
									<td align="center">0<sup>||</sup></td>
									<td align="center" colspan="2">
									</td>
								</tr>
								<tr>
									<td align="left" colspan="6"><bold>Medicines used</bold></td>
								</tr>
								<tr>
									<td align="left" rowspan="2">Vitamins and supplements</td>
									<td align="center">Yes</td>
									<td align="center">67</td>
									<td align="center">1<sup>‡</sup></td>
									<td align="center">2.78 [0.72;10.63]</td>
									<td align="center">0.124<sup>§</sup></td>
								</tr>
								<tr>
									<td align="center">No</td>
									<td align="center">17</td>
									<td align="center">0<sup>||</sup></td>
									<td align="center" colspan="2">
									</td>
								</tr>
								<tr>
									<td align="left" rowspan="2">Bile acid</td>
									<td align="center">Yes</td>
									<td align="center">62</td>
									<td align="center">1<sup>‡</sup></td>
									<td align="center">24.32 [27.321; 261.608]</td>
									<td align="center">0.004<sup>§</sup></td>
								</tr>
								<tr>
									<td align="center">No</td>
									<td align="center">22</td>
									<td align="center">0<sup>||</sup></td>
									<td align="center" colspan="2">
									</td>
								</tr>
								<tr>
									<td align="left" rowspan="2">Antianemic</td>
									<td align="center">Yes</td>
									<td align="center">35</td>
									<td align="center">1<sup>‡</sup></td>
									<td align="center">2.60 [1.02; 6.58]</td>
									<td align="center">0.042<sup>§</sup></td>
								</tr>
								<tr>
									<td align="center">No</td>
									<td align="center">49</td>
									<td align="center">0<sup>||</sup></td>
									<td align="center" colspan="2">
									</td>
								</tr>
								<tr>
									<td align="left" rowspan="2">Anti-hemorrhagic</td>
									<td align="center">Yes</td>
									<td align="center">33</td>
									<td align="center">1<sup>‡</sup></td>
									<td align="center">1.95 [0.77; 4.91]</td>
									<td align="center">0.155<sup>§</sup></td>
								</tr>
								<tr>
									<td align="center">No</td>
									<td align="center">51</td>
									<td align="center">0<sup>||</sup></td>
									<td align="center" colspan="2">
									</td>
								</tr>
								<tr>
									<td align="left" rowspan="2">Anticoagulant</td>
									<td align="center">Yes</td>
									<td align="center">20</td>
									<td align="center">1<sup>‡</sup></td>
									<td align="center">3.12 [0.91;7.17]</td>
									<td align="center">0.046<sup>§</sup></td>
								</tr>
								<tr>
									<td align="center">No</td>
									<td align="center">64</td>
									<td align="center">0<sup>||</sup></td>
									<td align="center" colspan="2">
									</td>
								</tr>
								<tr>
									<td align="left" rowspan="2">Loop Diuretic</td>
									<td align="center">Yes</td>
									<td align="center">55</td>
									<td align="center">1<sup>‡</sup></td>
									<td align="center">2.56 [0.90;7.29]</td>
									<td align="center">0.074<sup>§</sup></td>
								</tr>
								<tr>
									<td align="center">No</td>
									<td align="center">29</td>
									<td align="center">0<sup>||</sup></td>
									<td align="center" colspan="2">
									</td>
								</tr>
								<tr>
									<td align="left" rowspan="2">Antiviral</td>
									<td align="center">Yes</td>
									<td align="center">79</td>
									<td align="center">1<sup>‡</sup></td>
									<td align="center">0.164<sup>**</sup></td>
									<td align="center">--</td>
								</tr>
								<tr>
									<td align="center">No</td>
									<td align="center">5</td>
									<td align="center">0<sup>||</sup></td>
									<td align="center" colspan="2">
									</td>
								</tr>
								<tr>
									<td align="left" rowspan="2">Immunosuppressant</td>
									<td align="center">Yes</td>
									<td align="center">56</td>
									<td align="center">1<sup>‡</sup></td>
									<td align="center">4.50 [1.38;14.69]</td>
									<td align="center">0.009<sup>§</sup></td>
								</tr>
								<tr>
									<td align="center">No</td>
									<td align="center">28</td>
									<td align="center">0<sup>||</sup></td>
									<td align="center" colspan="2">
									</td>
								</tr>
							</tbody>
						</table>
						<table-wrap-foot>
							<fn id="TFN6">
								<p><sup>*</sup>Confidence interval; <sup>†</sup>p-value; <sup>‡</sup>Yes; <sup>§</sup>Chi-squared test; <sup>||</sup>No; <sup>¶</sup>Graft Versus Host Disease; <sup>**</sup>Fisher’s exact test</p>
							</fn>
						</table-wrap-foot>
					</table-wrap>
				</p>
				<p>The adjusted model demonstrated that the heavier weight for the diagnosis was presented by the case group, so that only Aplastic Anemia did not present a statistical difference between the groups. The other tested variables were related to the chance of performing HSCR in a lower or higher ratio, according to the results shown in <xref ref-type="table" rid="t6">Table 3</xref>.</p>
				<p>The final multiple logistic regression model showed a significance level with a p-value &lt;0.05, with statistical evidence of association of the case group with the variables of sepsis and bile acid. Therefore, the chance of patients in this study affected by sepsis who used bile acid to undergo retransplantation was greater in relation to patients who did not develop sepsis and who did not use such medications.</p>
				<p>It is worth mentioning that Hypothesis 1 for this study of “Clinical and sociodemographic variables are associated with the need to perform HSCR among patients submitted to HSCT”, was tested and accepted.</p>
				<p>The cumulative survival probability was calculated from the total number of patients investigated in this study (n = 84), among which 49 (58.33%) completed the treatment and were discharged from the hospital, while 35 (41.67%) died. The zero (initial) time considered was the patient’s entry into the service in question to start treatment, and closure was characterized by treatment completion (when the patient was discharged from the hospital) or death. The minimum survival time was 6.67 months, and the maximum was 91.7 months. The mean overall survival (OS) was 26.97 months and 50% of the sample had an OS of 17.55 months. </p>
				<p>In general, the greater the number of months, the lower the OS. <xref ref-type="fig" rid="f4">Figure 2</xref> below shows the OS curve of the total number of individuals analyzed in this study.</p>
				<p>
					<fig id="f4">
						<label>Figure 2</label>
						<caption>
							<title>Overall survival curve between the <italic>case</italic> and <italic>control</italic> groups. Natal, RN, Brazil, 2019 (n=84)</title>
						</caption>
						<graphic xlink:href="1518-8345-rlae-30-e3569-gf4.png"/>
					</fig>
				</p>
				<p>There was no statistically significant difference for OS between groups (Log Rank = 0.583). When determining survival by study group, it was possible to observe that the curve remained similar for both until the outcome (<xref ref-type="fig" rid="f4">Figure 2</xref>), whether treatment completed or death, with a small difference for the control group in which the OS was up to 91.7 months compared to the case group, which was approximately 80 months.</p>
			</sec>
			<sec sec-type="discussion">
				<title>Discussion</title>
				<p>The epidemiological profile description of the transplant patients reveals a slight predominance of males with a diagnosis of acute myeloid leukemia and the main cause of death was sepsis. The sociodemographic data in a multicenter study conducted in Europe which retrospectively followed-up patients with acute leukemia recurrence after the first HSCT are similar to those found in this study in which the mean age of the patients was 36.76 years, 58.04% were men, 21% had ± 24-month survival, 90% of patients died, and the most frequent causes were progressive disease with 136 (55.06%), sepsis in 34 (13.76%), and GVHD in 29 (11.74%)<xref ref-type="bibr" rid="B11"><sup>11</sup></xref>.</p>
				<p>HSCR is considered a complex and aggressive procedure, as it exposes patients to a new conditioning regime and debilitating toxicities. As in the first transplant, this phase demands specific care with a multidisciplinary team which provides care support during hospitalization and in the post-transplant with outpatient care. The treatment is long and involves risks that predispose the patient to a wide range of complications which need to be managed so that they do not threaten their survival and quality of life<xref ref-type="bibr" rid="B12"><sup>12</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B13"><sup>13</sup></xref>.</p>
				<p>As in post-HSCT, allogeneic post-transplantation can present some complications such as infections, toxicities, GVHD and graft failure, which comprise the main causes of long hospitalization periods and death<xref ref-type="bibr" rid="B14"><sup>14</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B15"><sup>15</sup></xref>. Cellular and molecular mechanisms that mediate graft rejection are also triggers for developing GVHD and its control is performed by using immunosuppressants. Such complications are important problems, cause significant morbidity and mortality, and limit the transplant success and may culminate in the need for HSCR<xref ref-type="bibr" rid="B4"><sup>4</sup></xref>.</p>
				<p>Graft failure and disease relapse are the main reasons that lead to retransplantation mentioned in a study<xref ref-type="bibr" rid="B16"><sup>16</sup></xref>. Factors associated with graft failure include HLA incompatibility, underlying disease, type of conditioning regimen, source of CPH employed, low HPC dose, ex vivo T cell depletion, major ABO incompatibility, grafts from female donors to male recipients and disease status at the transplantation time, infection or sepsis and non-adherence to drug therapy with ursodeoxycholic acid and immunosuppressants in the post-HSCT period<xref ref-type="bibr" rid="B17"><sup>17</sup></xref>. The latter two mentioned were pointed out by the results of this research as factors which increase the chances of retransplantation.</p>
				<p>Relapse is the main cause of treatment failure and its prognosis is poor<xref ref-type="bibr" rid="B18"><sup>18</sup></xref>. Malignant cells can escape the cytotoxic lesion associated with the pre-transplant conditioning regime and the immune control created by the medullary and immune reconstitution in the post-transplant and cause disease relapse which does not respond to the chemotherapeutic drugs previously used, requiring a more cytotoxic drug arsenal<xref ref-type="bibr" rid="B19"><sup>19</sup></xref>.</p>
				<p>HSCT affects the intestinal microbiota, microbiome-metabolome and liver axis which can alter intestinal homeostasis and the severity of GVHD<xref ref-type="bibr" rid="B20"><sup>20</sup></xref>. The use of ursodeoxycholic acid is considered useful in the prophylaxis and treatment of some liver conditions, especially from DECH for being one of the reasons that may lead to the need for HSCR according to the results presented by this study. A retrospective study investigated the use of ursodeoxycholic acid and found a decreased incidence of sinusoidal obstruction syndrome and other liver complications<xref ref-type="bibr" rid="B21"><sup>21</sup></xref>.</p>
				<p>The most commonly used bile acid in HSCT protocols is ursodeoxycholic, and its inappropriate use at a dosage lower than that prescribed had a direct relationship with retransplantation (OR = 16.12; CI = 95%: 2.05-128.12; p = 0.001) among the participants of this study with regard to protective factors against GVHD and other liver diseases. The liver is one of the target organs of GVHD, and significant changes in the serum bilirubin and alkaline phosphatase levels may indicate involvement of this condition<xref ref-type="bibr" rid="B22"><sup>22</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref>.</p>
				<p>Immunosuppressant is used to protect against graft rejection and the need for HSCR, the inappropriate use of such medication in this study is linked to increased chances of HSCR (OR = 4.50; CI = 95 %; 1.38-14.69; p = 0.009), meaning that ingesting a lower dose than recommended in the medical prescription increases the chance of a new transplant. Patients who received an allogeneic transplant routinely receive immunosuppression starting with D-1 (one day before the procedure) to avoid graft rejection or failure, and for a long time after HSCT with calcineurin inhibitors and others<xref ref-type="bibr" rid="B4"><sup>4</sup></xref>. </p>
				<p>However, the polypharmacy experienced by patients using various oral medications, especially in the post-HSCT outpatient phase, is a limiting factor which makes it difficult to adhere to treatment in an appropriate and continuous manner<xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>. Without the correct intake of daily doses of medication, such as immunosuppressants and ursodeoxycholic acid, the patient can progress to graft failure, disease recurrence or GVHD, as demonstrated by the results of this study.</p>
				<p>Such medications are prescribed to control symptoms, infections, graft rejection, and supportive medications, among others. The therapeutic scheme is complex due to the type, number and different schedule of medications, in addition to the frequent changes in prescriptions. Patients and family members assume the burden of managing polypharmacy after discharge, and adherence is essential to minimize the chances of infection, GVHD, or disease relapse<xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>.</p>
				<p>Although this strategy has supported great advances in modern transplant medicine, especially in controlling acute rejection, it is linked to significant problems which include the toxicity of drugs and the increased risk of opportunistic infections, among others. In addition, the immunosuppressive regimen chosen may insufficiently control graft rejection or failure, as well as GVHD. As a result, many patients have a need for retransplantation, which can be clinically challenging being limited by the low availability of donated organs, tissues or cells<xref ref-type="bibr" rid="B4"><sup>4</sup></xref>.</p>
				<p>Sociodemographic factors such as low education, poor socioeconomic and lack of social support status may be directly related to the infection rates, as the patient may not understand the guidelines to avoid infections or may not have sufficient economic conditions to continue with the necessary treatment. A study carried out by researchers from several countries highlighted that 66.49% of patients did not adhere to the use of immunosuppressive drugs<xref ref-type="bibr" rid="B27"><sup>27</sup></xref>. </p>
				<p>Difficulty in adherence to drug therapy after HSCT can have a significant negative impact on survival, as it increases the risk of developing infections and disease relapse, which are some of the reasons with the highest odds ratios for the need for retransplantation pointed out by this study<xref ref-type="bibr" rid="B28"><sup>28</sup></xref>.</p>
				<p>The infections can easily progress to sepsis in immunosuppressed HSCT candidates<xref ref-type="bibr" rid="B29"><sup>29</sup></xref>. As shown in the results of this study, patients with sepsis are more likely to have retransplantation (OR = 6.03; CI = 95%: 1.386-26.205; p = 0.017).</p>
				<p>Patients are often unable to ingest medications orally with the advent of oropharyngeal mucositis, nausea and vomiting during hospitalization, so those who have an intravenous presentation are replaced. However, as for bile acid, the pharmaceutical presentation is only in 50 mg, 150 mg and 300 mg tablets, and 300 mg tablets are generally prescribed every 12 hours for allogeneic transplantation protocols. As previously discussed, bile acid was a protective factor against hepatic GVHD, sinusoidal obstruction syndrome, and dyslipidemia, among others which affect the liver.</p>
				<p>Diseases that recur after a first HSCT and graft failure or rejection usually present a poor prognosis. The attempt to achieve a better outcome for patient survival with the addition of an HSCR increased overall survival by 10%. A retransplant indication is only concentrated in patients with disease persisting after the first HSCT and in the reasons mentioned above<xref ref-type="bibr" rid="B5"><sup>5</sup></xref>.</p>
				<p>HSCR seems a little promising approach, but there are few treatment options for relapse after the first transplant such as chemotherapy with new drugs, infusion of donor lymphocytes for allogeneic transplantation, retransplantation or a combination of them. In this context, HSCR is the treatment which favors greater OS<xref ref-type="bibr" rid="B7"><sup>7</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B16"><sup>16</sup></xref>.</p>
				<p>In a North American study carried out with children and adolescents with relapse of acute myeloid leukemia after a first HSCT, it was determined that survival was 88% in 100 days, 56% in 12 months, and 48% in 120 months. This fact suggests that HSCR after initial transplant failure resulted in long-term disease-free survival in 50% of children with recurrent acute myeloid leukemia<xref ref-type="bibr" rid="B30"><sup>30</sup></xref>.</p>
				<p>Patients undergoing HSCT or HSCR generally require complex care and nursing care through all its phases, from indication of the patient to perform the procedure until their discharge from the hospital and follow-up at the hospital. Implementing nursing care systematization (NCS) and compliance with all its stages is urgent in this context<xref ref-type="bibr" rid="B31"><sup>31</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B33"><sup>33</sup></xref>, given that the patient can evolve quickly with complications associated with the underlying disease or toxicities.</p>
				<p>Promoting data which support decision-making and appropriate implementations in patient care is expected to substantially contribute to improving the clinical practice of healthcare professionals, especially nurses, and make them decisive professionals in providing care to the patient in being able to recognize the possible risk factors responsible for HSCR situations.</p>
				<p>It is important that the multidisciplinary team, especially nurses, develop care plans that support the patient’s adherence to treatment and make correct use of medication dosages, such as immunosuppressants and ursodeoxycholic acid as a way to minimize the involvement of infections, disease relapse and graft failure, as these constitute important factors that lead to retransplantation.</p>
				<p>In addition to a personalized care plan that meets the health needs of each patient, it is essential to invest in social support, which can be represented by the figure of the family member/caregiver and the health team, especially the nursing team. Teamwork which involves the patient, the family member/caregiver and health professionals must be developed, with a focus on improving the quality of life and survival after retransplantation.</p>
				<p>As this is a study with a secondary data source, it should be noted that there may be some biases such as loss of information due to weaknesses in records and information systems. In addition, the sample size and study design are also emphasized, because despite meeting the proposed objectives and answering the research question and the tested hypothesis, 84 medical records did not standardize the context of HSCT and HSCR in Brazil, which makes generalizations and more elaborate statistical analyzes impossible.</p>
			</sec>
			<sec sec-type="conclusions">
				<title>Conclusion</title>
				<p>This case-control study presented relevant scientific evidence on the performance of HSCR with regard to the clinical-epidemiological profile and performed a comparison in relation to the factors associated with the procedure and patient survival. Is it concluded that the predictive reason for retransplantation in the studied sample was disease relapse. The clinical variables of sepsis and bile acid showed a direct relationship and odds ratio with retransplantation. Sociodemographic factors are also related to HSCR, especially regarding the importance of adhering to treatment, even in the in-hospital and post-HSCT phase. </p>
			</sec>
		</body>
		<back>
			<ack>
				<title>Acknowledgements</title>
				<p>The research team thanks Hospital Rio Grande for granting the letter of consent and authorization to carry out the research, as well as the patients for accepting to participate in this study and for the relevant contribution to science.</p>
			</ack>
			<fn-group>
				<fn fn-type="presented-at" id="fn8">
					<p>Paper extracted from doctoral dissertation “Fatores associados ao retransplante de células-tronco hematopoéticas: um estudo caso-controle”, presented to Universidade Federal do Rio Grande do Norte, Natal, RN, Brazil. This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) - Finance Code 001, Brazil.</p>
				</fn>
			</fn-group>
		</back>
	</sub-article>
	<sub-article article-type="translation" id="s2" xml:lang="es">
		<front-stub>
			<article-id pub-id-type="doi">10.1590/1518-8345.5794.3568</article-id>
			<article-categories>
				<subj-group subj-group-type="heading">
					<subject>Artículo Original</subject>
				</subj-group>
			</article-categories>
			<title-group>
				<article-title>Análisis de factores asociados al Retrasplante de Células Madre Hematopoyéticas: un estudio de caso-control</article-title>
			</title-group>
			<contrib-group>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-5322-7987</contrib-id>
					<name>
						<surname>Azevedo</surname>
						<given-names>Isabelle Campos de</given-names>
					</name>
					<xref ref-type="aff" rid="aff7"><sup>1</sup></xref>
					<xref ref-type="aff" rid="aff8"><sup>2</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-9123-232X</contrib-id>
					<name>
						<surname>Ferreira</surname>
						<given-names>Marcos Antonio</given-names>
						<suffix>Júnior</suffix>
					</name>
					<xref ref-type="aff" rid="aff9"><sup>3</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-7492-2735</contrib-id>
					<name>
						<surname>Nascimento</surname>
						<given-names>Anália Andréia de Araújo</given-names>
					</name>
					<xref ref-type="aff" rid="aff7"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-4672-2303</contrib-id>
					<name>
						<surname>Vitor</surname>
						<given-names>Allyne Fortes</given-names>
					</name>
					<xref ref-type="aff" rid="aff7"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-6835-0574</contrib-id>
					<name>
						<surname>Teston</surname>
						<given-names>Elen Ferraz</given-names>
					</name>
					<xref ref-type="aff" rid="aff9"><sup>3</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0003-3586-1313</contrib-id>
					<name>
						<surname>Frota</surname>
						<given-names>Oleci Pereira</given-names>
					</name>
					<xref ref-type="aff" rid="aff9"><sup>3</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-8140-8320</contrib-id>
					<name>
						<surname>Santos</surname>
						<given-names>Viviane Euzébia Pereira</given-names>
					</name>
					<xref ref-type="aff" rid="aff7"><sup>1</sup></xref>
				</contrib>
			</contrib-group>
			<aff id="aff7">
				<label>1</label>
				<institution content-type="original"> Universidade Federal do Rio Grande do Norte, Departamento de Enfermagem, Natal, RN, Brasil.</institution>
			</aff>
			<aff id="aff8">
				<label>2</label>
				<institution content-type="original"> Bolsista da Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brasil.</institution>
			</aff>
			<aff id="aff9">
				<label>3</label>
				<institution content-type="original"> Universidade Federal de Mato Grosso do Sul, Instituto Integrado de Saúde, Campo Grande, MS, Brasil.</institution>
			</aff>
			<author-notes>
				<corresp id="c3">
					<label>Autor de correspondencia:</label> Isabelle Campos de Azevedo. E-mail: <email>isabellebr2511@gmail.com</email>
				</corresp>
				<fn fn-type="edited-by" id="fn9">
					<label>Editor Asociado</label>
					<p> Juan Manuel Carmona Torres</p>
				</fn>
				<fn fn-type="con" id="fn10">
					<label>Contribución de los autores</label>
					<p><bold>Concepción y dibujo de la pesquisa:</bold> Isabelle Campos De Azevedo, Marcos Antonio Ferreira Júnior, Allyne Fortes Vitor, Elen Ferraz Teston, Oleci Pereira Frota, Viviane Euzébia Pereira Santos. <bold>Obtención de datos:</bold> Isabelle Campos De Azevedo, Anália Andréia De Araújo Nascimento. <bold>Análisis e interpretación de los datos:</bold> Isabelle Campos De Azevedo, Marcos Antonio Ferreira Júnior, Anália Andréia De Araújo Nascimento, Oleci Pereira Frota, Viviane Euzébia Pereira Santos. <bold>Análisis estadístico:</bold> Isabelle Campos De Azevedo, Marcos Antonio Ferreira Júnior, Anália Andréia De Araújo Nascimento, Allyne Fortes Vitor, Elen Ferraz Teston. <bold>Obtención de financiación:</bold> Isabelle Campos De Azevedo, Marcos Antonio Ferreira Júnior. <bold>Redacción del manuscrito:</bold> Isabelle Campos De Azevedo, Marcos Antonio Ferreira Júnior, Anália Andréia De Araújo Nascimento, Allyne Fortes Vitor, Elen Ferraz Teston, Oleci Pereira Frota, Viviane Euzébia Pereira Santos. <bold>Revisión crítica del manuscrito en cuanto al contenido intelectual importante:</bold> Isabelle Campos De Azevedo, Marcos Antonio Ferreira Júnior, Allyne Fortes Vitor, Elen Ferraz Teston, Oleci Pereira Frota, Viviane Euzébia Pereira Santos. Todos los autores aprobaron la versión final del texto.</p>
				</fn>
				<fn fn-type="conflict" id="fn11">
					<label>Conflicto de intereses</label>
					<p> Los autores han declarado que no existe ningún conflicto de intereses.</p>
				</fn>
			</author-notes>
			<abstract>
				<title>Resumen</title>
				<sec>
					<title>Objetivo: </title>
					<p> analizar los factores asociados con el fracaso del Trasplante de Células Madre Hematopoyéticas (TCMH) en pacientes sometidos al Retrasplante de Células Madre Hematopoyéticas (RCMH). </p>
				</sec>
				<sec>
					<title>Método: </title>
					<p> estudio cuantitativo de tipo caso-control que abordó pacientes sometidos al RCMH. Para esto, se utilizó una muestra pareada de dos controles para cada caso (2:1). El grupo caso estuvo formado por los registros médicos de todos los pacientes que fueron sometidos al RCMH (28) y el grupo control (56) por los que fueron sometidos a un solo trasplante. Tres variables guiaron el emparejamiento: género, diagnóstico y tipo de trasplante. </p>
				</sec>
				<sec>
					<title>Resultados: </title>
					<p> un total de 24 (85.71%) pacientes en el grupo caso fueron retransplantados debido a la recaída de la enfermedad y 4 (14.29%) por el fracaso del injerto. Hubo una diferencia estadística en el análisis entre los pacientes que no usaron ácido ursodesoxicólico, analgésicos opioides e inmunosupresores. La necesidad de RCMH entre los que usaron estos medicamentos de manera inapropiada se encontraba 16,12 - 12,79 y 4,5 veces más probable, respectivamente, que aquellos que los usaron correctamente. </p>
				</sec>
				<sec>
					<title>Conclusión: </title>
					<p> hubo diferencia en cuanto a las razones que llevaron al retrasplante de los sujetos analizados. Este estudio concluyó que la razón predictiva del retrasplante, en la muestra estudiada, fue la recidiva de la enfermedad. </p>
				</sec>
			</abstract>
			<kwd-group xml:lang="es">
				<title>Descriptores:</title>
				<kwd>Rechazo de Injerto</kwd>
				<kwd>Recurrencia</kwd>
				<kwd>Trasplante de Células Madre Hematopoyéticas</kwd>
				<kwd>Trasplante de Médula Ósea</kwd>
				<kwd>Análisis de Supervivencia</kwd>
				<kwd>Epidemiología Analítica</kwd>
			</kwd-group>
		</front-stub>
		<body>
			<boxed-text id="bx3">
				<sec>
					<title>Destacados</title>
					<p>(1) Primer estudio brasileño sobre Retrasplante de Células Madre Hematopoyéticas (RCMH).</p>
					<p>(2) Presenta evidencia sobre el perfil clínico de los pacientes sometidos a RCMH.</p>
					<p>(3) La razón predictiva de RCMH fue la recaída de la enfermedad.</p>
					<p>(4) La recaída de la enfermedad puede estar asociada con el fracaso del tratamiento.</p>
				</sec>
			</boxed-text>
			<sec sec-type="intro">
				<title>Introducción</title>
				<p>El trasplante de células madre hematopoyéticas (TCMH) se considera una forma de tratamiento para hemopatías malignas, así como de otras enfermedades hematopoyéticas, linfáticas y del sistema inmunitario<xref ref-type="bibr" rid="B1"><sup>1</sup></xref>; este se caracteriza por la infusión intravenosa de células madres hematopoyéticas (CMH) para corregir fallas cuantitativas o cualitativas de la médula ósea<xref ref-type="bibr" rid="B2"><sup>2</sup></xref>.</p>
				<p>El trasplante de células madre hematopoyéticas (TCMH) se puede ser clasificado según su tipo: autólogos cuando las CMH son del propio paciente; alogénicos cuando las células son de donantes (de familiares o no) con antígeno leucocitario humano compatible (ALH); y, singénicos cuando las CMH son de un gemelo idéntico. Las células utilizadas para este tipo de trasplante se pueden recolectar de: la médula ósea, la sangre periférica, la sangre del cordón umbilical y de la placenta<xref ref-type="bibr" rid="B2"><sup>2</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B3"><sup>3</sup></xref>.</p>
				<p>Es fundamental que las células infundidas proliferen en el receptor de forma permanente, sin ser rechazadas y lograr el éxito del TCMH; también el nuevo sistema inmunitario recibido del donante debe tolerar los tejidos del receptor para evitar infecciones. La enfermedad del injerto contra el huésped EICH/<italic>GVDH</italic> puede ser grave y fatal. Además, el sistema inmunitario debe estar funcionando correctamente; también, en la etapa de la enfermedad hay que considerar las complicaciones, las comorbilidades en el momento del trasplante y la asistencia sanitaria durante todo el proceso<xref ref-type="bibr" rid="B4"><sup>4</sup></xref>. </p>
				<p>Para el propósito de este estudio, la condición en la cual el TCMH realizado no pudo establecerse en el paciente - que lo recibió (para resolver la insuficiencia medular inicial) y por esa razón fue requerido un retrasplante como condición terapéutica - será considerará como un fracaso.</p>
				<p>El fracaso del TCMH está directamente relacionado con todas las fases del procedimiento, lo que es representado por el fracaso o rechazo del injerto y la recaída de la enfermedad, que ocurre en aproximadamente en el 20% de los pacientes trasplantados<xref ref-type="bibr" rid="B5"><sup>5</sup></xref>. Un estudio realizado en Alemania corrobora esta estadística, ya que 24,89% de los 229 pacientes que se sometieron al TCMH, entre enero de 2005 y diciembre de 2015, requirieron retrasplante<xref ref-type="bibr" rid="B6"><sup>6</sup></xref>. No hay datos epidemiológicos de estudios sobre RCMH realizados en Brasil, siendo este el primer estudio sobre el tema.</p>
				<p>En esta perspectiva, constituye un estudio epidemiológico - realizado con el objetivo de investigar los factores asociados al RCMH - que puede identificar posibles características o complicaciones que podrían ocurrir durante el proceso del trasplante y así contribuir significativamente para el éxito o fracaso de procedimientos, como la Enfermedad de Injerto Contra Huésped (EICH), la falla del injerto o recaída, entre otros<xref ref-type="bibr" rid="B6"><sup>6</sup></xref>.</p>
				<p>La falla del TCMH puede culminar en la necesidad de un retrasplante y nuevamente expondrá al paciente a todas las etapas del procedimiento y a los riesgos de morbilidad y mortalidad. El retrasplante de células madre hematopoyéticas (RCMH) puede definirse como la única opción/forma de tratamiento para el rechazo/fracaso del injerto o recidiva, con posibilidad de aumentar la supervivencia o promover la remisión de la enfermedad en los pacientes que se han sometido previamente al TCMH<xref ref-type="bibr" rid="B7"><sup>7</sup></xref>. El pronóstico para los pacientes con progresión de la enfermedad después del primer TCMH es deprimente, así el RCMH es una opción potencialmente curativa<xref ref-type="bibr" rid="B8"><sup>8</sup></xref>.</p>
				<p>Al considerar que el perfil epidemiológico de los pacientes así como los factores asociados al retrasplante varían según la enfermedad subyacente y la evolución clínica del tratamiento, el presente estudio se basó en la siguiente pregunta de investigación: ¿Existe asociación entre las características clínicas y sociodemográficas con el retrasplante de células madre hematopoyéticas?</p>
				<p>Este estudio se justifica principalmente por la complejidad que implica el procedimiento de TCMH<xref ref-type="bibr" rid="B9"><sup>9</sup></xref> y porque la identificación de las variables que pueden conducir al riesgo de un RCMH requiere una investigación exhaustiva. Esto a su vez justifica la necesidad de realizar estudios longitudinales como este, para identificar y analizar esos factores intrínsecos del proceso de retrasplante y producir conocimiento que apoye la asistencia a la salud, el desarrollo o mejora de los protocolos de atención institucional y las políticas públicas para el funcionamiento efectivo de los servicios de trasplante.</p>
				<p>En este contexto, se espera que los resultados aquí presentados pueden contribuir para sistematizar y mejorar la organización y planificación de la atención a los pacientes del TCMH; además, fomentar la formación de profesionales de la salud, especialmente de enfermería, con el fin de capacitarlos para brindar atención especializada en TCMH y a sus interfaces (a partir de la identificación de factores que conducen al RCMH) y también para prevenir las complicaciones asociadas.</p>
				<p>Por tanto, el objetivo del presente estudio es analizar los factores asociados al fracaso del trasplante de células madre hematopoyéticas en pacientes sometidos al RCMH. </p>
			</sec>
			<sec sec-type="methods">
				<title>Método</title>
				<sec>
					<title>Estudio y diseño</title>
					<p>Este estudio implementó un enfoque cuantitativo de tipo caso-control, de diseño analítico, observacional, longitudinal e individual, con una relación de 1 caso/2 controles en pacientes en sometidos al TCMH. El Fortalecimiento del Reporte de Estudios Observacionales en Epidemiología (FREOE) utilizado para estudios observacionales fue seguido, como recomendado por la red EQUATOR.</p>
				</sec>
				<sec>
					<title>Lugar y período del estudio</title>
					<p>El estudio se realizó en un hospital de referencia para dar atención de alta complejidad, ubicado en Natal (RN), en Brasil, autorizado, acreditado y calificado para realizar TCMH por el Sistema Único de Salud Brasileño (SUS), a partir de 2004. Los datos fueron recolectados entre los meses de julio y agosto de 2018.</p>
				</sec>
				<sec>
					<title>Participantes</title>
					<p>La muestra estuvo compuesta por todos los pacientes con historia clínica registrada que realizaron TCMH, en el servicio en estudio, entre enero de 2008 y diciembre de 2017, durante un total de 10 años del procedimiento. Este marco de tiempo se justifica por el hecho de que las historias clínicas de los años entre 2004 y 2007 no fueron registradas en el Servicio de Archivo Médico Estadístico.</p>
					<p>La población de estudio estuvo constituida por todas las historias clínicas registradas por el servicio, con una muestra inicial de 389 registros de pacientes que realizaron el procedimiento de TCMH, independientemente del tipo de trasplante adoptado; sin embargo, cinco fueron excluidos por inelegibilidad o información incompleta. Después de excluir registros médicos inelegibles o con información incompleta, la muestra de cohorte final consistió en 384 registros médicos de pacientes sometidos al TCMH.</p>
					<p>Del total de pacientes 31 fueron sometidos al RCMH, caracterizándolos como el grupo caso y con el registro de un solo trasplante realizado que se utilizó para componer el grupo control. Tres casos fueron excluidos de la muestra, ya que no fue posible compararlos con los controles disponibles en la población de este estudio; uno de ellos con diagnóstico de trombocitemia esencial, otro de síndrome mielodisplásico y el último paciente con diagnóstico de mieloma múltiple (uno de los tipos más prevalentes de cáncer hematológico); sin embargo, el tipo de trasplante realizado fue alogénico por la imposibilidad de utilizar el CMH del propio paciente para el TCMH autólogo, totalizando así 28 casos. </p>
					<p>El emparejamiento de la muestra buscaba la máxima similitud entre los individuos. El grupo control en relación al grupo caso se definió comparando las variables de género, diagnóstico y tipo de TCMH realizado. Se utilizó la variable edad para ofrecer mayor similitud entre las edades de casos y controles, ya que las edades no eran iguales para algunos emparejamientos, siendo más bien aproximadas. </p>
					<p>La variable registro se utilizó como información adicional para diferenciar mejor las historias clínicas y minimizar el sesgo de selección. Es importante resaltar que los registros muestrales de 12 niños y adolescentes forman parte de la muestra, y que fueron emparejados entre sí para que se cumpliera el grado de similitud. En este contexto, la muestra final estuvo conformada por 84 pacientes: 28 casos y 56 controles, este último extraído de las 353 historias clínicas restantes. Se creó un diagrama de flujo, presentado en la <xref ref-type="fig" rid="f5">Figura 1</xref>, para una mejor comprensión de la selección de registros médicos por grupo.</p>
					<p>
						<fig id="f5">
							<label>Figura 1</label>
							<caption>
								<title>Diagrama de flujo de síntesis de la selección de registros médicos que compusieron los grupos de caso y control. Natal, RN, Brasil, 2019 (n=84)</title>
							</caption>
							<graphic xlink:href="1518-8345-rlae-30-e3569-gf5.png"/>
						</fig>
					</p>
					<p>Los criterios de inclusión para el grupo caso fueron: ser un paciente sometido a RCMH autólogo, alogénico o singénico, de cualquier edad y de ambos sexos. Los criterios de inclusión para el grupo control fueron: pacientes sometidos a un solo TCMH autólogo, alogénico o singénico, de cualquier edad y de ambos sexos.</p>
				</sec>
				<sec>
					<title>Recolección de datos y variables</title>
					<p>Se implementó un instrumento de recolección de datos que abordó variables sociodemográficas y clínicas, las que fueron: fecha y lugar de nacimiento, lugar de residencia, edad, sexo, raza, nivel educativo, estado civil, ocupación, situación con el tiempo de trasplante del servicio, tiempo entre el ingreso y el TCMH, tiempo total de seguimiento por el servicio de trasplante, diagnóstico de enfermedad subyacente, tipo de TCMH realizado, tipo de RCMH realizado, tipo de células infundidas, motivo para la indicación del trasplante, toxicidades presentadas, tratamientos instituidos, presencia de EICH aguda o crónica y supervivencia del paciente trasplantado. Cabe señalar que todas las variables fueron recolectadas de los registros médicos.</p>
					<p>Los investigadores que recopilaron los datos recibieron capacitación en dos etapas; la primera se refería al objeto de estudio y sus interfaces y la segunda al instrumento de recolección de datos y sus especificidades; estos estaban cegados en cuanto a los objetivos del estudio, así como a la hipótesis a ser comprobada, como una forma de minimizar el sesgo de confusión al intentar hacer alguna asociación entre las respuestas. </p>
				</sec>
				<sec>
					<title>Procesamiento y análisis de datos</title>
					<p>Se construyeron tablas con frecuencias absolutas y relativas por género, totales, medias y desviaciones estándar, para la descripción de la muestra. La prueba de Chi-Cuadrado se utilizó para probar la significación estadística, la prueba exacta de Fisher se utilizó para calcular la probabilidad de asociación entre las características analizadas y el grupo caso (según la naturaleza de cada variable), y se utilizó la prueba U de Mann-Whitney para comparar las tendencias centrales de dos muestras independientes de igual tamaño y comparar dos grupos emparejados o no emparejados para verificar si pertenecían o no a la misma población y si los requisitos de los dos grupos - para aplicar la prueba t de Student - no se cumplieron. Se utilizó la prueba de Kolmogorov-Smirnov para verificar la normalidad de los datos.</p>
					<p>Se utilizaron análisis bivariados y multivariados para evaluar la asociación entre las variables seleccionadas y estimar la magnitud del <italic>Odds Ratio</italic> (OR), respectivamente. Las pruebas de Razón de Verosimilitud, Wald y Pseudo R<sup>2</sup> (Cox y Snell = 0,240; Nagelkerke = 0,333) se utilizaron para asegurar la significación de las variables en los modelos de Regresión Logística, así como en la prueba de la hipótesis determinar si las variables independientes, en el modelo, están significativamente relacionadas con la variable dependiente.</p>
					<p>La variable dependiente (retrasplante de células madre hematopoyéticas = Y) se adoptó para la regresión logística; la influencia de una o más variables independientes, causales o explicativas (X1, X2, X3,...) se verificó en la variable dependiente. Para este análisis se utilizó la siguiente ecuación: </p>
					<p>
						<disp-formula id="e3">
							<mml:math>
								<mml:msub>
									<mml:mrow>
										<mml:mi>γ</mml:mi>
									</mml:mrow>
									<mml:mrow>
										<mml:mi>i</mml:mi>
									</mml:mrow>
								</mml:msub>
								<mml:mi>
								</mml:mi>
								<mml:mo>=</mml:mo>
								<mml:msub>
									<mml:mrow>
										<mml:mi>β</mml:mi>
									</mml:mrow>
									<mml:mrow>
										<mml:mn>0</mml:mn>
									</mml:mrow>
								</mml:msub>
								<mml:mo>+</mml:mo>
								<mml:msub>
									<mml:mrow>
										<mml:mi>β</mml:mi>
									</mml:mrow>
									<mml:mrow>
										<mml:mn>1</mml:mn>
									</mml:mrow>
								</mml:msub>
								<mml:msub>
									<mml:mrow>
										<mml:mi>X</mml:mi>
									</mml:mrow>
									<mml:mrow>
										<mml:mn>1</mml:mn>
									</mml:mrow>
								</mml:msub>
								<mml:mo>+</mml:mo>
								<mml:msub>
									<mml:mrow>
										<mml:mi>β</mml:mi>
									</mml:mrow>
									<mml:mrow>
										<mml:mn>2</mml:mn>
									</mml:mrow>
								</mml:msub>
								<mml:msub>
									<mml:mrow>
										<mml:mi>X</mml:mi>
									</mml:mrow>
									<mml:mrow>
										<mml:mn>2</mml:mn>
									</mml:mrow>
								</mml:msub>
								<mml:mo>+</mml:mo>
								<mml:mi>
								</mml:mi>
								<mml:mo>…</mml:mo>
								<mml:mo>+</mml:mo>
								<mml:msub>
									<mml:mrow>
										<mml:mi>β</mml:mi>
									</mml:mrow>
									<mml:mrow>
										<mml:mi>i</mml:mi>
									</mml:mrow>
								</mml:msub>
								<mml:msub>
									<mml:mrow>
										<mml:mi>X</mml:mi>
									</mml:mrow>
									<mml:mrow>
										<mml:mi>i</mml:mi>
									</mml:mrow>
								</mml:msub>
								<mml:mo>+</mml:mo>
								<mml:msub>
									<mml:mrow>
										<mml:mi>ε</mml:mi>
									</mml:mrow>
									<mml:mrow>
										<mml:mi>i</mml:mi>
									</mml:mrow>
								</mml:msub>
							</mml:math>
						</disp-formula>
					</p>
					<p>Al analizar el modelo de regresión logística final, el estadístico Chi-Cuadrado de los residuos (<italic>Overall Statistics</italic>) presentó el valor de p &gt; 0,05, lo que significa que ninguna de las variables excluidas del modelo contribuiría significativamente en el poder predictivo del modelo. Se encontró que el valor p &gt; 0.05 no fue estadísticamente significativo con la prueba de Hosmer-Lemeshow, lo que indicó que se obtuvo un buen ajuste del modelo final. Por lo tanto, se concluyó que el modelo final ajustado de regresión logística fue adecuado.</p>
					<p>Los cálculos de supervivencia se realizaron aplicando el método de Kaplan-Meier considerando el punto de entrada inicial del paciente en el estudio como la fecha del TCMH y el último evento como el punto final, pudiendo ser: muerte, abandono, seguimiento en el momento de la recogida de datos y tratamiento finalizado. Se utilizó el método estadístico Log-Rank para comparar las tasas de supervivencia por variables que serán enumeradas. Se adoptó un nivel de significación de 0,05 para todos los análisis.</p>
				</sec>
				<sec>
					<title>Aspectos éticos </title>
					<p>El Protocolo de Investigación de este estudio fue presentado al Comité de Ética en Investigación de la Universidad Federal de Rio Grande del Norte, de acuerdo con la Resolución N° 466/12 del Consejo Nacional de Salud del Ministerio de la Salud que trata de la investigación con seres humanos, para la evaluación de sus aspectos éticos y metodológicos<xref ref-type="bibr" rid="B10"><sup>10</sup></xref>; este fue aprobado bajo dictamen 2.596.384 y CAAE: 80927417.9.0000.5537, aprobado el 18 de abril de 2018.</p>
				</sec>
			</sec>
			<sec sec-type="results">
				<title>Resultados</title>
				<p>La edad varió entre dos y 55 años y la media fue de 34,11 años (± 14,20) (<xref ref-type="table" rid="t7">Tabla 1</xref>), 51 (60,71%) participantes eran del sexo masculino, 65 (77,38%) vivían en el estado de Rio Grande del Norte, 41 (48.81%) eran casados y 49 (58.33%) tenían un empleo remunerado. Como la media de edad rondaba los 34 años y la variable edad presentaba una variabilidad significativa, se consideraron dos grupos de edad hasta los 35 años y mayores de 35 años, para organizar mejor esta información en la <xref ref-type="table" rid="t7">Tabla 1</xref>. La variable edad se consideró continua para cálculos de asociación y otros.</p>
				<p>Del total, 42 (50,00%) recibieron atención en el sector de TCMH por cerca de 21 meses y 43 (51,19%; p&lt;0,001) esperaron hasta 15 días entre el inicio del régimen de acondicionamiento hasta el primer TCMH.</p>
				<p>Los diagnósticos que culminaron en el RCMH se muestran en la <xref ref-type="table" rid="t7">Tabla 1</xref>. Fallecieron 35 (41,67%) de los pacientes estudiados, de los cuales 16 (57,14%) sucedió entre los que fueron retrasplantados. Las causas de muerte más prevalentes fueron sepsis con 28 (33,34%), falla multiorgánica en 14 (16,67%) e infección pulmonar en ocho (9,52%). Además, se realizaron 51 (60,71%) TCMH alogénicos, de los cuales 17 (60,71%) fueron retrasplantes (<xref ref-type="table" rid="t7">Tabla 1</xref>).</p>
				<p>El TCMH alogénico ocurrió en 39 (76,47%) de los individuos, siendo la fuente de CMH más utilizada la sangre periférica en 64 (85,33%) de los TCMHs. El motivo más indicado de retrasplante fue la recidiva de la enfermedad en 24 (85,71%). Además, se realizó RCMH alogénico en 26 (92,86%) pacientes, siendo de familiares en 21 (75,00%) con HMC de sangre periférica (75,00%). Los pacientes que desarrollaron EICH tuvieron 9,17 veces más probabilidades de realizar el RCMH.</p>
				<p>El tiempo medio para realizar el retrasplante fue de 14,74 meses, siendo el motivo más prevalente del TCMH la recidiva de la enfermedad (24; 85,14%); 42 (50,00%) tuvieron una supervivencia de alrededor de 17 meses.</p>
				<p>
					<table-wrap id="t7">
						<label>Tabla 1</label>
						<caption>
							<title>Análisis bivariado entre el desempeño y no desempeño del RCMH y las variables independientes (n=84). Natal, RN, Brasil, 2019</title>
						</caption>
						<table>
							<colgroup>
								<col/>
								<col span="4"/>
								<col/>
								<col/>
							</colgroup>
							<thead>
								<tr>
									<th align="left" rowspan="3">Variables</th>
									<th align="center" colspan="4">Grupos </th>
									<th align="center" rowspan="3"><italic>Odds Ratio</italic> [95%CI<sup>*</sup>]</th>
									<th align="center" rowspan="3"><italic>p</italic> <sup>†</sup></th>
								</tr>
								<tr>
									<th align="center" colspan="2"><italic>caso</italic> (n=28)</th>
									<th align="center" colspan="2"><italic>control</italic> (n=56)</th>
								</tr>
								<tr>
									<th align="center">n</th>
									<th align="center">%</th>
									<th align="center">n</th>
									<th align="center">%</th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td align="left" colspan="7"><bold>Género</bold></td>
								</tr>
								<tr>
									<td align="left">Masculino</td>
									<td align="center">17</td>
									<td align="center">60.71</td>
									<td align="center">34</td>
									<td align="center">60.71</td>
									<td align="center" rowspan="2">1.00 [0.39; 2.53]</td>
									<td align="center" rowspan="2">1.000<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left">Femenino</td>
									<td align="center">11</td>
									<td align="center">39.29</td>
									<td align="center">22</td>
									<td align="center">39.29</td>
								</tr>
								<tr>
									<td align="left" colspan="7"><bold>Intervalo de edad</bold></td>
								</tr>
								<tr>
									<td align="left">Hasta 35 años</td>
									<td align="center">13</td>
									<td align="center">46.43</td>
									<td align="center">26</td>
									<td align="center">46.43</td>
									<td align="center" rowspan="2">1.00 [0.40; 2.48]</td>
									<td align="center" rowspan="2">1.000<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left">Arriba de 35 años</td>
									<td align="center">15</td>
									<td align="center">53.57</td>
									<td align="center">30</td>
									<td align="center">53.57</td>
								</tr>
								<tr>
									<td align="left" colspan="7"><bold>Diagnóstico</bold></td>
								</tr>
								<tr>
									<td align="left">Leucemia mieloide aguda</td>
									<td align="center">8</td>
									<td align="center">28.57</td>
									<td align="center">16</td>
									<td align="center">28.57</td>
									<td align="center" rowspan="7">--</td>
									<td align="center" rowspan="7">1.000<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left">Linfoma no Hodgkin</td>
									<td align="center">6</td>
									<td align="center">21.43</td>
									<td align="center">12</td>
									<td align="center">21.43</td>
								</tr>
								<tr>
									<td align="left">Mieloma múltiple</td>
									<td align="center">5</td>
									<td align="center">17.86</td>
									<td align="center">10</td>
									<td align="center">17.86</td>
								</tr>
								<tr>
									<td align="left">Leucemia linfoblástica aguda</td>
									<td align="center">4</td>
									<td align="center">14.29</td>
									<td align="center">8</td>
									<td align="center">14.29</td>
								</tr>
								<tr>
									<td align="left">Anemia aplásica</td>
									<td align="center">3</td>
									<td align="center">10.71</td>
									<td align="center">6</td>
									<td align="center">10.71</td>
								</tr>
								<tr>
									<td align="left">Enfermedad de Hodgkin</td>
									<td align="center">1</td>
									<td align="center">3.57</td>
									<td align="center">2</td>
									<td align="center">3.57</td>
								</tr>
								<tr>
									<td align="left">Leucemia mieloide crónica</td>
									<td align="center">1</td>
									<td align="center">3.57</td>
									<td align="center">2</td>
									<td align="center">3.57</td>
								</tr>
								<tr>
									<td align="left" colspan="7"><bold>TCMH<sup>§</sup> realizado</bold></td>
								</tr>
								<tr>
									<td align="left">Alogénico</td>
									<td align="center">17</td>
									<td align="center">60.71</td>
									<td align="center">34</td>
									<td align="center">60.71</td>
									<td align="center" rowspan="2">1.00 [0.39; 2.53]</td>
									<td align="center" rowspan="2">1.000<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left">Autólogo</td>
									<td align="center">11</td>
									<td align="center">39.29</td>
									<td align="center">22</td>
									<td align="center">39.29</td>
								</tr>
								<tr>
									<td align="left" colspan="7"><bold>EICH<sup>||</sup></bold></td>
								</tr>
								<tr>
									<td align="left">No</td>
									<td align="center">24</td>
									<td align="center">85.71</td>
									<td align="center">55</td>
									<td align="center">98.21</td>
									<td align="center" rowspan="2">9.17 [0.97; 86.38]</td>
									<td align="center" rowspan="2">0.040<sup>¶</sup></td>
								</tr>
								<tr>
									<td align="left">Si</td>
									<td align="center">4</td>
									<td align="center">14.29</td>
									<td align="center">1</td>
									<td align="center">1.79</td>
								</tr>
								<tr>
									<td align="left" colspan="7"><bold>Situación con RGH<sup>**</sup></bold></td>
								</tr>
								<tr>
									<td align="left">Tratamiento terminado</td>
									<td align="center">12</td>
									<td align="center">42.86</td>
									<td align="center">37</td>
									<td align="center">66.07</td>
									<td align="center" rowspan="2">0.38 [0.15; 0.97]</td>
									<td align="center" rowspan="2">0.042<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left">Muerte</td>
									<td align="center">16</td>
									<td align="center">57.14</td>
									<td align="center">19</td>
									<td align="center">33.93</td>
								</tr>
								<tr>
									<td align="left" colspan="7"><bold>Seguimiento hasta TCMH</bold></td>
								</tr>
								<tr>
									<td align="left">Hasta 15 días</td>
									<td align="center">17</td>
									<td align="center">39.53</td>
									<td align="center">26</td>
									<td align="center">60.47</td>
									<td align="center" rowspan="2">1.78 [0.71; 4.49]</td>
									<td align="center" rowspan="2">0.217<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left">Más de 15 días</td>
									<td align="center">11</td>
									<td align="center">26.83</td>
									<td align="center">30</td>
									<td align="center">73.17</td>
								</tr>
								<tr>
									<td align="left" colspan="7"><bold>Seguimiento hasta el servicio TCMH<sup>§</sup></bold></td>
								</tr>
								<tr>
									<td align="left">Hasta 21 meses</td>
									<td align="center">12</td>
									<td align="center">28.57</td>
									<td align="center">30</td>
									<td align="center">71.43</td>
									<td align="center" rowspan="2">0.65 [0.26; 1.62]</td>
									<td align="center" rowspan="2">0.355<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left">Más de 21 meses</td>
									<td align="center">16</td>
									<td align="center">38.10</td>
									<td align="center">26</td>
									<td align="center">61.90</td>
								</tr>
								<tr>
									<td align="left" colspan="7"><bold>Supervivencia</bold></td>
								</tr>
								<tr>
									<td align="left">Hasta 17,5 meses</td>
									<td align="center">13</td>
									<td align="center">30.95</td>
									<td align="center">29</td>
									<td align="center">69.05</td>
									<td align="center" rowspan="2">0.81 [0.32; 2.00]</td>
									<td align="center" rowspan="2">0.643<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left">Más de 17,5 meses</td>
									<td align="center">15</td>
									<td align="center">35.71</td>
									<td align="center">27</td>
									<td align="center">64.29</td>
								</tr>
							</tbody>
						</table>
						<table-wrap-foot>
							<fn id="TFN7">
								<p><sup>*</sup>Intervalo de confianza; <sup>†</sup>valor de p; <sup>‡</sup>Prueba de Chi-Cuadrado; <sup>§</sup>Trasplante de células madre hematopoyéticas; <sup>||</sup>Enfermedad injerto contra huésped; <sup>¶</sup>Prueba exacta de Fisher; <sup>**</sup>Hospital Rio Grande</p>
							</fn>
						</table-wrap-foot>
					</table-wrap>
				</p>
				<p>Un total de 24 (85,71%) de los pacientes del grupo caso, de este estudio, fueron retrasplantados por recidiva de la enfermedad y cuatro (14,29%) por fracaso del injerto. Al considerar el promedio de meses de seguimiento (29.26; p&lt;0.001), por parte del servicio de trasplantes, y la situación con el servicio en relación a la muerte (OR = 0,38; IC = 95%: 0,15-0,97; p = 0,042), respectivamente, es posible comprender que cuanto mayor es el período de atención hospitalaria, mayor será la posibilidad de que los pacientes sean retrasplantados y de terminar en muerte. Esto se debe a que la estadía hospitalaria, en este contexto, está directamente relacionada con complicaciones graves, como infección o sepsis que pueden conducir al fracaso del injerto y la recurrencia de la enfermedad. </p>
				<p>En la <xref ref-type="table" rid="t8">Tabla 2</xref> se presentan las variables referentes a los medicamentos que exponen al paciente a una mayor probabilidad de ser retrasplantado. Además, se encontró una diferencia estadísticamente significativa para los pacientes que se sometieron al TCMH y que desarrollaron comorbilidades genitourinarias, toxicidades hematológicas y edema; las chances de que estos pacientes sometidos a retrasplante fueron 3,32, 3,22 y 2,81 veces mayores, respectivamente, en comparación con pacientes que no desarrollaron la comorbilidad y toxicidades mencionadas. </p>
				<p>
					<table-wrap id="t8">
						<label>Tabla 2</label>
						<caption>
							<title>Análisis bivariado de medicinas administradas y toxicidades presentadas según los grupos estudiados (n=84). Natal, RN, Brasil, 2019</title>
						</caption>
						<table>
							<colgroup>
								<col/>
								<col span="4"/>
								<col/>
								<col/>
							</colgroup>
							<thead>
								<tr>
									<th align="left" rowspan="3">Variables</th>
									<th align="center" colspan="4">Grupos </th>
									<th align="center" rowspan="3"><italic>Odds Ratio</italic> [95%CI<sup>*</sup>]</th>
									<th align="center" rowspan="3"><italic>p</italic><sup>†</sup></th>
								</tr>
								<tr>
									<th align="center" colspan="2">caso (n=28) </th>
									<th align="center" colspan="2">control (n=56) </th>
								</tr>
								<tr>
									<th align="center">n</th>
									<th align="center">%</th>
									<th align="center">n</th>
									<th align="center">%</th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td align="left" colspan="7"><bold>Medicamentos administrados</bold></td>
								</tr>
								<tr>
									<td align="left" colspan="7"><bold>Ácido ursodesoxicólico</bold></td>
								</tr>
								<tr>
									<td align="left">Si</td>
									<td align="center">27</td>
									<td align="center">96.43</td>
									<td align="center">35</td>
									<td align="center">62.50</td>
									<td align="center" rowspan="2">16.12 [2.05-128.12]</td>
									<td align="center" rowspan="2">0.001<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left">No</td>
									<td align="center">1</td>
									<td align="center">3.57</td>
									<td align="center">21</td>
									<td align="center">37.50</td>
								</tr>
								<tr>
									<td align="left" colspan="7"><bold>Inmunosupresor</bold></td>
								</tr>
								<tr>
									<td align="left">Si</td>
									<td align="center">24</td>
									<td align="center">85.71</td>
									<td align="center">32</td>
									<td align="center">57.14</td>
									<td align="center" rowspan="2">4.50 [1.38-14.69]</td>
									<td align="center" rowspan="2">0.009<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left">No</td>
									<td align="center">4</td>
									<td align="center">14.29</td>
									<td align="center">24</td>
									<td align="center">42.86</td>
								</tr>
								<tr>
									<td align="left" colspan="7"><bold>Toxicidades presentadas</bold></td>
								</tr>
								<tr>
									<td align="left" colspan="7"><bold>Genitourinaria</bold></td>
								</tr>
								<tr>
									<td align="left">Si</td>
									<td align="center">9</td>
									<td align="center">32.14</td>
									<td align="center">7</td>
									<td align="center">12.50</td>
									<td align="center" rowspan="2">3.32 [1.08; 10.17]</td>
									<td align="center" rowspan="2">0.031<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left">No</td>
									<td align="center">19</td>
									<td align="center">67.86</td>
									<td align="center">49</td>
									<td align="center">87.50</td>
								</tr>
								<tr>
									<td align="left" colspan="7"><bold>Hematológica</bold></td>
								</tr>
								<tr>
									<td align="left">Si</td>
									<td align="center">21</td>
									<td align="center">75.00</td>
									<td align="center">27</td>
									<td align="center">48.21</td>
									<td align="center" rowspan="2">3.22 [1.18; 8.79]</td>
									<td align="center" rowspan="2">0.019<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left">No</td>
									<td align="center">7</td>
									<td align="center">25.00</td>
									<td align="center">29</td>
									<td align="center">51.79</td>
								</tr>
								<tr>
									<td align="left" colspan="7"><bold>Edema</bold></td>
								</tr>
								<tr>
									<td align="left">Si</td>
									<td align="center">19</td>
									<td align="center">67.86</td>
									<td align="center">24</td>
									<td align="center">42.86</td>
									<td align="center" rowspan="2">2.81 [1.08; 7.30]</td>
									<td align="center" rowspan="2">0.031<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left">No</td>
									<td align="center">9</td>
									<td align="center">32.14</td>
									<td align="center">32</td>
									<td align="center">57.14</td>
								</tr>
								<tr>
									<td align="left" colspan="7"><bold>Oftalmológica</bold></td>
								</tr>
								<tr>
									<td align="left">Si</td>
									<td align="center">8</td>
									<td align="center">28.57</td>
									<td align="center">7</td>
									<td align="center">12.50</td>
									<td align="center" rowspan="2">2.80 [0.90; 8.75]</td>
									<td align="center" rowspan="2">0.070<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left">No</td>
									<td align="center">20</td>
									<td align="center">71.43</td>
									<td align="center">49</td>
									<td align="center">87.50</td>
								</tr>
								<tr>
									<td align="left" colspan="7"><bold>Sepsis</bold></td>
								</tr>
								<tr>
									<td align="left">Si</td>
									<td align="center">8</td>
									<td align="center">28.57</td>
									<td align="center">8</td>
									<td align="center">14.29</td>
									<td align="center" rowspan="2">2.40 [0.79; 7.28]</td>
									<td align="center" rowspan="2">0.116<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left">No</td>
									<td align="center">20</td>
									<td align="center">71.43</td>
									<td align="center">48</td>
									<td align="center">85.71</td>
								</tr>
							</tbody>
						</table>
						<table-wrap-foot>
							<fn id="TFN8">
								<label><sup>*</sup></label>
								<p>Intervalo de confianza; <sup>†</sup>Valor de p; <sup>‡</sup>Prueba de Chi-Cuadrado</p>
							</fn>
						</table-wrap-foot>
					</table-wrap>
				</p>
				<p>Hubo diferencia estadística en el análisis entre los pacientes que no usaban ácido ursodesoxicólico e inmunosupresores. La posibilidad de necesitar el RCMH entre aquellos que usaron estos medicamentos de manera inapropiada, por falta de adherencia al tratamiento fue 16,12 y 4,5 veces mayor, respectivamente, que aquellos que usaron esos medicamentos correctamente. Cabe señalar que el primero y el último son medicamentos esenciales, utilizados de forma obligatoria en los protocolos de trasplante alogénico y retrasplante. La no adherencia a los fármacos relacionados con el ácido ursodesoxicólico y los inmunosupresores se registró en 51 (60,71%) de las historias clínicas encuestadas.</p>
				<p>El retrasplante fue considerado una variable dependiente para la aplicación del modelo de regresión logística adoptado para este estudio, y los grupos se codificaron como control (0) y caso (1). La variable dependiente se convirtió posteriormente en una razón de probabilidad y luego en una variable basada en logaritmos. Las variables que mostraron significación estadística (p&lt;0,05) se organizaron en un modelo de regresión logística múltiple, que en principio asumió un valor de p&lt;0,20, para analizarlos en conjunto (<xref ref-type="table" rid="t9">Tabla 3</xref>).</p>
				<p>
					<table-wrap id="t9">
						<label>Tabla 3</label>
						<caption>
							<title>Regresión logística múltiple ajustada según las variables que presentaron significación estadística, agrupadas con el resultado del retrasplante (n=84). Natal, RN, Brasil, 2019</title>
						</caption>
						<table>
							<colgroup>
								<col span="2"/>
								<col span="2"/>
								<col/>
								<col/>
							</colgroup>
							<thead>
								<tr>
									<th align="left" colspan="2">Variables </th>
									<th align="center" colspan="2">Frecuencia </th>
									<th align="center"><italic>Odds Ratio</italic> [95%CI<sup>*</sup>]</th>
									<th align="center"><italic>p</italic> <sup>†</sup></th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td align="left" colspan="6"><bold>Diagnóstico</bold></td>
								</tr>
								<tr>
									<td align="left" colspan="2">Leucemia mieloide aguda </td>
									<td align="center">24 </td>
									<td align="center">1<sup>‡</sup></td>
									<td align="center" rowspan="7">--</td>
									<td align="center" rowspan="7">1.000<sup>§</sup></td>
								</tr>
								<tr>
									<td align="left" colspan="2">Leucemia mieloide crónica </td>
									<td align="center">3 </td>
									<td align="center">1<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left" colspan="2">Leucemia linfoblástica aguda </td>
									<td align="center">12 </td>
									<td align="center">1<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left" colspan="2">Linfoma no Hodgkin </td>
									<td align="center">18 </td>
									<td align="center">1<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left" colspan="2">Enfermedad de Hodgkin </td>
									<td align="center">3 </td>
									<td align="center">1<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left" colspan="2">Mieloma múltiple </td>
									<td align="center">15 </td>
									<td align="center">1<sup>‡</sup></td>
								</tr>
								<tr>
									<td align="left" colspan="2">Anemia aplásica </td>
									<td align="center">9 </td>
									<td align="center">0<sup>||</sup></td>
								</tr>
								<tr>
									<td align="left" colspan="6"><bold>Toxicidades</bold></td>
								</tr>
								<tr>
									<td align="left" rowspan="2">Hematológica</td>
									<td align="left">Si</td>
									<td align="center">48</td>
									<td align="center">1<sup>‡</sup></td>
									<td align="center">3.22 [1.18; 8.79]</td>
									<td align="center">0.019<sup>§</sup></td>
								</tr>
								<tr>
									<td align="left">No</td>
									<td align="center">36</td>
									<td align="center">0<sup>||</sup></td>
									<td align="center" colspan="2">
									</td>
								</tr>
								<tr>
									<td align="left" rowspan="2">Edema</td>
									<td align="left">Si</td>
									<td align="center">43</td>
									<td align="center">1<sup>‡</sup></td>
									<td align="center">2.81 [1.08; 7.30]</td>
									<td align="center">0.031<sup>§</sup></td>
								</tr>
								<tr>
									<td align="left">No</td>
									<td align="center">41</td>
									<td align="center">0<sup>||</sup></td>
									<td align="center" colspan="2">
									</td>
								</tr>
								<tr>
									<td align="left" colspan="6"><bold>Comorbilidad</bold></td>
								</tr>
								<tr>
									<td align="left" rowspan="2">EICH<sup>¶</sup></td>
									<td align="left">Si</td>
									<td align="center">5</td>
									<td align="center">1<sup>‡</sup></td>
									<td align="center">9.17 [0.97; 86.38]</td>
									<td align="center">0.040<sup>§</sup></td>
								</tr>
								<tr>
									<td align="left">No</td>
									<td align="center">79</td>
									<td align="center">0<sup>||</sup></td>
									<td align="center" colspan="2">
									</td>
								</tr>
								<tr>
									<td align="left" colspan="6"><bold>Infecciones</bold></td>
								</tr>
								<tr>
									<td align="left" rowspan="2">Genitourinaria</td>
									<td align="left">Si</td>
									<td align="center">16</td>
									<td align="center">1<sup>‡</sup></td>
									<td align="center">3.32 [1.08; 10.17]</td>
									<td align="center">0.031<sup>§</sup></td>
								</tr>
								<tr>
									<td align="left">No</td>
									<td align="center">68</td>
									<td align="center">0<sup>||</sup></td>
									<td align="center" colspan="2">
									</td>
								</tr>
								<tr>
									<td align="left" rowspan="2">Sepsis</td>
									<td align="left">Si</td>
									<td align="center">16</td>
									<td align="center">1<sup>‡</sup></td>
									<td align="center">6.03 [1.386-26.205]</td>
									<td align="center">0.017<sup>§</sup></td>
								</tr>
								<tr>
									<td align="left">No</td>
									<td align="center">68</td>
									<td align="center">0<sup>||</sup></td>
									<td align="center" colspan="2">
									</td>
								</tr>
								<tr>
									<td align="left" colspan="6"><bold>Medicinas usadas</bold></td>
								</tr>
								<tr>
									<td align="left" rowspan="2">Vitaminas y suplementos</td>
									<td align="left">Si</td>
									<td align="center">67</td>
									<td align="center">1<sup>‡</sup></td>
									<td align="center">2.78 [0.72;10.63]</td>
									<td align="center">0.124<sup>§</sup></td>
								</tr>
								<tr>
									<td align="left">No</td>
									<td align="center">17</td>
									<td align="center">0<sup>||</sup></td>
									<td align="center" colspan="2">
									</td>
								</tr>
								<tr>
									<td align="left" rowspan="2">Ácido biliar</td>
									<td align="left">Si</td>
									<td align="center">62</td>
									<td align="center">1<sup>‡</sup></td>
									<td align="center">24.32 [27.321; 261.608]</td>
									<td align="center">0.004<sup>§</sup></td>
								</tr>
								<tr>
									<td align="left">No</td>
									<td align="center">22</td>
									<td align="center">0<sup>||</sup></td>
									<td align="center" colspan="2">
									</td>
								</tr>
								<tr>
									<td align="left" rowspan="2">Antianémico</td>
									<td align="left">Si</td>
									<td align="center">35</td>
									<td align="center">1<sup>‡</sup></td>
									<td align="center">2.60 [1.02; 6.58]</td>
									<td align="center">0.042<sup>§</sup></td>
								</tr>
								<tr>
									<td align="left">No</td>
									<td align="center">49</td>
									<td align="center">0<sup>||</sup></td>
									<td align="center" colspan="2">
									</td>
								</tr>
								<tr>
									<td align="left" rowspan="2">Antihemorrágico</td>
									<td align="left">Si</td>
									<td align="center">33</td>
									<td align="center">1<sup>‡</sup></td>
									<td align="center">1.95 [0.77; 4.91]</td>
									<td align="center">0.155<sup>§</sup></td>
								</tr>
								<tr>
									<td align="left">No</td>
									<td align="center">51</td>
									<td align="center">0<sup>||</sup></td>
									<td align="center" colspan="2">
									</td>
								</tr>
								<tr>
									<td align="left" rowspan="2">Anticoagulante</td>
									<td align="left">Si</td>
									<td align="center">20</td>
									<td align="center">1<sup>‡</sup></td>
									<td align="center">3.12 [0.91;7.17]</td>
									<td align="center">0.046<sup>§</sup></td>
								</tr>
								<tr>
									<td align="left">No</td>
									<td align="center">64</td>
									<td align="center">0<sup>||</sup></td>
									<td align="center" colspan="2">
									</td>
								</tr>
								<tr>
									<td align="left" rowspan="2">Diurético de asa</td>
									<td align="left">Si</td>
									<td align="center">55</td>
									<td align="center">1<sup>‡</sup></td>
									<td align="center">2.56 [0.90;7.29]</td>
									<td align="center">0.074<sup>§</sup></td>
								</tr>
								<tr>
									<td align="left">No</td>
									<td align="center">29</td>
									<td align="center">0<sup>||</sup></td>
									<td align="center" colspan="2">
									</td>
								</tr>
								<tr>
									<td align="left" rowspan="2">Antiviral</td>
									<td align="left">Si</td>
									<td align="center">79</td>
									<td align="center">1<sup>‡</sup></td>
									<td align="center">0.164<sup>**</sup></td>
									<td align="center">--</td>
								</tr>
								<tr>
									<td align="left">No</td>
									<td align="center">5</td>
									<td align="center">0<sup>||</sup></td>
									<td align="center" colspan="2">
									</td>
								</tr>
								<tr>
									<td align="left" rowspan="2">Inmunosupresor</td>
									<td align="left">Si</td>
									<td align="center">56</td>
									<td align="center">1<sup>‡</sup></td>
									<td align="center">4.50 [1.38;14.69]</td>
									<td align="center">0.009<sup>§</sup></td>
								</tr>
								<tr>
									<td align="left">No</td>
									<td align="center">28</td>
									<td align="center">0<sup>||</sup></td>
									<td align="center" colspan="2">
									</td>
								</tr>
							</tbody>
						</table>
						<table-wrap-foot>
							<fn id="TFN9">
								<p><sup>*</sup>Intervalo de Confianza; <sup>†</sup>Valor de p; <sup>‡</sup>Si; <sup>§</sup>Prueba Chi-Cuadrado; <sup>||</sup>No; <sup>¶</sup>Enfermedad de injerto contra huésped; <sup>**</sup>Prueba exacta de Fisher</p>
							</fn>
						</table-wrap-foot>
					</table-wrap>
				</p>
				<p>El modelo ajustado demostró que el mayor peso para el diagnóstico lo presentó el grupo caso, por lo que solo la Anemia Aplásica no presentó diferencia estadística entre los grupos. Las demás variables comprobadas se relacionaron con la probabilidad de realizar el RCMH en menor o mayor proporción, según los resultados mostrados en la <xref ref-type="table" rid="t9">Tabla 3</xref>.</p>
				<p>El modelo final de regresión logística múltiple mostró un nivel de significación con un valor de p &lt; 0,05, con evidencia estadística de asociación del grupo caso con las variables sepsis y ácido biliar. Por lo tanto, la posibilidad de que los pacientes de este estudio afectados por sepsis, que usaron ácido biliar para someterse a un retrasplante, fue mayor en relación a los pacientes que no desarrollaron sepsis y que no usaron dichos medicamentos.</p>
				<p>Cabe mencionar que la Hipótesis 1, para este estudio de “Variables clínicas y sociodemográficas, están asociadas a la necesidad de realizar el RCMH en los pacientes sometidos a TCMH”, fue probado y aceptado.</p>
				<p>La probabilidad de supervivencia acumulada se calculó a partir del número total de pacientes investigados en este estudio (n = 84), entre los cuales 49 (58,33%) completaron el tratamiento y fueron dados de alta del hospital, mientras que 35 (41,67%) fallecieron. El tiempo cero (inicial) considerado fue el ingreso del paciente al servicio en cuestión para iniciar el tratamiento y el cierre se caracterizó por la finalización del tratamiento (cuando el paciente fue dado de alta del hospital o murió). El tiempo mínimo de supervivencia fue de 6,67 meses y el máximo de 91,7 meses. La supervivencia media general (SG) fue de 26,97 meses y 50% de la muestra tuvo una SG de 17,55 meses. </p>
				<p>En general, a mayor número de meses, menor SG. La <xref ref-type="fig" rid="f6">Figura 2</xref>, a continuación, muestra la curva SG del número total de individuos analizados en este estudio.</p>
				<p>
					<fig id="f6">
						<label>Figura 2</label>
						<caption>
							<title>Curva de supervivencia general entre los grupos caso y control. Natal, RN, Brasil, 2019 (n=84)</title>
						</caption>
						<graphic xlink:href="1518-8345-rlae-30-e3569-gf6.png"/>
					</fig>
				</p>
				<p>No hubo diferencia estadísticamente significativa para SG entre los grupos (<italic>Log Rank</italic> = 0,583). Al determinar la supervivencia por grupo de estudio, se pudo observar que la curva se mantuvo similar para ambos hasta el desenlace (<xref ref-type="fig" rid="f6">Figura 2</xref>), ya sea el tratamiento completo o la muerte, con una pequeña diferencia para el grupo control en el cual el SG fue hasta 91,7 meses, en comparación con el grupo caso, que fue de aproximadamente 80 meses.</p>
			</sec>
			<sec sec-type="discussion">
				<title>Discusión</title>
				<p>La descripción del perfil epidemiológico de los pacientes trasplantados revela un ligero predominio del sexo masculino con diagnóstico de leucemia mieloide aguda, siendo la principal causa de muerte la sepsis. Los datos sociodemográficos en un estudio multicéntrico realizado en Europa que hizo un seguimiento retrospectivo de pacientes con recurrencia de leucemia aguda, después del primer TCMH, son similares a los encontrados en este estudio en el cual la edad media de los pacientes fue de 36,76 años, 58,04% eran hombres, 21% tuvo una supervivencia de ± 24 meses, 90% de los pacientes fallecieron y las causas más frecuentes fueron: enfermedad progresiva con 136 (55,06%), sepsis con 34 (13.76%), y con EICH 29 (11.74%)<xref ref-type="bibr" rid="B11"><sup>11</sup></xref>.</p>
				<p>El RCMH se considera un procedimiento complejo y agresivo, ya que expone a los pacientes a un nuevo régimen de acondicionamiento y toxicidades debilitantes. La primera fase del trasplante demanda cuidados específicos con un equipo multidisciplinario que ofrezca apoyo asistencial durante la hospitalización y en el postrasplante, con atención en ambulatorio. El tratamiento es largo e implica riesgos que predisponen al paciente a una amplia gama de complicaciones que necesitan ser administradas para que no amenacen su supervivencia y calidad de vida<xref ref-type="bibr" rid="B12"><sup>12</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B13"><sup>13</sup></xref>.</p>
				<p>El post-TCMH alogénico puede presentar algunas complicaciones como infecciones, toxicidades, EICH y fracaso del injerto, las que son las principales causas de hospitalización prolongada y muerte<xref ref-type="bibr" rid="B14"><sup>14</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B15"><sup>15</sup></xref>. Los mecanismos celulares y moleculares que median el rechazo del injerto también son desencadenantes del desarrollo de EICH y su control se realiza mediante el uso de inmunosupresores. Esas complicaciones son problemas importantes, causan morbilidad y mortalidad significativas, limitan el éxito del trasplante y pueden culminar en la necesidad de RCMH<xref ref-type="bibr" rid="B4"><sup>4</sup></xref>.</p>
				<p>El fracaso del injerto y de la recidiva de la enfermedad son los principales motivos que llevan al retrasplante mencionados en un estudio<xref ref-type="bibr" rid="B16"><sup>16</sup></xref>. Los factores asociados con el fracaso del injerto incluyen: incompatibilidad con ALH, enfermedad subyacente, tipo de régimen de acondicionamiento, fuente de CPH empleada, dosis baja de CMH, agotamiento de células T ex vivo, incompatibilidad mayor ABO, injertos de mujeres donantes a hombres receptores, estado de la enfermedad en el momento del trasplante, infección o sepsis y falta de adherencia al tratamiento farmacológico con ácido ursodesoxicólico e inmunosupresores en el periodo post-TCMH<xref ref-type="bibr" rid="B17"><sup>17</sup></xref>. Estos dos últimos mencionados fueron señalados por los resultados de esta investigación como factores que aumentan las posibilidades de retrasplante.</p>
				<p>La recaída es la principal causa de fracaso del tratamiento y su pronóstico es pésimo<xref ref-type="bibr" rid="B18"><sup>18</sup></xref>. Las células malignas pueden escapar de la lesión citotóxica - asociada con el régimen de acondicionamiento previo al trasplante y con el control inmunitario creado por la reconstitución medular e inmunitaria en el postrasplante y causar la recidiva de la enfermedad que no responde a los fármacos quimioterapéuticos utilizados previamente - lo que requiere un arsenal de fármacos más citotóxicos<xref ref-type="bibr" rid="B19"><sup>19</sup></xref>.</p>
				<p>El TCMH afecta a la microbiota intestinal, microbioma-metaboloma y eje el hepático, lo que puede alterar la homeostasis intestinal y la gravedad de la EICH<xref ref-type="bibr" rid="B20"><sup>20</sup></xref>. El uso de ácido ursodesoxicólico se considera útil en la profilaxis y tratamiento de algunas afecciones hepáticas, especialmente en la EICH por ser una de las razones que puede llevar a la necesidad del RCMH, de acuerdo con los resultados presentados por este estudio. Un estudio retrospectivo investigó el uso de ácido ursodesoxicólico y encontró una disminución en la incidencia del síndrome de obstrucción sinusoidal y en otras complicaciones hepáticas<xref ref-type="bibr" rid="B21"><sup>21</sup></xref>.</p>
				<p>El ácido biliar comúnmente utilizado en los protocolos del TCMH es el ursodesoxicólico; su uso inadecuado con dosis inferiores a las prescritas tuvo una relación directa con el retrasplante (OR = 16,12; CI = 95%: 2,05-128,12; p = 0.001) entre los participantes de este estudio con respecto a los factores protectores contra EICH y otras enfermedades hepáticas. El hígado es uno de los órganos que puede ser afectado por el EICH; cambios significativos en los niveles séricos de bilirrubina y fosfatasa alcalina pueden indicar la participación en ese resultado adverso<xref ref-type="bibr" rid="B22"><sup>22</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref>.</p>
				<p>El inmunosupresor se usa para evitar el rechazo del injerto y la necesidad de realizar el RCMH; el uso inapropiado de dicho medicamento, en este estudio, está relacionado con mayores posibilidades del RCMH (OR = 4,50; CI = 95 %; 1,38-14,69; p = 0,009), lo que significa que ingerir una dosis inferior a la recomendada en la prescripción médica aumenta la posibilidad de un nuevo trasplante. Los pacientes que realizaron un trasplante alogénico reciben rutinariamente inmunosupresión comenzando con D-1 (un día antes del procedimiento) para evitar el rechazo o falla del injerto y durante mucho tiempo después de TCMH con inhibidores de la calcineurina y otros medicamentos<xref ref-type="bibr" rid="B4"><sup>4</sup></xref>. </p>
				<p>Sin embargo, la polifarmacia que experimentan los pacientes que utilizan diversos medicamentos orales, especialmente en la fase ambulatoria post-TCMH, es un factor limitante que dificulta la adherencia al tratamiento de manera adecuada y continuada<xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>. Sin la ingestión correcta de las dosis diarias de medicación, como inmunosupresores y ácido ursodesoxicólico, el paciente puede progresar a falla del injerto, a la recurrencia de la enfermedad o EICH, como lo demuestran los resultados de este estudio.</p>
				<p>Dichos medicamentos se recetan para controlar síntomas, infecciones, rechazo del injerto y como apoyo de otros medicamentos, entre otros. El esquema terapéutico es complejo debido al tipo, número, diferente horario de medicamentos y a frecuentes cambios en las recetas. Los pacientes y familiares asumen la carga de administrar la polifarmacia después del alta médica. La adherencia es esencial para minimizar las posibilidades de infección, EICH o recaída de la enfermedad<xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>.</p>
				<p>Aunque esta estrategia ha respaldado grandes avances en la medicina moderna de trasplantes, especialmente en el control del rechazo agudo, está vinculada a problemas significativos que incluyen la toxicidad de los medicamentos y el aumento del riesgo de infecciones oportunistas, entre otros. Además, el régimen inmunosupresor elegido puede controlar insuficientemente el rechazo del injerto o su fracaso, así como el EICH. Como resultado, muchos pacientes tienen una necesidad de retrasplante, lo que puede ser un desafío clínico al estar limitado por la baja disponibilidad de órganos, tejidos o células donadas<xref ref-type="bibr" rid="B4"><sup>4</sup></xref>.</p>
				<p>Factores sociodemográficos como baja educación, bajo nivel socioeconómico y falta de apoyo social, pueden estar directamente relacionados con las tasas de infección, ya que el paciente puede no entender las indicaciones para evitar contagios o no tener las condiciones económicas suficientes para continuar con el tratamiento necesario. Un estudio, realizado por investigadores de varios países, resaltó que 66,49% de los pacientes no adhirieron al uso de fármacos inmunosupresores<xref ref-type="bibr" rid="B27"><sup>27</sup></xref>. </p>
				<p>La dificultad en la adherencia a la terapia con medicamentos después de TCMH puede tener un impacto negativamente significativo en la supervivencia, ya que aumenta el riesgo de desarrollar infecciones y recaídas de la enfermedad, que constituyen algunos de los motivos con mayores <italic>Odds Ratios</italic> para la necesidad de retrasplante, señalados por este estudio<xref ref-type="bibr" rid="B28"><sup>28</sup></xref>.</p>
				<p>Las infecciones pueden progresar fácilmente para sepsis en pacientes inmunodeprimidos candidatos al TCMH<xref ref-type="bibr" rid="B29"><sup>29</sup></xref>. Como se muestra en los resultados de este estudio, los pacientes con sepsis tienen más probabilidades de someterse a un nuevo trasplante (OR = 6,03; CI = 95%: 1,386-26,205; p = 0,017).</p>
				<p>Los pacientes a menudo no pueden ingerir medicamentos por vía oral con la aparición de mucositis orofaríngea, náuseas y vómitos durante la hospitalización; así, las drogas orales que tienen presentación intravenosa son sustituidas. Sin embargo, la presentación farmacéutica de los ácidos biliares solo se presenta en tabletas de 50 mg, 150 mg y 300 mg; los comprimidos de 300 mg generalmente se prescriben cada 12 horas para los protocolos de trasplante alogénico. Como se discutió anteriormente, el ácido biliar fue un factor protector contra la EICH hepática, el síndrome de obstrucción sinusoidal y la dislipidemia, entre otros que afectan al hígado.</p>
				<p>Las enfermedades que retornan después de un primer TCMH debido al fracaso o rechazo del injerto, suelen presentar un mal pronóstico. El intento de lograr un mejor resultado para la supervivencia del paciente con la adición de un RCMH aumentó la supervivencia general en un 10 %. La indicación de retrasplante solo se concentra en pacientes con enfermedad persistente después del primer TCMH y por las razones mencionadas anteriormente<xref ref-type="bibr" rid="B5"><sup>5</sup></xref>.</p>
				<p>El RCMH parece un enfoque poco prometedor, pero hay pocas opciones de tratamiento para la recaída después del primer trasplante, por ejemplo la quimioterapia con nuevos medicamentos, la infusión de linfocitos de donante para trasplante alogénico y el retrasplante o una combinación de ellos. En este contexto, el RCMH es el tratamiento que favorece mayor SG<xref ref-type="bibr" rid="B7"><sup>7</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B16"><sup>16</sup></xref>.</p>
				<p>En un estudio norteamericano realizado con niños y adolescentes con recidiva de leucemia mieloide aguda después de un primer TCMH, se determinó que la supervivencia fue del 88% a los 100 días, del 56% a los 12 meses y del 48% a los 120 meses. Este hecho sugiere que el RCMH después del fracaso inicial del trasplante dio como resultado una supervivencia libre de la enfermedad, a largo plazo, de 50 % de niños con leucemia mieloide aguda recurrente<xref ref-type="bibr" rid="B30"><sup>30</sup></xref>.</p>
				<p>Los pacientes sometidos a TCMH o RCMH generalmente requieren cuidados complejos y cuidados de enfermería en todas sus fases, desde la indicación del paciente para realizar el procedimiento hasta su alta hospitalaria y seguimiento en el hospital. En este contexto, es urgente implementar la Sistematización de la Atención de Enfermería (SAE) y el cumplimiento de todas sus etapas<xref ref-type="bibr" rid="B31"><sup>31</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B33"><sup>33</sup></xref>, dado que el paciente puede evolucionar rápidamente para complicaciones asociadas a la enfermedad de base o a toxicidades.</p>
				<p>Se espera que la promoción de datos que respalden la toma de decisiones y las implementaciones adecuadas, en la atención al paciente, contribuyan sustancialmente para mejorar la práctica clínica de los profesionales de la salud, especialmente las enfermeras, y convertirlos en profesionales resolutivos, en la atención al paciente, al ser capaces de reconocer los posibles factores de riesgo responsables de las situaciones del RCMH.</p>
				<p>Es importante que el equipo multidisciplinario, especialmente de enfermería, desarrolle planes de atención que apoyen la adherencia del paciente al tratamiento y hagan un uso correcto de las dosis de medicamentos (como inmunosupresores y ácido ursodesoxicólico) como una forma de minimizar el inicio de infecciones, las recaídas de la enfermedad y el fracaso del injerto, ya que estos constituyen factores importantes que llevan al retrasplante.</p>
				<p>Además de un plan de atención personalizado que se adapte a las necesidades de salud de cada paciente, es fundamental invertir en apoyo social, que puede ser representado por la figura del familiar/cuidador y el equipo de salud, especialmente el equipo de enfermería. Se debe desarrollar un trabajo en equipo que involucre al paciente, al familiar/cuidador y a los profesionales de la salud, con un enfoque en mejorar la calidad de vida y la supervivencia después del retrasplante.</p>
				<p>Como se trata de un estudio con una fuente de datos secundaria, cabe señalar que pueden existir algunos sesgos, como pérdida de información por fallas en los registros y sistemas de información. Además, también se enfatiza el tamaño de la muestra y el diseño del estudio, porque a pesar de cumplir con los objetivos propuestos y dar respuesta a la pregunta de investigación y a la hipótesis propuesta, 84 registros médicos no estandarizaron el contexto de TCMH y RCMH en Brasil, lo que no permite hacer generalizaciones y análisis estadísticos más elaborados.</p>
			</sec>
			<sec sec-type="conclusions">
				<title>Conclusión</title>
				<p>Este estudio de caso-control presentó evidencia científica relevante sobre el desempeño del RCMH en cuanto al perfil clínico-epidemiológico y realizó una comparación de los factores asociados al procedimiento y a la supervivencia del paciente. Se concluye que el factor predictivo del retrasplante, en la muestra estudiada, fue la recaída de la enfermedad. Las variables clínicas sepsis y ácidos biliares mostraron una relación directa y <italic>Odds Ratio</italic> con el retrasplante. Los factores sociodemográficos también están relacionados con el RCMH, especialmente en cuanto a la importancia de la adherencia al tratamiento, incluso en las fases intrahospitalaria y post-TCMH.</p>
			</sec>
		</body>
		<back>
			<ack>
				<title>Agradecimientos</title>
				<p>El equipo de investigación agradece al Hospital Rio Grande por otorgar la carta de consentimiento y la autorización para llevar a cabo la investigación, así como a los pacientes por aceptar participar en este estudio y haber dado un relevante aporte a la ciencia</p>
			</ack>
			<fn-group>
				<fn fn-type="presented-at" id="fn12">
					<p>Artículo parte de la tesis de doctorado “Fatores associados ao retransplante de células-tronco hematopoéticas: um estudo caso-controle”, presentada en la Universidade Federal do Rio Grande do Norte, Natal, RN, Brasil. El presente trabajo fue realizado con apoyo de la Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) - Código de Financiamiento 001, Brasil.</p>
				</fn>
			</fn-group>
		</back>
	</sub-article>
</article>